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SUMMARY
The osteoclast is the principal cell involved in bone resorption. Although its 
mononuclear precursor is thought to be of haemopoietic origin the true identity of 
this elusive cell remains controversial. In an attempt to address this problem a panel 
of murine monoclonal antibodies has been produced that react with human 
osteoclasts and may help delineate the ontogenic pathway of these cells. However, 
the production of antibodies reactive with human osteoclasts has been hampered by 
the lack of osteoclasts in normal bone. This thesis describes how this problem was 
overcome using osteoclastoma-derived osteoclasts as the immunogen. It initially 
outlines the characterization of these cells, their isolation from the tumour tissue and 
their subsequent use in the immunization schedules. Following the production of 
antibody secreting hybrids, the thesis goes on to describe how their supernatants 
were screened by immunocytochemistry, to detect anti-osteoclast reactivity. This 
was initially performed on osteoclastoma tissue and then on undecalcified sections 
of adult human bone. Further immunocytochemical screening was performed on a 
wide range of tissue and blood cell substrates to check the selectivity of their 
reactivity for osteoclasts. The characterization of one of the Mabs, reactive with the 
p3 chain of the vitronectin receptor, is also described, as is its use as a tool for the 
isolation of osteoclasts from heterogeneous populations of cells. The thesis also 
describes the characterization of an osteoclast-reactive antibody that was produced 
from an immunization schedule that used primary cultures of human osteoblast-like 
cells as the immunogen. The possible reasons for this are discussed. Finally, 
potential human sources of osteoclasts for in vitro studies are assessed. These 
include human leukaemia cell lines, long-term bone marrow cultures and co-culture 
systems.
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ABBREVIATIONS
ACD Acid citrate dextrose.
APAAP Alkaline phosphatase anti-alkaline phosphatase
CAD Carbonic anhydrase isoenzyme n.
CFU Colony forming unit.
CSF Colony stimulating factor.
DHS Donor horse serum.
DMSO Dimethylsulphoxide.












RBCs Red blood cells.
RT Room temperature.
SDS Sodium dodecylsulphate.
TBS Tris buffered saline.
TNF Tumour necrosis factor.
TPA 12-o-tetradecanoylphorbol 13-acetate.
TRAP Tartrate-resistant acid phosphatase.
TRIS [Tris(hydroxymethyl)aminomethane].
v
WHO World Health Organization.












1.1 The ultra-structure of 
bQng
2
U (i) Cortical bone 2
I* 1 (ii) Trabecular bone 3
I.l(ii) Woven bone 3
1.2 Bone formation 3
I.2(i) Intramembranous ossification 4
I.2(ii) Endochondral ossification 4
1.3 Bone matrix and mineral 5
1.3 ( i) Organic matrix conmonents 5
I.3(i)a Collagen 5

















1.5 Bone cell regulatory factors 13
I.5 (i) Systemic factors 13
I.5(i)a Parathyroid hormone (PTH) 




I.5(i)c 1,25-dihydroxyvitamin D3 
(1,25D3)
17
1.5 (i)d Glucocorticoids 19
I.5(i)e Oestrogens 19
I.5(i)f Retinoids 21




1.6(H) Tumour necrosis factor (TNF) 23
I.6(iii) Interferon-y (IFN-y) 24
I.6(iv) Transforming growth factor- p 
(TGF-p)
24
I.6(v) Insulin-like growth factors 
(IGFs)
26
I.6(vi) Fibroblast growth factor and 
platelet -derived growth factor
27
I.6(vii) Transforming growth factor-a 
/ epidermal growth 
factor (TGF-a EGF)
28
I.6(viii) LIF and IL-6 28





1*7 (iv) G-CSF 34
1.8 PQNF CFFFS 34
I .8 (i) The osteoblast 34
I.8(ii) Osteocytes 35
I.8(iii) Lining cells 35
I.8(iv) Origin of the osteoblast 36
I.8(v) Osteoblast culture ststems 37
I.8(v)a Rodent organ cultures 37






I.8(v)d Human explant cultures 38
I.8(v)e Transformed human 
osteoblast cell lines
39
1 .9 The osteoclast 39
1.9(i) Morphology 39
1.9(ii) Bone resorption 41
1.9(ii)a Energy requirements 41
1.9(ii)b Attachment to the 
bone surface
41
1.9(ii)c The role of plasminogen 
activator (PA) in osteoclast 
resorption
42
1.9(ii)d Acidification of the 
resorption compartment
43
1.9(ii)c Lysosomal enzymes 44
1.10 Osteoclast phenotypic 
markers
44
1.11 The origin of the osteoclast 47
1.11(1) Monophyletic origin of bone 48
ix
cells
























Osteoclasts and the 
monocyte/macrophage lineage




Bone marrow culture systems
Requirements for osteoclast 
differentiation in in vitro 
systems
Co-culture systems
Human long-term marrow 
cultures
Human leukaemic cell lines
- HL-60
Human leukaemic cell lines
- FLG 29.1
Monoclonal antibodies 
Tissues used for the study
Osteoclastomas
Osteophytes

































ILl(iii) Preparation of tissue for 69
immunocytochemistry
n.l(iv) Indirect immunofluorescence 69
II. 1 (v) Alkaline phosphatase anti- alkaline
phosphatase (APAAP) 70
II. 1 (vi) Cell enrichment using Dynabeads 70
II. 1 (vii) Preparation of poly-l-lysine coated 71
slides
II. 1 (viii) Human long-term marrow cultures 71
II. 1 (ix) Preparation of Cytospin cell 72
suspensions
II.l(x) Cell culture 73
11.2 MATERIALS 74
11.3 EQUIPMENT 75
11.4 SOLUTIONS AND BUFFERS 76
n.4(i) Media for cell culture 76
II.4(ii) Liquid nitrogen freezing mixture 77
for cryopreservation of cells
II.4(iii) Aqueous mountant for IF 77
and Giemsa
II.4(iv) Ethidium bromide for IF 77
counterstain
II.4(v) Erythrocyte lysing solution 77
II.4(vi) TRAP reagents 78
II .4 (vii) Immunisation reagents 78
II.4(vii)a Preparation of HAT and HT 78
media
II.4(viii) APAAP reagents 79
II.4(viii)a Substrate 79
II.4(viii)b TRIS buffered saline 80
II.4(ix) Western blotting and dot 80
blotting reagents
































Characterization of osteoclastoma 
giant cells
Osteoclastoma tissue culture 
for the demonstration of 
multinuclearity and TRAP activity
Resorption assay using 
devitalised bovine cortical 
bone slices
Sperm whale dentine
Preparation of osteoclastoma 
for immunizations
Percoll density gradient isolation 
of osteoclastoma giant cells




Preparation of mouse thymocytes 
("feeder cells")
Preparation of spleen cells
Preparation of myeloma cells
Fusion
Termination of HAT selection 
Removal of supemates 






























(IF) on tissue sections and 
imprint preparations
Characterization of the giant 
cells
Monoclonal antibody production 
and initial screening
Screening of hybridomas on 
osteoclastoma tissue and imprints











CHARACTERIZATION OF THE 
TISSUE AND CELLULAR REACTIVITY 
OF THE MONOCLONAL ANTIBODIES












APAAP on osteophyte 
tissue
APAAP staining of cultured 
human bone marrow giant 
cells and synovial tissue
Characterization by indirect 
IF on human tissues 
and blood cells
Characterization on rat rabbit 
and marmoset bone.
The effects of fixation on the 














IV.3(viii) Enzyme dot blots 119
IV.3(ix) Enrichment of osteoclasts from 119
tumour with Dynabeads
IV.4 RESULTS 121
IV.4(i) Reactivity of Mabs with human T21
osteoclasts in bone sections
IV.4(ii) Characterization on cultured 121
bone marrow and inflammatory 
giant cells
IV.4(iii) Characterization on tissues and 126
blood cell substrates
IV.4(iv) Reactivities against rat, rabbit 135
and marmoset bone
IV.4(v) Effect of fixation on the reactivity 135
of the Mabs
IV.4(vi) Western blotting 135
IV.4(vii) Enzyme dot blots 139








V .3(i) Characterization of C22 152
V.3(i)a Indirect immunofluorescence of 152
normal platelets
V.3(i)b FACS analysis 152
V.3(i)c Immunoprecipitation 153









C22 reactivity on fixed 
normal platelets
FACS analysis of C22 







POTENTIAL SOURCES OF 
OSTEOCLAST PRECURSORS 
IN  VITRO















of FLG 29.1 cells
U937 and HL-60 cells in culture 
with 1,25D3 andretinoic acid
U937 and HL-60 cells cultured 
with a mix of IL-lp, IL-3,IL-6 
and GM-CSF
TPA treatment of U937 and 
HL-60 cells




of osteoclastoma-derived cell 
populations
FLG 29.1 cells
U937 and HL-60 cultures


































VII. 1 (i) Problems associated with
Mab technology
VII. 1 (ii) Osteoclast precursors for
in vitro studies
VII. 1 (iii) Establishment of osteoclast
precursor cell line.


















1.1 The ultra-structure of bone 
Bone, together with cartilage, make up the skeletal system and together they have 
three main functions:
(i) Mechanical: support and site for muscle attachment.
(ii) Protection : for vital organs, bone marrow and the central nervous system.
(iii) Metabolic : reserves of ions such as calcium, phosphate and magnesium for 
the preservation of mineral homeostasis.
Macroscopically long bones consist of a cylindrical tube in the midshaft called the 
diaphysis. This broadens at both ends to form the epiphysis and between these two 
regions, adjacent to the epiphyseal disc is the metaphysis. In a growing bone the 
epiphyseal disc or growth plate is responsible for logitudinal growth of the bone. It 
consists of a layer of cartilage which proliferates and then calcifies to form new 
bone. At the end of the growth period this area becomes fully calcified and in 
humans the majority of bones lose their potential for growth when full ossification 
has been achieved.
Bone can be divided into three types based on differences in their structure. These 
are termed cortical, trabecular and woven bone.
I.l(i) Cortical bone
The external surface of all bones is formed from a thick calcified layer of compact 
or cortical bone. In the diaphysis the cortex surrounds the medullary cavity in 
which the haemopoietic bone marrow is found. Cortical bone is composed of 
Haversian systems through which blood vessels are channelled. They are also 
populated by osteogenic cells including osteocytes which reside in lacunae and 
communicate via cannaliculi. Since there is relatively little turnover of this bone, it 
probably does not play a major role in mineral homeostasis. The main functions of 
this type of bone are structural and protective.
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1.1 (ii) Trabecular bone
Towards the metaphysis and epiphysis, the cortex becomes progressively thinner. 
The internal space is filled with a fine network of calcified trabeculae surrounded by 
stromal spaces. These contain fat, blood vessels and haemopoietic marrow. The 
surface of the trabeculae are lined with osteogenic cells, including the lining cells 
which are located in metabolically quiescent areas and the osteoblasts in areas of 
bone formation. In addition there are areas of resorption, characterized by the 
presence of osteoclasts. Because of its higher rate of turnover the trabecular bone 
plays an important role in mineral homeostasis. In addition it has a structural role 
particularly at the end of long bones and within vertebral bodies.
1.1 (iii) Woven bone
In normal circumstances the orientation of the collagen fibres in bone alternates 
from layer to layer giving it a characteristic lamellar structure. However, when bone 
is formed rapidly during processes such as fracture healing there is no organization 
of collagen fibres, and they appear in randomly orientated bundles. This gives rise 
to woven bone. Apart from forming the fracture callus it is also the first type of 
bone to appear in histogenesis. In these situations it is only temporary and is 
replaced by normal cortical or trabecular bone.
1.2 Bone formation
Two types of bone exist in the skeleton, flat bones which include the skull, scapula, 
mandible and ileum and long bones which include the tibia, femur and humerus. 
These two forms are histogenically distinct. The flat bones are derived from 
intramembranous bone formation and the long bones from both endochondral and 
intramembranous bone formation. The main difference between these is the 
presence (endochondral) or absence (intramembranous) of a cartilage phase.
3
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I.2(i) Intram em branous ossification
This occurs by the differentiation of primitive mesenchymal cells into osteoblasts 
which produce bone matrix without the requirement of a cartilagenous precursor. 
The type of matrix initially produced by these cells has the characteristics of woven 
bone; irregular bundles of collagen fibres, large and numerous osteocytes and 
irregularly distributed areas of calcification. This is later remodelled and replaced by 
lamellar bone.
I.2(ii) Endochondral Ossification
Mesenchymal cells differentiate into chondroblasts and secrete the cartilagenous 
matrix. The chondroblasts become progressively embedded in the matrix they are 
producing and are then termed chondrocytes. These cells sit in lacunae and unlike 
osteocytes they will continue to proliferate for some time. This process occurs, in 
part because of the gel-like consistency of the cartilage. Appositional growth 
occurs at the perichondrium as the mesenchymal cells continue to proliferate and 
differentiate. Within the cartilage, interstitial growth takes place as a result of 
synthesis of new matrix between the chondrocytes. The proliferating zone of the 
growth plate is characterized by the presence of vertical columns of chondrocytes 
called isogenous groups. These expand the plate interstitially until they enter the 
hypertrophic zone where they eventually die. During this phase the cartilage in this 
area selectively calcifies. This is followed by osteoclastic resorption which removes 
only part of the calcified cartilage before the area is invaded by osteoblasts that 
differentiate and lay down new woven bone on the cartilaginous remnants. The 
trabeculae formed from this initial phase are called the primary spongiosa. As this 
woven bone is eventually remodelled lower in the growth plate, it is replaced with 
lamellar bone forming mature trabeculae, termed secondary spongiosa.
4
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1.3 Bone matrix and mineral
The matrix of bone is composed of both organic and inorganic elements. 
Mineralized matrix is formed by the organized deposition of type I collagen fibres 
and ground substance. Interspersed between, and on top of these structures are 
spindle-shaped crystals of hydroxyapatite [Caio(PC>4)6(C)H2)] which are organized 
in the same direction as the collagen fibres. The ground substance (glycoproteins 
and proteoglycans) is highly anionic and consequently has a high ionic binding 
capacity. This is thought to be important in the calcification process and in the 
binding of hydroxyapatite to collagen.
I.3(i) Organic matrix components 
I.3(i)a Collagen
The majority of bone protein consists of approximately 85-90% type I collagen, the 
remainder being composed of non-collagenous proteins, glycosaminoglycans and 
lipids. Type I collagen is a triple helix composed of two identical al(I) chains and 
one structurally similar but genetically different a2 chain (I). These are helical 
polypeptides which twist together to form a right-handed super-helix. This is 
formed because every third residue within these molecules is a glycine. This amino 
acid does not have a large side chain so provides a convenient folding element for 
these molecules. Collagen is initially secreted as a precursor procollagen molecule 
which contains non-helical regions at both the N- and C-terminals which are 
cleaved to form tropocollagen. This polypeptide then aggregates to the extracellular 
fibrils. The three cleaved C-terminal fragments become stabilized by interchain 
disulphide bonds giving rise to a molecule called pColl-l-C. This cleavage product 
can be measured by radioimmunoassay (Simon et a/, 1984) as a marker for bone 
formation.
It has been demonstrated that collagen fibrils are arranged in parallel in normal 
mature bone, but a more random profile is observed in woven bone. The osteoid
5
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seam secreted by osteoblasts (vide infra) is composed primarily of collagen and is 
detectable histologically before mineralization has taken place. The collagen 
molecules form cross-linkages with pyridinoline and deoxy-pyridinoline, both of 
which are found in bone and collagen (Robins et al, 1990). The urinary rates of 
excretion of both molecules have been proposed as quantitative markers of whole 
body bone resorption (Eastell et al, 1990)
I.3(i)b Non-collagenous matrix proteins
These proteins represent approximately 10% of the organic portion of bone. Despite 
their relatively small contribution to the total bone mass it is becoming apparent that 
they have important functions in the maintenance of bone . These include the 
regulation of mineralization, cell-matrix interactions and the coupling of the bone 
formation and resorption process. They also include proteins whose function has 
not been elucidated but whose measurement in serum or urine has provided 
valuable markers for bone turnover.
I.3(i)c Osteocalcin (bone gla-protein)
Osteocalcin is a bone specific protein of low molecular weight (5.3 Kd) that is 
characterized by the presence of three y-carboxyglutamic acid (Gla) residues within 
its amino acid sequence. Osteocalcin has been shown to inhibit the in-vitro 
formation of hydroxyapatite and is modulated by 1,25-dihydroxyvitamin D3 (Price 
and Baukol, 1980). In addition osteocalcin has been shown to have chemotactic 
activity for osteogenic cells (Lucas et al, 1988) and may play a role in osteoclast 
recruitment and resorption (Glowacki et al, 1987). Serum levels of this protein have 
been used as an index of bone turnover. However its true physiological function is 
still unknown. A number of groups have demonstrated its distribution in bone by 
immunostaining at both the light and electron microscope levels (Bronkers et al, 
1985, Bianco et al, 1985; Camarda et al, 1988). These studies showed that 
osteocalcin was present in the mineralized matrix but, unlike other products of the
6
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osteoblasts such as type I collagen, it could not be demonstrated in osteoid. 
Recently a monoclonal antibody has been raised against the intracellular proform of 
osteocalcin and has been used in similar localization experiments. These indicated 
that the protein was present in young osteocytes of developing bone but not in 
surface osteoblasts (Bianco et al, 1991). In addition it was demonstrated, using 
alkaline phosphatase staining in parallel with the immunostaining, that osteocalcin 
positive osteocytes were negative for alkaline phosphatase but osteoblasts negative 
for osteocalcin were positive for the enzyme. These observations suggest that 
osteocalcin and alkaline phosphatase are differentiation markers for osteoblasts; 
alkaline phosphatase for early and osteocalcin for late cells of this lineage.
Bone cells synthesize a number of proteins that affect cell attachment; bone 
sialoprotein, osteopontin, thrombospondin and fibronectin.
I.3(i)d Bone sialoprotein
This protein has a molecular weight of approx 60 Kd. It has been cloned and 
sequenced (Oldberg et al, 1988) and has a number of distinctive features. It 
contains the RGD (arg-gly-asp) sequence important in integrin binding, possibly 
via the vitronectin receptor (Oldberg et al 1988). It contains several stretches of 
glutamic acid residues which may be important in its calcium binding capacity. In 
bone this protein has been immunolocalized in the mineralized matrix and within 
mature osteoblasts and young osteocytes. No staining has been detected in 
preosteogenic cells in the periosteum or in surrounding, non-osteogenic soft tissue 
(Bianco et al, 1991). Although originally thought to be bone specific, BSP has also 
been localised immunologically and by in-situ hybridization in hypertrophic 





Although it is prominent in bone, the mRNA for osteopontin has been detected in a 
range of tissues such as renal distal tubules and placenta. It has been cloned and 
sequenced (Oldberg et al, 1986), and like BSP has been shown to contain the RGD 
binding sequence which may be responsible for anchoring cells to the bone mineral, 
hence its name (Oldberg et al, 1986). Osteopontin mRNA has been detected in 
osteoblasts actively laying down osteoid matrix in human adult and foetal bone. The 
mRNA has also been detected in high levels in human osteoclasts both directly 
apposed to, and away from the bone surface (Merry et al, 1992). A positive 
mononuclear population has also been detected in these tissue substrates which may 
represent an osteoclast precursor population prior to their fusion to form the 
multinucleated cell. In support of these results Nomura et al (1988) suggested that 
labelled cells in their study of osteopontin mRNA distribution were possibly 
osteoclasts, and Marks et al (1987) immunolocalized osteopontin in rat osteoclasts. 
These observations may indicate that synthesis of matrix proteins is not the 
exclusive domain of osteoblasts or it may suggest an important role for osteopontin 
in cell/cell or cell/matrix adhesion.
I.3(i)f Thrombospondin
This glycoprotein has a molecular weight of 450 Kd and is found in a number of 
tissue sites. Apart from osteoblasts (Clezardin et al, 1989; Gehron-Robey et al, 
1989) it is also found in the a-granules of platelets and in a large number of 
cultured cells such as fibroblasts, macrophages and osteosarcoma cells. There is 
evidence to suggest that it has a number of functions such as roles in cell adhesion 
(Roberts etal, 1987), and in platelet aggregation (Leung, 1984).
I.3(i)g Osteonectin
This is the most abundant non-collagen protein in bone and constitutes 
approximately 2% of protein in developing bone. It is a phosphorylated
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glycoprotein with a molecular weight of 32 Kd and is found in other cells such as 
platelets (Stennerr et al, 1986) and in growing cells and tissues undergoing rapid 
proliferation and remodelling. It has recently been demonstrated, however that 
platelet and bone osteonectin differ both structurally and immunologically (Malaval 
et al 1990; Kelm and Mann, 1990). It has been suggested that platelet osteonectin is 
involved, with thrombospondin, in the platelet aggregation process (Clezardin et al, 
1991). Bone osteonectin appears to promote the the deposition of calcium 
phosphate mineral onto type I collagen (Termine et al, 1981; Romberg et al, 1984) 
and the in-vitro spreading of endothelial and fibroblastic cells on plastic or collagen 
coated plates (Sage et al, 1989).
I.3(i)h Proteoglycans
These macromolecules consist of acidic polysaccharide side chains 
(glycosaminoglycans) attached to a central core protein. There are two types of 
glycosaminoglycans in bone; chondroitin sulphate, which is the most predominant 
form, and heparan sulphate.
The majority of bone glycosaminoglycans are attached to two small proteoglycan 
core proteins that are similar but separate gene products (Fisher et al, 1987). These 
are called PGI (biglycan) and PGII (decorin) and differ in that the former molecule 
has two chondroitin side chains and the latter molecule only one. PG I appears 
more abundant in developing foetal or young bone than in adult bone, while PG II 
is found at all stages of development. Although their function has not been fully 
elucidated, they may be important for the integrity of most connective tissue 
matrices (Termine, 1990).
1.4 Bone remodelling
The concept of bone remodelling was first proposed by Frost (1964) using 
morphological and morphometric studies. He demonstrated that remodelling
9
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occurred asynchronously at many discrete sites in the skeleton and consisted of a 
predictable cycle of events (figure 3). It has been estimated that at any given time 
within the adult skeleton there are approximately 1.5xl06 sites of bone remodelling 
and that annually between 20 and 30% of the trabecular bone volume is resorbed 
and reformed (Baron et al> 1983).
The remodelling cycle is composed of a complex series of cellular events that are 
responsible for the coordinated resorption and subsequent formation of new bone. 
These events are regulated by systemic hormones and local factors that direct their 
effects on a number of cell populations, such as osteoblasts, osteocytes, osteoclasts 
and haemopoietic cells. These factors control the recruitment, replication and 
ultimately the function of these cell types in order to achieve the end-product of a 
mineralized matrix.
I.4(i) Quiescence
At this stage the bone is covered by a layer of flattened, metabolically inactive lining 
cells primarily of osteoblastic origin. In addition this heterogeneous layer is thought 
to consist of osteoblast and osteoclast precursors as well as cells responsible for 
the transduction of systemic, local and mechanical signals (Gowen, 1991).
I.4(ii) Activation
The cycle begins with the recruitment of haemopoietic osteoclast precursors to a 
remodelling site where they undergo proliferation, differentiation and fusion into 
mature multinucleated cells. The precursors have been shown to express fluoride 
inhibitable non-specific esterase, characteristic of cells of the mononuclear 
phagocytic lineage (Bozdech and Bainton, 1977). The events responsible for the 
attachment of the precursors to the bone surface are not fully understood. However, 
it may be initiated by the retraction of the lining cell cytoplasm (Jones and Boyde,
1 0
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1976) and the formation of pseudopods from the osteoclast precursors that attach 
them to the exposed matrix. This activation phase lasts about 3 to 4 days.
I.4(iii) Resorption
The mononuclear cells may initiate the resorption phase of the cycle and then begin 
to fuse, forming mature multinucleated osteoclasts. The resorption phase lasts for 
approximately 2 days in which time the osteoclasts resorb a predefined quantum of 
osteoid and mineralised matrix.
I.4(iv) Reversal
Resorption is followed by a period of functional inactivity, termed the reversal 
phase, in which the osteoclasts are replaced by TRAP positive mononuclear cells. 
The identity of these latter cells are not known but it has been suggested that they 
may be the product of osteoclast fission (Baron et al, 1983). This observation was 
based on the fact that the number of mononuclear cells approximated the number of 
nuclei present in the osteoclast they replaced. Reversal lasts for approximately 4 
days in which time a cement-line is laid down consisting of glycoproteins and 
glycosaminoglycans. This is thought to act as a chemoattractant for osteoblast 
precursors which proliferate and differentiate at the resorption site and initiates the 
next step in the cycle.
I.4(v) Formation
The mature osteoblasts lay down new matrix until the resorption site has been 
totally replaced. This matrix is mineralised and to complete the cycle the site is 
covered with functionally quiescent lining cells. The success of these events 
depends on whether the resorption site is completely replaced by new matrix as 
happens in the normal individual. Failure to refill these sites is characteristic of both 
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Fig 1.1. The proposed cyclical events involved in normal bone remodelling are illustrated in
this diagram. The metabolically inactive quiescent stage is followed by the
activation of mononuclear osteoclast precursors to form resorbing multinucleated osteoclasts.
Following resorption there is a coupling stage in which the osteoclasts are
replaced by osteoblasts that actively refill the resorption lacunae with unmineralised osteoid.




1.5 Bone cell regulatory factors 
I.5(i) Systemic factors
I.5(i)a Parathyroid hormone (PTH) and Parathyroid hormone-related 
protein (PTHrp)
This polypeptide has a molecular weight of 9.5 Kd and plays a major role in the 
maintenance of serum calcium homeostasis. Its release from the parathyroid glands 
is controlled by perturbations in serum calcium concentrations. The main sites of 
action are in the kidney and in bone. Its role in the kidney is to increase calcium 
reabsorption, decrease phosphate reabsorption and stimulate the 1-hydroxylation of 
25-hydroxyvitamin D3. In bone PTH increases bone turnover (Reeve and Zanelli, 
1986). It has been demonstrated that PTH can stimulate bone resorption in-vitro 
(Bamicot, 1948; Raisz, 1963), but the mechanisms responsible for this action are 
not understood. Raisz and Niemann (1967) demonstrated that PTH could stimulate 
a rapid calcium efflux from bone after as little as 2 hours in the presence of the 
hormone, and it was suggested that this was mediated by osteoclasts. Bingham et al 
(1969) demonstrated an increase in metabolic activity after as little as 90 minutes 
following injection into rabbits. It was later observed that PTH caused an increase 
in the size of individual osteoclasts with a concomitant increase in nuclei number 
and ruffled border area (Holtrop et al, 1974). It has also been demonstrated that 
PTH stimulates carbonic anhydrase and subosteoclastic acidity (Anderson et al, 
1985,1986) as well as lysosomal enzymes (Vaes, 1968). PTH may also have a 
mitogenic effect on osteoclast precursors, which is apparent after exposure to the 
hormone for approximately 24 hours in culture (Feldman et al, 1980). The mode of 
action of PTH on these progenitors and on the mature osteoclast is thought to be 
indirect since PTH receptors have not been definitively demonstrated on these cells. 
Although Rao et al (1983) claimed to demonstrate PTH receptors on both rat 
osteoblasts and osteoclasts by immunocytochemistry, the binding of radiolabelled 
PTH was shown only to occur on chicken osteoblasts but not osteoclasts by Silve
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et al (1982). Because of the demonstration of biological responses by osteoblasts 
and the lack of direct effects on isolated osteoclasts (McSheehy and Chambers, 
1986) it is currently believed that the osteoblast is the major target for PTH and that 
it is the osteoblasts that mediate the resorptive action of this hormone.
The intracellular events linked to PTH-receptor binding appear complex. It has been 
demonstrated that adenylate cyclase activity is stimulated, but it is now believed that 
all the cellular responses to PTH cannot be explained through c-AMP generation 
alone, it would appear that more than one secondary messenger is involved.
PTH has a mitogenic effect on osteoblasts and inhibits mature osteoblast function.
It has been demonstrated in organ cultures Dietrich et al, (1976) and in osteoblast­
like cell cultures (Beresford et al, 1984) that PTH inhibits the synthesis of matrix 
components, but that this effect is short-lived since it is followed after a number of 
days by long term stimulation (Howard et al, 1981b). A role for osteoblasts in 
mediating osteoclastic bone resorption is based on a number of experimental 
observations. PTH was shown by Jones and Boyde (1976) to cause the 
cytoplasmic retraction of lining cells, exposing the underlying matrix for the 
attachment of osteoclasts. This effect was initially discounted by a number of 
groups who suggested that it was due the action of collagenase (Sakamoto and 
Sakamoto, 1982) or plasminogen activator (Hamilton et al, 1984). However, Jones 
et al, (1985) countered these claims by suggesting from their observations using 
scanning electron microscopy that collagenolysis did not occur after exposure of 
bone to PTH. The work of Chambers' group demonstrated that isolated osteoclasts 
were incapable of forming resorption pits in the absence of osteoblasts (McSheehy 
and Chambers, 1986).
The actions of PTHrp on bone activity are extensively reviewed by Moseley and 
Gillespie (1992). This onco-foetal hormone is produced by many tumours, 
particularly those of squamous cell origin and is responsible for the hypercalcaemia
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associated with malignant disease (Merendino et al, 1986; Moseley et al, 1987; 
Suva et a/,1987). It is found in normal skin keratinocytes and it is suggested that it 
may play a role in normal calcium metabolism in the foetus. Although they are 
transcribed from distinct genes the N-terminal portion of PTHrp shows great 
homology with the receptor-binding N-terminal portion of PTH (Goltzman et al, 
1989) with eight of the first 13 amino acids being identical. They have been shown 
to react at common receptor binding sites in kidney and bone (Juppner et al, 1988; 
Nissenson et al, 1988). Thus PTHrp appears to bind to the PTH receptor to 
stimulate adenylate cyclase (Fukayama et a l , 1988; Kemp et al, 1987) and mimic 
the effects of PTH in altering calcium and phosphate handling in the kidneys and 
stimulating bone resorption. The observation that PTH-rp is synthesized by bone 
cells themselves may suggest that this molecule has important autocrine and 
paracrine functions in the bone environment.
I.5(i)b Calcitonin
Calcitonin is secreted primarily by the thyroid C-cells and the main biological effect 
of this 32-amino acid peptide is the inhibition of osteoclastic bone resorption 
(Raisz, 1983; Deftos and Glowacki, 1984; Nicholson et al, 1986). This effect 
occurs within minutes of its administration and consequently has been used to 
control diseases characterized by increased bone resorption such as osteoporosis 
and Paget's disease.
It has been demonstrated that the calcitonin gene consists of 6 exons and 5 introns 
(Deftos and Roos, 1989). Exon 4 codes for calcitonin in the thyroid C-cells and 
exon 5 for the calcitonin gene-related peptide (CGRP) in the central nervous 
system. This latter molecule is involved in vasodilation and has been shown to 
function as a neurotransmitter. Its effects in bone appear to be similar to those of 
calcitonin. Although less potent than calcitonin it has been shown to inhibit all of
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the osteoclast-activating factors so far tested (D'Souza et al, 1986; Roos et al, 1986; 
Yamamoto etal, 1986; Zaidi et al, 1987).
The effects of calcitonin on osteoclasts includes shape changes and a decrease in 
bone resorbing activity by the induction of functional quiescence (Goltzman and 
Tannenbaum, 1987). These shape changes are characterized by a decrease in 
motility, the retraction of cytoplasmic extensions and shrinkage of the ruffled 
border. It has also been suggested that in-vivo administration of calcitonin may 
detach osteoclasts from the bone surface (Baron and Vignery, 1981) and reduce 
their numbers within minutes (Hedlund et al, 1983), perhaps by fission into 
mononuclear cells (Baron and Vignery, 1981).
Calcitonin inhibition of osteoclastic bone resorption only occurs transiently and this 
may be due to the down regulation of its receptor or the modulation of secondary 
messengers such as protein kinase C (Findley et al, 1989). This phenomenon is 
termed "escape" and may be prevented by the administration of glucocorticoids 
(Au, 1975; Binstock and Mundy, 1980; Raisz et al, 1972). Bone marrow culture 
studies indicate that calcitonin may also have a modulating effect on osteoclast 
precursors perhaps by inhibiting their differentiation into mature osteoclasts. This 
may therefore enhance the inhibition of osteoclastic function by this hormone. In 
addition it has been suggested that calcitonin may also affect the function of other 
haemopoietic cells such as monocytes. Calcitonin-induced deactivation of these 
cells has been described (Nong et al, 1989) and this may be responsible for 
inhibiting their secretion of osteoclast-activating cytokines (Skjodt and Russell, 
1992).
A number of studies suggest that calcitonin may have a stimulatory role in bone 
formation (Baron and Saffar, 1977; Gruber et al, 1984) and it has been 
demonstrated that both transformed and normal osteoblast-like cells respond to
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calcitonin (Eilon et al, 1983; Forrest et al, 1985; Findley and Martin, 1986; Farley 
et al, 1988). The types of effect include an increase in replication and synthesis of 
both alkaline phosphatase and collagen. These effects were detected in both human 
and murine cell lines and occurred in a dose dependent manner. Although these 
observations suggest a direct effect of calcitonin on bone forming osteoblasts, it has 
been suggested that the long-term anabolic effects of the hormone in-vivo may in 
fact be due to preferential inhibition of osteoclastic function. This may induce an 
imbalance in the remodelling cycle leading to a prolonged formation step (Skjodt 
and Russell, 1992).
I.5(i)c 1,25-dihydroxyvitamin D3 (1,25D3)
1,25D3 is a seco-steroid and is the major biologically active metabolite of vitamin 
D3. Its receptors, like those of other steroid hormones are located intracellularly, 
show broad tissue distribution (Haddad, 1987) and show sequence homology with 
thyroid hormone receptors (Franklyn and Sheppard, 1989). 1,25D3 is primarily 
synthesized by renal tubule cells from the la-hydroxylation of its liver-derived 
substrate 25(OH)D3. In addition to renal tissue it has been demonstrated that a 
number of other cell types are capable of la-hydroxylation of 25(OH)D3 in-vitro . 
These, among many others, include y-interferon and lipopolysaccharide activated 
peripheral blood monocytes and alveolar macrophages, human bone marrow 
macrophages (Koeffler et al, 1985; Reichel et al, 1987) and human osteoblast-like 
cells (Howard et al, 1981b). Although 1,25D3 is a systemic hormone responsible 
for a miriad of effects on multiple extra-skeletal tissues it is suggested that it may 
also exert a number of effects on bone cells. These may be endocrine as well as 
paracrine and autocrine effects which may modulate osteoblast and osteoclast 
function either directly or via an intermediary. It has been demonstrated that like 
PTH, 1,25D3 is a potent stimulator of both in-vitro (Raisz et al, 1973; Reynolds et 
al, 1973) and in-vivo (Reynolds et al, 1976) bone resorption at physiological 
levels. In vivo administration of 1,25D3 in osteopetrotic infants (Key et al, 1984)
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and rodents (Holtrop et al, 1981) is characterized by an increase in osteoclast 
numbers . 1,25D3 stimulates osteoclast precursors to differentiate and fuse to form 
multinucleated osteoclasts (Roodman et al, 1987), the area of the ruffled border 
increases (Holtrop and Raisz, 1979) and there is a concomitant increase in ~  
lysosomal enzyme production (Delaisse et al, 1988). In-vitro studies utilising bone 
marrow cultures from several species (Holtrop et al, 1981; Ibbotson et al, 1984; 
MacDonald etal, 1987; Roodman et al, 1985 ) have shown that 1,25D3 is capable 
of stimulating the formation of osteoclast-like cells which demonstrate the presence 
of calcitonin receptors and a ruffled border (Takahashi et al, 1988; Sasaki et al,
1989). In contrast these features are not demonstrable on the macrophage 
polykaryons which also develop in these cultures (Teti et al, 1988).
There is no direct evidence to suggest that 1,25D3 acts directly on mature 
osteoclasts; no receptors for it have been detected in mature osteoclasts (Merke et al,
1986) and no response to it has been demonstrated by isolated osteoclasts 
(Chambers and Dunn, 1982). 1,25D3 may therefore have a direct effect on 
immature osteoclasts or its effects may be mediated via other cell types at the bone 
surface. Studies suggest that 1,25D3 may activate osteoclasts indirectly by initially 
activating intermediary cells at the bone surface. For instance it has been 
demonstrated that 1,25D3, in a similar manner to other osteotropic factors, can 
stimulate the release of osteoclast-activating factors from osteoblasts (McSheehy et 
al, 1987). In addition 1,25D3 has been shown to modulate the activity of immune 
cells, thus controlling the release of cytokines responsible for osteoclast activation. 
These include T-cells which require activation before expressing the 1,25D3 
receptor and monocytes which express it constitutively. 1,25D3 acts on activated T- 
cells to inhibit the release of cytokines such as GM-CSF, EL-2 and IFN-y, 
although controversy exists regarding this latter molecule. The mechanism 
responsible for this is believed to involve a reduction in stability of the cytokine 
mRNA. The effects on monocytes appear to be multifactorial and include the
18
Ch I
modulation of IL-1 release, either stimulatory or inhibitory, the stimulation of other 
monocyte products such as TNF-a and PGE2, and alterations in class IIMHC 
expression on antigen presenting cells.
I.5(i)d Glucocorticoids
These are steroid hormones with marked effects on bone. In-vitro, glucocorticoids 
inhibit the formation of osteoclasts and inhibit their resorptive capacity in organ 
cultures. It has been demonstrated that the potency of these effects depend upon the 
resorption stimulus; they are more effective, for example, at inhibiting IL-1 (OAF) 
induced resorption than they are at inhibiting resorption induced by PTH (Mundy et 
a l  1978).
In contrast, long-term administration of glucocorticoids in vivo causes bone loss 
with a marked reduction in trabecular mass (Bressot et al, 1979). This effect is 
indirect and is due to glucocorticoid-induced inhibition of calcium absorption in the 
gut. This in turn leads to stimulation of parathyroid activity leading to secondary 
hyperparathyroidism (Hahn et al, 1979) and ultimately to increased osteoclastic 
resorption.
I.5(i)e Oestrogens
The sex steroids play important roles in skeletal maturation in the young growing 
individual and in the prevention of the bone loss associated with aging. Oestrogen 
deficiency is a cause of postmenopausal bone loss and can be prevented by 
oestrogen replacement (Christiansen et al, 1980). It has been demonstrated that 
oestradiol can increase trabecular bone volume in ovariectomized rats and is also 
able to maintain vertebral bone mass in postmenopausal women (Moore et al,




Experimental evidence suggests that the osteoblast is the oestrogen target in bone. 
Functional receptors have been demonstrated in animal and human-derived 
osteoblast-like cells (Komm et al, 1988; Erikson etal, 1988) and oestradiol has 
been shown to have an in vitro regulatory effect on osteoblast function. The 
responses of osteoblasts to exogenous oestrogen have been observed in normal and 
transformed cultures of animal-derived cells and in human osteosarcoma cell lines. 
These effects include stimulation of proliferation and induction of insulin-like 
growth factor I mRNA in primary and immortalized rat calvarial cells (Ernst et al, 
1989). In addition, other effects include: inhibition of proliferation of UMR 106 rat 
osteosarcoma cells (Gray et al, 1987), increased type I procollagen gene 
transcription in rat calvarial and osteosarcoma cells (Ernst et al, 1989; Vorderstrasse 
and Wirren, 1990) and a stimulation of TGFp mRNA levels in rat and human 
osteosarcoma cells (Lee et al, 1989; Komm et al, 1988).
In contrast there have been few direct effects described of oestradiol on normal 
adult human osteoblast-like cells. Those that have include a stimulation of steady 
state mRNA levels for procollagen (Colvard et al, 1989) and TGFp (Oursler et al, 
1989). Conflicting results have been obtained regarding proliferation of these cells 
with stimulation (Kasperk et al, 1989) and no effect (Keeting et al, 1991) being 
reported. The major drawbacks of these primary osteoblast-like cultures is the 
presence of heterogeneous populations of cells and osteoblasts at different stages of 
differentiation. It is therefore uncertain whether the responses measured in this 
system are truly osteoblastic.
Although direct stimulation of osteoclasts by oestrogens has been reported (Tobias 
and Chambers, 1989), the general view is that they do not have a direct effect on 
these cells (Caputo etal, 1976; Stewart and Stem, 1987). They may act indirectly 
by altering cytokines that have functional effects on osteoclasts. For example 
oestrogens enhance transcription of TGFp, an inhibitor of osteoclast activity
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(Oursler et al, 1989), and also have an immunosuppressive effect, reducing the 
release of IL-1 (Pacifici et al, 1987) and TNFa (Gowen et al, 1989b) from 
monocytes.
I.5(i)f Retinoids
An excess of vitamin A leads to increased bone loss in vivo. Similarly it has been 
demonstrated that the actions of retinoids on osteoclasts may be explained by their 
ability to modulate the release of osteotropic cytokines. They have been shown to 
stimulate the release of EL-1 and IL-3 (Treschsel et al, 1985) and inhibit the release 
ofEFN-Y(Abb and Deinhardt, 1980).
I.5(i)g Thyroid Hormones
The thyroid hormones T3 and T4 play important roles in the regulation of normal 
growth and in skeletal development. Osteoblastic cells express thyroid receptors 
(Krieger et al, 1988) and respond to thyroid binding by proliferating (Ernst et al,
1988). Excess thyroid hormone can cause bone loss and it appears that the 
hormones stimulate calcitonin-inhibitable osteoclastic resorption in organ cultures 
(Mundy et al, 1976).
I.5(i)h Prostaglandins
Arachidonic acid may be oxidized via one of two pathways to produce a large 
family of active compounds. If oxidation occurs via cyclooxygenase, a class of 
compounds called prostaglandins (also prostacyclins and thromboxanes) are 
produced, and lipoxygenase produces a group of metabolites which includes the 
leukotrienes. A role for these latter compounds in bone metabolism has not yet been 
clearly demonstrated. The predominant arachidonic acid cyclooxygenase metabolite 
in bone is thought to be PGE2 (Raisz and Martin, 1983). It has been demonstrated 
that this metabolite stimulates bone resorption by increasing both the number and 
activity of osteoclasts (Schelling et al, 1980). However, the osteotropic effects of
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the prostaglandins are very complex, since it has been demonstrated that these 
potent stimulators of resorption demonstrate a transient inhibition of function on 
isolated osteoclasts (Ali and Chambers, 1983; Chambers and Ali, 1983).This 
suggests that the target cell which mediates the actions of the prostaglandins is 
missing from the isolated cell system. It would appear therefore that prostaglandins 
have two effects on osteoclasts. The first is a transient inhibition of osteoclastic 
function followed by a sustained enhancement of resorption, probably via a 
secondary mediator.
Prostaglandins have also been shown to have a variety of effects on osteoblasts 
such as stimulation of proliferation (Hakeda et al, 1987) and in vitro collagen 
synthesis (Hakeda et al, 1985) and promotion of bone formation (Ueda et al,
1980).
1.6 Cvtokines
The study of cytokines and their effects on bone first began with the description of 
a blood mononuclear cell-derived factor which stimulated bone resorption in organ 
cultures (Horton etal, 1972). This factor, termed osteoclast-activating factor (OAF) 
has since been shown to consist of at least ten different cytokines, some of which 
are discussed below with particular reference to their effects on bone (reviewed by 
Gowen, 1991). The net effect of cytokines on a tissue is the result of their ability to 
interact with one another, either in a synergistic or antagonistic fashion. In doing so 
they are able to modulate receptor expression and to alter their own and each others 
production.
I.6(i) Interleukin-1 (IL-1)
IL-1 was the first cytokine to be positively linked to osteoclast activation, firstly 
using purified material (Gowen et al, 1983) and then recombinant protein (Gowen 
and Mundy,1986). IL-1 is a very potent stimulator of in-vitro bone resorption and
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it has been demonstrated that it can do this in isolation at concentrations as low as 
lpM, or lower when combined with other factors. The effect of this cytokine 
appears to be through the stimulation of osteoclast precursors as demonstrated by 
histological and cell culture studies (Gowen and Mundy, 1986; Pfeilschifter et al, 
1989).
In addition to its effects on osteoclasts it has also been demonstrated that IL-1 can 
act on osteoblasts by stimulating their proliferation (Gowen et al, 1985). It has 
therefore been demonstrated that IL-1 can stimulate both facets of bone turnover, 
and this has been further demonstrated by the observation that bone resorption and 
formation could be increased in a coupled manner by a subcutaneous injection of 
EL-1 over the calvariae of mice (Boyce et al, 1989).
I.6(ii) Tumour necrosis factor (TNF)
TNF exists in two forms termed TNFa and TNFp (lymphotoxin). Many of the 
actions of TNF are shared with EL-1, but it is considerably less potent.
Experimental data show that both factors are synthesized by the same cells in 
response to the same agents and act synergistically in affecting bone cell responses 
(Stashenko etal, 1987; Gowen, 1988). TNF stimulates osteoclastic bone resorption 
in organ cultures (Bertolini et al, 1986), an effect that is dependent on prostaglandin 
secretion (Tashjian etal, 1987). Experiments using short-term injections of TNF 
have demonstrated that this cytokine stimulates resorption and induces 
hypercalcaemia in vivo. Similar effects have been demonstrated in nude mice that 
have been implanted with Chinese hampster ovarian cells, transfected with the 
human TNF gene. These mice exhibited hypercalcaemia and increased bone 
resorption, while the control group that had been implanted with tumour cells 
containing the empty vector showed none of these effects (Johnson et al, 1989).
TNFp has identical effects on osteoclastic bone resorption as TNFa, binds to the 
same receptor and shows considerable sequence homology. Garrett et al (1987)
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demonstrated the link between lymphotoxin and the increased bone resorption 
associated with multiple myeloma. In their in vitro system they showed that the 
myeloma cells expressed lymphotoxin mRNA and that the protein was secreted into 
the culture medium. In addition they demonstrated that lymphotoxin-inducecT 
osteoclastic resorption could be terminated by the addition of neutralizing antibody 
to the cytokine.
I.6(iii) Interferon-y (IFN-y)
This cytokine is produced by activated T-cells and unlike other immune cell 
products it has an inhibitory effect on osteoclastic resorption. This appears to be 
due to the inhibition of proliferation of osteoclast precursors and their differentiation 
into mature osteoclasts (Takahashi et al, 1987). Unlike calcitonin IFN-y-induced 
inhibition has no effect on osteoclast morphology. It appears to be more effective at 
inhibiting TNF and IL-1 induced resorption than bone resorption induced by PTH 
and 1,25D3 (Gowen and Mundy, 1986).
I.6(iv) Transforming Growth factor p (TGF-p)
These represent a family of regulatory molecules that are present in most cells of the 
body and most also express receptors for these molecules (reviewed by Mundy and 
Bonewald, 1992). TGFp was first isolated from platelets,which represents the 
most abundant source of this molecule. It is stored in the platelet a-granules and is 
released by degranulation (Assoian et al, 1983). The second major source is bone 
where it has been shown to be synthesized by osteocytes and bone lining cells 
(Ellingsworth et al, 1986; Gehron-Robey et al, 1987). There are two major classes 
of TGFp peptides (Derynck et al, 1985; Marquardt et al, 1987). The best 
characterized members of the first class are TGFpl and TGFp2. These bind to the 




The effects of TGFp on bone cells are complex and it has become apparent that the 
model system in which this cytokine is studied is of importance as regards whether 
a stimulatory (Tashjian et al, 1985) or inhibitory (Pfeilschifter et al, 1988) effect is 
demonstrated. For example in the foetal rat long bone system, during prolonged 
culture periods, osteoclast formation and resorption, stimulated by submaximal 
doses of IL-1, PTH and 1,25D3, are inhibited (Pfeilschifter et alt 1988). It suggests 
that TGFp is blocking the formation of mature osteoclasts from their precursors. 
Similarly, the formation of osteoclasts in the human long-term marrow cultures can 
be inhibited by the addition of TGFp (Chenu et al, 1988). This effect is presumably 
on the precursor cells which are unable to proliferate, differentiate and fuse to form 
the mature osteoclast. In contrast to these observations, resorption can be stimulated 
in neonatal mouse calvariae by the addition of TGFp. This is caused by TGFp- 
stimulated prostaglandin release (Tashjian et al, 1985) and can be inhibited by the 
addition of indomethacin. Dramatic changes are also seen when TGFp is injected 
subcutaneously over mouse calvariae. The marrow space becomes populated with 
large resorbing osteoclasts and unlike DL-1 and PTH induced resorption this does 
not occur on the periosteal layer. These effects of TGFp are also inhibited by 
indomethacin, suggesting a prostaglandin-mediated response (Mundy and 
Bonewald, 1992).
The effects of TGFp on osteoblasts are also complex. Its effects on different 
sources of isolated osteoblasts are variable. In some models such as MC3T3 and 
SaOS-2 cells TGFp stimulates proliferation and inhibits differentiated function 
(Noda and Rodan, 1986; Gehron-Robey et al, 1987) while in others , including 
MG63 and ROS 17/2.8 cells it has the opposite effect. In organ cultures of rat 
calvariae the proliferation of the periosteal cells and slight increase in protein 
synthesis that occur can be enhanced by removal of TGFp from the system. This 
cytokine also affects the bone formng cells in the mouse calvaria system. On 
addition of TGFp the periosteal layer thickens, hypertrophic osteoblasts lay down
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osteoid adjacent to the periosteal bone and this finally becomes mineralised to form 
woven bone. This effect persists after the TGFp has been removed and appears to 
be mediated by prostaglandins since it can be blocked to some extent by 
indomethacin.
TGFp is present in the bone matrix in a latent form, and can be activated by 
changes in pH (Pfeilschifter et ah 1990a). It is interesting then that the osteoclast 
resorption compartment may provide the ideal environment for the activation of this 
cytokine, which may then control subsequent events in the bone remodelling cycle. 
Its pivotal role may include the inhibition of osteoclastic resorption, and since it has 
been shown to have a chemotactic effect on osteoblasts (Pfeilschifter et ah 1990b) it 
may attract these cells and stimulate new bone formation.
I.6(v) Insulin-like growth factors (IGFs)
Also called Somatomedins, IGFs have a molecular weight of approximately 7.5 
Kd. Two forms, called IGF-1 and IGF-2 have been characterized and both types 
appear to have effects on in-vitro bone cell function. IGF-1 stimulates proliferation 
and type 1 collagen synthesis in foetal rat calvariae organ cultures. Recently,
Canalis et alt (1989) demonstrated that PTH stimulates the release of IGF-1 from 
bone organ cultures and Mundy et al (1990) suggest that this may make IGF-1 an 
important factor in the coupling of bone formation to bone resorption. This is based 
on the observations that IGF-1 is synthesized by bone cells and incorporated into 
the matrix where it may be released subsequently by resorption to stimulate 
osteoblastic function. A similar role has been suggested for IGF-2 (Mohan et al,
1988). The actions of sex hormones may involve IGF. Ernst et al (1989) have 
shown that IGF-1 is produced by oestrogen stimulated bone cells and that the 
actions of oestrogen similar to those of IGF-1 can be ablated by the addition of anti- 
IGF-1 antibody. In addition the actions of IGFs are enhanced by binding proteins 
(BPs) which are produced by bone cells and their production is modulated by
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systemic hormones such as growth hormone (Ernst and Rodan, 1990). Five of 
these BPs have been identified that have a number of functions including transport 
in the circulation, increasing the serum half-life of the cytokine and providing tissue 
specificity (reviewed by Schmid and Ernst, 1992).
It appears that microglobulin may also have a stimulatory effect on bone 
formation through modulation of IGF-1 binding to its receptor (Canalis et al,
1987).
I.6(vi) Fibroblast growth factor and platelet-derived growth factor
Two classes of polypeptide growth factors that have pronounced effects on bone 
are fibroblast growth factors (FGF) and platelet derived growth factors (PDGF). It 
has been demonstrated that FGFs are potent stimulators of angiogenesis (Thomas et 
a/,1985; Esch et al, 1985) which is an important process during bone development 
and fracture repair. Studies on bone cells have demonstrated that FGF stimulates 
proliferation of rat foetal calvariae-derived cells and rat osteosarcoma cells but 
suppresses their differentiation-related features (Rodan et al, 1987, 1989). Also 
stimulation of osteoclastic resorption could be demonstrated with FGF at a 
concentration of 10' 10 M (Simmons and Raisz, 1989). PDGF is produced by 
platelets (Kohler and Lipton, 1974) and macrophages (Shimokodo et al, 1985) both 
of which are involved in wound healing. PDGF has chemotactic activity for 
monocytes, neutrophils and fibroblasts and is mitogenic for cells of mesenchymal 
origin, including bone cells (reviewed by Ross et al, 1986). The information 
regarding its effects on bone are sparse but it has been shown to affect some of the 
differentiated functions of osteoblasts and stimulates prostaglandin-mediated 
osteoclast resorption (Tashjian etal, 1982).
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I.6(vii) Transforming growth factor-a / epidermal growth factor (TGF- 
a /  EGF
TGF-a and EGF are related polypeptides that exert their biological effects through 
the EGF receptor. They are both stimulators of cell growth and replication and are 
both powerful stimulators of osteoclastic bone resorption. It has been observed that 
both polypeptides act as growth factors for osteoclast precursors, although TGF-a 
appears more potent. It functions via the EGF receptor to cause proliferation of the 
osteoclast precursors.TGF-a has also been shown to cause hypercalcaemia in vivo. 
and has been linked to the increased bone resorption and hypercalcaemia that occurs 
with solid tumours (reviewed by Ibbotson and D'Souza,1992).
I.6(viii) LIF and IL-6
These factors are grouped under the heading of differentiation inducing factors 
because of their putative function in promoting differentiation and fusion of 
osteoclasts in vitro. However reports of stimulation (Lowik et al, 1989; Reid et al,
1989) and inhibition (Al-Humidan etal, 1991; Lorenzo et al, 1990) of bone 
resorption have clouded the issue of their roles in vivo. In addition, a report on 
oestradiol-inhibited release of IL-6 from human osteoblasts (Girasole et al, 1990) 
has not been demonstrable in two further reports (Rickard et al, 1992; Chaudhary et 
al, 1991).
1.7 Colony-stimulating factors 
The CSFs are a family of glycoproteins that have the ability to stimulate the 
formation of colonies of haemopoietic bone marrow precursors in semi-solid 
medium. At this time there are five CSFs that have been well characterized 
according to their ability to stimulate the proliferation and maturation of specific cell 
types from their precursors. These are interleukin-3 (IL-3), granulocyte- 
macrophage colony stimulating factor (GM-CSF), macrophage colony-stimulating 
factor M-CSF, G-CSF and erythropoietin (EPO). In addition to these factors a new
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growth factor termed stem cell growth factor (SCF) is being characterized and has 
been shown to be the ligand for the cell surface receptor c-kit (Spangrude et al, 
1988; Anderson et a/,1990; Zsebo et al, 1990).
A rich source of CSFs in bone marrow and spleen are stromal cells. These cells, 
which are of mesenchymal origin, are found in many tissue sites in which they 
form a lattice with which other cells such as haemopoietic cells can form intimate 
contact Osteoblastic cells are considered to be part of the stromal system and are 
capable of secreting CSFs that may be important for the development of 
osteoclasts, which are of haemopoietic origin, in the bone environment (Owen,
1985). It is believed that the formation of mature osteoclasts from their precursors 
requires cell to cell contact in order that the stromal cells can induce the 
differentiation of the precursor target cells.
I.7(i) IL-3
With regard to bone cells this CSF appears to function by augmenting the 
maturation of osteoclasts. Despite the well documented affects of this factor its 
source remains unclear. Although stromal cells secrete a number of cytokines they 
do not appear to secrete IL-3. The only animal source so far described is the 
activated T-cell. Scheven et al> (1986) demonstrated that preculture of purified 
murine stem cells with IL-3 and subsequent culture of these with foetal metatarsal 
bone caused the formation of osteoclasts. This activity could be enhanced by the 
addition of IL-1 and M-CSF. Further work by Barton and Mayor (1989), using 
unselected murine marrow cells cultured in the presence of IL-3, demonstrated the 
formation of numerous TRAP positive cells that formed osteoclast-like 
polykaiyons. However their osteoclastic phenotype could not be verified since the 
resorption capabilities of these cells was not tested. In contrast to the work of 
Kurihara (vide infra) the formation of these polykaryons was independent of 
1,25D3. Hattersley and Chambers (1990) demonstrated the formation of calcitonin
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receptor positive mononuclear cells after culturing murine marrow cells with 
devitalised bone and IL-3. These cells were not capable of resorbing bone when 
cultured with IL-3 alone, but the addition of 1,25D3 to the EL-3 cultures induced 
multinucleation. In addition bone resorption was demonstrable above that seen with 
1,25D3 alone. This suggests that IL-3 is capable of affecting the proliferation and 
differentiation of more mature osteoclast progenitors as well as stem cells. The 
single exception to these data is the work of Shinar et al (1990) who could not 
demonstrate the formation of TRAP positive cells in murine marrow cultures in the 
presence of EL-3.
I.7(ii) GM-CSF
This factor does not appear to have direct effects on osteoclastic resorption but it 
does have well documented effects on osteoclastic development, for example in the 
long-term marrow culture systems (vide infra). In contrast to the reports of 
increased osteoclastic development, there are suggestions that GM-CSF may reduce 
the rate of appearance of osteoclasts in mouse marrow cultures (Shinar et al, 1990; 
Hattersley and Chambers, 1990). Horowitz and Jilka (1992) suggest a number of 
possibilities to explain the discrepancies in GM-CSF effects. Firstly they suggest 
that if the osteoclast and macrophage are derived from the same progenitor, then it 
may be feasible that these progenitors are being diverted away from the osteoclast 
pathway towards that of either the macrophage or granulocyte. Secondly, they 
suggest that if the osteoclast progenitors (CFU-GM) express receptors for EL-3, 
GM-CSF and M-CSF they may be suppressed from osteoclast development. This 
is based on observations in other systems which show that GM-CSF and IL-3 can 
suppress the effect of M-CSF, by inhibition of the mRNA and protein of its 
receptor, c-fms (Gliniak and Rohrschneider, 1990). This effect by GM-CSF is 
concentration dependent and as this rises so the number of M-CSF colonies 
decreases and the number of granulocyte colonies increases. 11-3 can also suppress 
the number of colonies stimulated by M-CSF. Since the effects of GM-CSF are
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concentration dependent then this may explain the discrepancies in experimental 
data. A third explanation is that the osteoclast is derived from either an alternate 
CFU-GM or a more immature progenitor. This idea is based on experiments that 
utilised spleen-derived colony forming cells from single lineages that were — 
stimulated with IL-3 and subsequently placed on bone slices in the presence or 
absence of stromal cells and 1,25E>3. Only multilineage and GM-derived cells were 
capable of resorption, although the multilineage cells were more efficient at this than 
the GM cells (38% and 17% respectively). When cultured in IL-3 alone or in the 
absence of stromal cells the cells were unable to resorb bone (Hattersley et al>
1991). The suggestion is that if the stromal cells are a prerequisite for osteoclast 
formation then these latter cells may be producing other osteoclast-inducing factors. 
If one of these is GM-CSF then the effect on the GM-colony cells may be to inhibit 
the formation of osteoclasts, thus explaining the difference in resorbing cells 
compared to the multilineage cells. This assumes that the GM-colony cells are more 
mature than the multilineage-colony cells and are capable of responding to this 
factor.
I.7(iii) M-CSF
Similar to the data presented for GM-CSF there are conflicting reports as to the 
effects of M-CSF on osteoclast formation and function. These discrepancies may be 
explained by the effects of GM-CSF on the expression of the M-CSF receptor (vide 
supra), although the source of recombinant M-CSF, cell populations used and 
experimental design, among others, may contribute to these differences (reviewed 
by Horowitz and Jilka, 1992).
Osteoclast formation has been demonstrated in organ culture experiments using 
periosteum-free embryonic mouse bone rudiments and bone marrow cells in the 
presence of M-CSF (Burger et aU 1982). In addition it has been demonstrated that 
soluble M-CSF was capable of enhancing the formation of osteoclasts in long-term
31
Chi
marrow cultures (Macdonald et al, 1986) and this was further enhanced by the 
addition of 1,25D3. In this system the M-CSF induced the proliferation of the 
osteoclast precursors and the 1,25D3 enhanced their fusion. The strongest evidence 
to support the claim for a role for M-CSF in osteoclast development comes from the 
observations made concerning its function in restoring normal resorption in the 
osteopetrotic oplop strain of mouse (vide infra). The op!op mice have a reduced 
osteoclastic resorptive capacity, showing a severe deficiency in mature osteoclasts 
and also a concomitant deficiency in mature macrophages. However, unlike some 
strains of mice suffering from osteopetrosis, the oplop mutants cannot be cured of 
their defect by transplantation of normal haemopoietic cells (Marks et al, 1984). 
Wiktor-Jedrzejczak et al (1982) first suggested that it may be due to a lack of 
macrophage colony-stimulating factor (M-CSF) production from the haemopoietic 
stroma. This was confirmed by Yoshida et al (1990) who showed that the 
pathological changes seen in this strain of mice were the result of a single base 
insertion in the coding region of the M-CSF gene causing defective production of 
this factor. The restoration of osteoclast formation and resorptive capacity could be 
achieved by the administration of recombinant human M-CSF (Felix et al, 1990). 
Kodama etal (1991) confirmed the finding that M-CSF is essential for the 
differentiation normal macrophages and osteoclasts.
A number of experiments demonstrate the opposite effects to those outlined above. 
For instance, Shinar et al, (1990) observed that M-CSF failed to increase osteoclast 
formation, as determined by TRAP positivity. Similar findings were reported by 
Van de Wijngaert et al (1987). In addition it has also been demonstrated that the 
addition of recombinant human M-CSF to rat bone cell cultures inhibited bone 
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1.7(iv) G-CSF
The major function of this factor appears to be the induction of proliferation and 
differentiation of granulocyte precursors into mature neutrophils and their — 
subsequent activation. There is little direct evidence to suggest a direct link of G- 
CSF with bone cell function, although Schneider and Relfson (1988) suggested that 
the most effective cells for curing ia rats of their skeletal sclerosis were derived 
from the G-CFCs and not the M- or GM-CFCs. The adoptive transfer of these 
cells, derived from normal litter mates induced the formation of normal osteoclasts.
18 RONE CELLS.
1.8(0 The osteoblast
Osteoblasts are cuboidal mononuclear cells with a diameter of approximately 20-30 
pm. The morphology of the osteoblast is characteristic of a very metabolically active 
cell, and its extensive secretory organelles are polarised to the apical membrane.
The nucleus is situated at the opposite pole of the cell and between it and the rough 
endoplasmic reticulum lies the golgi apparatus. This structure is principally 
involved with producing the large amounts of type I collagen that are secreted from 
these cells. Also very characteristic of the osteoblast is the presence of substantial 
amounts of the enzyme alkaline phosphatase. Although its true function has not 
been elucidated, the observation that enzyme activity correlates with bone formation 
has led to speculation, for many years, that it is involved in mineralization. This is 
supported by the knowledge that the enzyme degrades pyrophosphate which is 
thought to be an inhibitor of mineralization.
In contrast to the mature adult, where osteoblasts are present only in areas of 
remodelling or repair, the entire surface of the developing skeleton is involved with 
osteoblastic activity. The activity of the osteoblast is characterized by a layer of 
osteoid between the secretory membrane of the cell and the layer of mineralized
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matrix beneath (Parfitt, 1983). The osteoblasts extend cytoplasmic extensions 
through the osteoid seam and mineralized matrix, via canaliculae to form gap 
junction-mediated contact with osteocytes (Doty, 1981). It is suggested that this 
contact provides a means of either chemical or electrical signalling between the 
cells. In addition, similar contact has also been described between the osteoblast 
and the stromal cells of the bone marrow, thus forming a continuous stromal 
network (Deldar, 1985). During the secretory process some of the osteoblasts 
become encased in the advancing seam of osteoid and are buried within lacunae of 
the mineralised matrix. At this stage these cells are termed osteocytes.
I.8(ii) Osteocytes
It is estimated that approximately 10-20% of osteoblasts become osteocytes, and 
that the metabolic activity of these cells is dramatically reduced by the process of 
encasement (Puzas, 1990). The cessation of metabolic activity is characterized, 
ultrastructurally, by a gradual diminution of excretory organelles (Doty, 1976). 
These cells do, however express long cytoplasmic processes within canaliculae that 
may be involved in signalling and the maintenance of matrix integrity.
I.8(iii) Lining cells
Although they are believed to be closely related, if not identical, to osteoblasts 
definitive evidence does not exist to show that lining cells are capable of 
transforming into osteoblasts. However, it is thought likely that they are able to do 
this (Parfitt, 1987). The morphology of these cells is somewhat different to that of 
metabolically active osteoblasts; they are present on quiescent, mature bone surfaces 
and appear flattened and express few organelles. Despite their quiescent 
appearance, it is suggested that lining cells may have a number of putative 
functions, such as the priming of the bone surface for osteoclast activation, or the 
secretion of CSFs in haematopoiesis.
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I.8(iv) Origin of the osteoblast
The exact lineage of the osteoblast is not well defined, but circumstantial evidence 
supports the theory that they are derived from bone marrow stroma. The stroma- 
derived osteoblast precursor, or preosteoblast, upon receiving the appropriate signal 
is thought to differentiate into the mature osteoblast. Early experiments by Kember 
(1960) and Owen (1963) utilised thymidine labelling in rabbits to demonstrate the 
maturation of preosteoblasts into osteoblasts. They showed that the label was 
initially detected in the preosteoblasts and after approximately 3 days was detectable 
in mature osteoblasts and later in osteocytes. The evidence to support the stromal 
origin of the preosteoblast is derived from a number of observations. In vivo, 
culture of bone marrow in diffusion chambers, impermeable to cells, provided 
some of this evidence (Friedenstein, 1966). These experiments resulted in the 
formation of bone within the chambers suggesting it was of donor rather than host 
origin. The osteogenesis and chondrogenesis occurring within these chambers was 
indistinguishable from the processes that took place within the skeleton (Ashton et 
al, 1980). In addition, from studies on presumed stromal marrow stem cells within 
fibroblastic colony forming units (CFU-F), colony-forming cultures have been 
established and cloned from single cell suspensions (Friedenstein et al, 1987). The 
transplantation of these colonies under the renal capsule of syngeneic partners gives 
rise to the entire stromal system of bone. Karyotype analysis of recipient stroma in 
these experiments excluded their participation. Further evidence for their bone 
marrow stroma origins comes from the fact that osteoblast-like stromal cell cultures 
and cell lines can be derived from primary bone marrow cultures (Kassem et al,
1989).
The above evidence would therefore suggest that osteogenic cells are likely to be 
derived from a pluripotent stem cell, derived from the CFU-F within the bone 
marrow, which also gives rise to chondroblasts, fibroblasts, adipocytes and 
marrow reticular cells (Owen, 1985).
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I.8(v) Osteoblast culture systems
A number of in vitro systems have been developed to study the behaviour of 
osteoblasts, and these have been phenotypically characterized for the presence of 
osteoblastic features. These include cell morphology, production of type I collagen, 
non collagenous matrix proteins and alkaline phosphatase, mineralization, in vivo 
osteogenesis, and responsiveness to osteotropic factors.
I.8(v)a Rodent organ cultures
This system allows the study, primarily using foetal or neonatal rodent bones, of 
osteoblasts in situ in their natural environment. It has been used to study matrix 
synthesis, particularly collagen (Canalis, 1983), but has a major drawback 
regarding the study of osteoblast function owing to the heterogeneity of the cell 
populations present.
I.8(v)b Osteoblast cells from rodent calvariae
Peck et al (1964) demonstrated that collagenase digestion of rodent calvariae 
produced cells expressing phenotypic characteristics of osteoblasts. Although 
heterogeneous populations of cells were derived from this technique, Wong and 
Cohn (1974) demonstrated that the purity of osteoblasts could be improved by 
sequential digestion. In addition, the purity can be improved even further using 
preparative dissection and cell separation techniques (Peck et al, 1977; Wong, 
1982). These preparations have been utilised to study osteoblast function, but their 
usefulness in culture is only finite as defined by a decrease in osteotropic hormone 
responsiveness (Rao et al, 1977) and a fall in the type I /type III collagen ratio 
(Scott et al, 1980).
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I.8(v)c Transformed osteoblast-like cell lines
Although osteoblast-like cell lines have been derived from normal embryonic rodent 
bone and bone marrow, the majority of cloned lines are derived from rodent and 
human osteosarcomas. The major advantages of these cells is that they are "  
immortal, grow rapidly and are fairly homogeneous with regard to phenotype. 
Rodent cell lines include the UMR and ROS series. The UMR cells have been 
shown to demonstrate responsiveness to osteotropic hormones, express high levels 
of alkaline phosphatase (Crawford et al, 1978; Partridge et al, 1981) and exhibit the 
ability to form mineralized nodules (Martin et al 1976; Underwood et al, 1979). In 
addition to these characteristics the ROS cells also synthesize type I collagen (Aubin 
etal, 1982) and osteocalcin (Price and Baukol, 1980). However, despite expressing 
a number of osteoclastic characteristics, no single line demonstrates a complete 
osteoblast phenotypic profile. Another disadvantage is that these transformed cells, 
by their very nature, are not under the same control as their untransformed 
counterparts and therefore will express abnormal functional or phenotypic 
characteristics which may not reflect normal bone cell activity (Rifas et al, 1989).
I.8(v)d Human explant cultures
The use of rodent-derived osteoblast-like cell lines in the study of human bone 
metabolism probably has limited use, since even in closely related species such as 
rat and mouse, differences in hormone responsiveness have been described (Wong 
et aU 1977). Therefore human models have been developed, such as the culture of 
osteoblasts from explants of human bone. The advantages of this system is that it is 
simple and many cells are produced which express osteoblastic characteristics. The 
main disadvantages, however, are that the cells are slow growing and despite the 




I.8(v)e Transformed human osteoblast cell lines
To overcome the problems of phenotypic heterogeneity, some groups have 
attempted to immortalize osteoblast-like cells, from these explant cultures, to 
produce homogeneous populations of osteoblast-like cells (Keeting et al, 1992, 
Williams et al, 1990). In our laboratory cultured osteoblasts were transfected with 
S V-40 DNA to produce a number of cell lines that express a variety of osteoblastic 
characteristics to varying degrees (Williams et al, 1990). These included 1,25E>3- 
induced expression of osteocalcin, alkaline phosphatase expression and the 
production of mineralised nodules. Although these cell lines provide an excellent 
model for studying osteoblastic function, the major disadvantage is that they appear 




It was first proposed by Kolliker in 1873 that osteoclasts were the cells responsible 
for bone resorption. The mature multinucleated osteoclast is a very large cell, 
which can be up to 100 pm in diameter. The number of nuclei per cell, usually 
between 10 and 20, can vary between 2 and 100. They are usually located centrally 
within the cytoplasm and contain either one or two nucleoli. The abundant 
cytoplasm of the osteoclast can show variable staining, ranging from basophilic in 
some cells to chromophilic or eosinophilic in others. It contains many organelles 
characteristic of its resorptive role, including abundant mitochondria, lysosomes, 
free ribosomes and golgi apparatus. Baron et al (1985) noted that one of the most 
consistent morphological features of the osteoclast is the perinuclear distribution of 
the Golgi. In-vivo , osteoclasts are most often situated directly apposed to the bone 
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Fig 1.2. The upper figure shows some of the morphological characteristics of the 
multinucleated osteoclast. The lower figure illustrates, in a simplified diagram, 
some of the biochemical processes involved in osteoclastic resorption.
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beneath the periosteum on the periosteal side. They are very scarce in normal adult 
bone, but the numbers rise sharply if they are activated by bone-resorbing factors. 
In normal circumstances the largest number of osteoclasts can be found in the 
metaphyses of growing bone. ~
1.9(h) Bone resorption 
The principal function of the osteoclast is the resorption of bone and it is only 
recently that the mechanisms involved with this process have been elucidated. After 
the cell has become attached to the bone an acidic micro-environment is created 
beneath it to solubilize the mineral content of the bone. The organic matrix is 
degraded by the exocytosis of lysosomal hydrolases and proteases (Blair et al,
1986), which also serve to maintain the exposure of the calcified material. Thus one 
cell type is capable of resorbing all the components of bone.
I.9(ii)a Energy Requirements
The resorptive function of the osteoclast requires energy which is derived from the 
production of ATP. It has been demonstrated by enyme histochemistry that 
resorbing osteoclasts utilize fatty acid metabolism as a source of acetyl-CoA for the 
Krebs' cycle. In addition, utilisation of glucose for energy and for biosynthesis 
does not occur in these cells (Dodds et al, 1992). These observations suggest that 
the shutdown of glycolysis for energy, and of the pentose phosphate shunt for 
biosynthesis may demonstrate the final step in osteoclast differentiation and their 
commitment to resorption.
I.9(ii)b Attachment to the bone surface
The most characteristic features of the osteoclast, detected most easily at the level of 
the electron microscope, are the ruffled border and surrounding clear zone.These 
are specialised structures which form the resorbing system of the osteoclast and are 
unique to these cells. They are polarized to the apical pole of the plasma membrane
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immediately apposed to the bone surface. The ruffled border is composed of fine 
finger-like projections forming small channels that extend to the bone surface. It is 
this area that is responsible for the resorption of bone. The resorptive area is sealed 
off from the surrounding extracellular space by the clear, or sealing, zone. This 
maintains a suitable micro-environment, beneath the ruffled border, for the action 
of resorptive agents. The clear zone, so named because of its lack of organelles, lies 
in direct apposition with the bone surface, contains contractile proteins (King and 
Holtrop, 1975; Marchisio et al, 1984), and is responsible for anchoring the 
osteoclast to the bone.
I.9(ii)c The role of plasminogen activator (PA) in osteoclast resorption
Experimental evidence suggests that the PA-plasmin system may play an important 
role in osteoclast resorption by removing the layer of collagen on the bone surface 
which separates the osteoclast from the bone mineral (Chambers et al, 1985). There 
are two major classes of PA termed tissue-PA and urokinase that are 
immunologically and genetically distinct molecules. These are responsible for 
converting plasminogen to plasmin, an enzyme that plays an important role in 
fibrinolysis and converts procollagenase into active collagenase (Werb et al, 1977). 
The latent collagenase is synthesized by osteoblasts in the bone environment 
(Sakomoto and Sakomoto, 1984) and is cleaved by the plasmin to form active 
enzyme that allows the osteoclast to attach to, and dissolve the mineral of the bone. 
In addition, the production of tissue-PA from normal rat osteoblast-like cells, and 
osteosarcoma cells appears to be increased by the major bone-resorbing factors 
PTH, 1,25D3 and PGE2 (Hamilton et al, 1984, 1986; Allan et al, 1986), suggesting 
that the system is under hormonal control. It has been reported recently that PA of 
both classes are present in rat osteoclasts (Grills et al, 1990), providing more 
evidence for a role in bone resorption for this enzyme system. Other proposed 
functions for the PA system have been suggested by Grills et al (1990), based on a 
number of observations. These include a role in cell motility and also a regulatory
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role which may be important in the coupling of bone formation to resorption. This 
latter proposal is based on data showing that TGFp is capable of inhibiting PA 
activity while also increasing the production of PA inhibitor in osteoblasts (Allan et 
al, 1989). TGFp is a potent stimulator of osteoblast function (Pfeilschifter etttl,
1987; Gehron-Robey et a/,1987) and is released from these cells in a latent form 
(Lawrence et al, 1984). This can be activated by acid pH, which the active 
osteoclast could provide, and proteolysis. Plasmin is capable of this proteolytic 
activation (Lyons et al, 1988), and since PA has been demonstrated in both 
osteoblasts and osteoclasts it is conceivable that both cell populations can contribute 
to the activity of this system in the bone environment.
I.9(ii)d Acidification of the resorption compartment
Baron et al (1985) demonstrated that the resorption compartment was acidic and that 
the osteoclast was actively responsible for this acidification. The protons required 
for this process are generated by carbonic anhydrase II from CO2 and H2O. 
However the the identity of the proton pump responsible for their release has still to 
be confirmed. The presence of a 100 kD lysosomal membrane protein on the ruffled 
border of the osteoclast has been identified, using a monoclonal antibody that 
recognizes the 100 kD proton/potassium ATPase purified from gastric mucosa 
(Baron etal, 1985).This group therefore concluded that the local acidification was 
due to the secretion of protons via a proton pump ATPase of the gastric type. While 
some groups have suggested that they are of the vacuolar type (Blair et al, 1989; 
Bekker and Gay, 1990; Vaananen et al, 1990), recent work suggests that the proton 
pumps associated with osteoclast membrane constitutes a new class (Chatteijee et 
al, 1991). This has been summised from the observation that in addition to the the 
vacuolar pump inhibitors Bafilomycin A, N-ethyl maleimide and DCCD, 
acidification could also be inhibited by the potassium ATPase inhibitor, vanadate.
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The basolateral portion of the osteoclast membrane has an important role to play in 
the maintenance of intracellular pH during bone resorption. It contains the 
chloride/bicarbonate exchanger, which removes bicarbonate ions from the 
cytoplasm. These are a by-product of the reaction, catalysed by carbonic anhydrase, 
to produce protons (Teti et al, 1989; Hall and Chambers, 1989). In addition there is 
also an enrichment of the sodium pump [(Na+, K+)ATPase] in this membrane 
(Baron et al, 1986). the sodium pumps may be involved in secondary active 
transport of calcium and/or protons in association with Na+, Ca++ exchanger and or 
Na+, H+ antiport.
I.9(ii)e Lysosomal enzymes
The majority of the enzymes within the osteoclast are found mainly in elements of 
the exocytic rather than the phagocytic pathway (Baron et al, 1985,1989). They are 
localised in the endoplasmic reticulum, the golgi and in vesicles. Baron et al (1988) 
demonstrated the presence of one of these enzymes, cathepsin C, in the bone 
resorbing compartment, by immunocytochemistry. Thus they provided direct 
evidence to show that osteoclasts secrete enzymes into this area. The process of 
delivery of these secretory enzymes is different in osteoclasts to that of most cells 
(Baron et al, 1989). Rather than targeting them to an intracellular organelle, the 
osteoclast secretes the enzyme directly. The enzyme is transported from the golgi in 
small vesicles bound to the mannose-6 phosphate receptor. The vesicles bind to the 
apical membrane and the enzyme is released into the acidified resorption space.
1.10 Osteoclast phenotypic markers
A number of enzymes can be demonstrated in osteoclasts that have been used as 
selective markers for this cell type. The most characteristic of these is tartrate- 
resistant acid phosphatase (TRAP) which although of unknown function has been 
regarded as specific for this cell type. More recently however, TRAP activity has 
been demonstrated in some macrophages (Efstratiadis and Moss, 1985). Carbonic
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anhydrase isoenzyme II (Gay et al, 1984) is also thought to be selective for 
osteoclasts. The importance of this enzyme in osteoclast function has been 
demonstrated, since a deficiency of it has been identified in an autosomal recessive 
form of osteopetrosis in association with renal acidosis (Sly et al, 1983, 1985). 
Baron etal, 1986 suggested that the immunocytochemical demonstration of the 
(Na+,K+)ATPase on osteoclasts was a good phenotypic marker. They showed a 
marked enrichment of the sodium pumps which they could not demonstrate on 
macrophages or monocytes. In contrast however, Vignery et al, (1989) provided 
evidence that macrophage polykaryons did in fact express high levels of polarized 
sodium pumps.
Plasma membrane antigens have been used to try to delineate the osteoclast 
phenotype. Monoclonal antibodies reactive against different haemopoietic cell lines 
have been extensively utilised to try to demonstrate a common ancestry. Shared 
reactivity has been shown with antibodies from panels raised against cells of the 
monocyte/macrophage (Athanasou etal, 1986; Athanasou and Quinn, 1990), 
granulocyte (Athanasou et al, 1988) and megakaryocyte/platelet lineages 
(Athanasou et al, 1986, 1988). Whether the presence of shared antigens indicates a 
common origin for these cell types is a matter for debate and is discussed below. 
Osteoclast-selective monoclonal antibodies have also been utilised (Horton et 
al, 1985; Oursler et al, 1985; Nijweide et al, 1985; Kukita and Roodman, 1989) in 
an attempt to identify the osteoclast precursor and to delineate the ontogenic 
pathway of these cells. Two of these monoclonal antibodies, 23C6 and 13C2 
(Horton etal, 1985), recognize different epitopes on the a chain of the vitronectin 
receptor. The production of a monoclonal antibody against the J33 chain of this 
receptor is described in this thesis. It has been suggested that the vitronectin 
receptor is a good marker for mature osteoclasts in bone, since other bone and 
marrow cells do not express this antigen (Horton 1990). Recent work in our 
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Table 1.2 Osteoclast phenotypic markers and their selectivity for this cell type.
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suggests that osteoclasts and osteoblasts express different integrin subunits (Clover 
et aly submitted). Osteoclasts appear to express a2, aV, pi and p3 integrins while 
osteoblasts express a l, a3, pi and occasionally a2. The different integrin 
expression may control ligand binding in the bone environment and this in turn may 
control cell behaviour in such functions as bone remodelling.
The calcitonin receptor is the only hormone receptor that has been definitively 
demonstrated on the surface of osteoclasts (Warshawsky et aly 1980). Kurihara et 
aly (1990) have recently utilised a number of osteoclast phenotypic markers in an 
effort to delineate the cellular events that occur during the process of osteoclast 
differentiation. They used antibodies against the vitronectin receptor and the 
vacuolar proton pump, as well as autoradiography with 125I labelled calcitonin to 
demonstrate its receptor. They showed in osteoclast-like cells from human long­
term marrow cultures that 30% of early precursors reacted with the 23C6 antibody. 
None of these cells demonstrated calcitonin receptors or the presence of amplified 
proton pump expression. These latter markers were first detected in the late 
precursors which all reacted with 23C6. All the multinucleated cells formed from 
the late precursors reacted with 23C6 and expressed amplified proton pump 
reactivity. In addition 80% of these cells also demonstrated calcitonin receptors.
1.11 The origin of the osteoclast 
The origin of the mononuclear osteoclast precursor is unknown. Evidence suggests 
that this elusive cell is derived from haemopoietic tissue (Kahn and Simmons 1975; 
Walker 1975; Jotereau and Le Douarin 1978; Ash et al 1980) and more specifically 
from cells of the mononuclear phagocyte lineage (Mundy and Roodman, 1987). In 
contrast other groups have suggested that the osteoclast and cells of the monocyte / 
macrophage lineage arise from different stem cells and differentiate along separate 




I .ll( i)  Monophyletic origin of bone cells
Bloom et al (1941) supported the theory that bone cells were derived from a~  
common precursor and for twenty years this concept influenced the interpretation of 
results obtained for bone cell differentiation. It was suggested by Tonna (1966) that 
the nuclei of the mature multinucleated osteoclast were derived from osteoblasts and 
Rasmussen and Bordier (1974) extended this theory by suggesting that osteoclast 
formation was reversible and that they could revert back to their former osteoblastic 
phenotype. However, it has now been demonstrated that the two cell types have 
different origins: osteoblasts from mesenchymal and osteoclasts from haemopoietic 
precursors.
I.lH ii) Haemopoietic origin of osteoclasts
More recently opinion has changed to support the idea that osteoclasts are derived 
from the fusion of haemopoietic precursors and much of the evidence for this is 
derived from the following experiments.
1.11 (ii)a Parabiosis experiments
In the early 1970s Gothlin and Ericsson (1973) performed experiments in which 
inbred rats were joined to each other via skin flaps to establish common blood 
circulation. One of the pair was subsequently irradiated to destroy its haemopoietic 
tissue and the other shielded. Both animals had their right femurs fractured and 
their cross circulation was arrested while ^H-thymidine was injected into the 
shielded partner. The cross-circulation was re-established after 20 minutes and 
between days 7 and 28 the parabiotic pairs were killed and their fracture callouses 
examined by autoradiography and electron microscopy. The shielded rat 
demonstrated the presence of the radiolabel in both osteoblasts and osteoclasts 
while its irradiated partner only showed labeled osteoclasts. Similar experiments
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have utilised implantation of bone matrix into the parabiotic rats instead of femoral 
fractures (Buring, 1975). Again, only the shielded rats demonstrated label in both 
populations of cells. Both sets of experiments thus indicate that osteoclasts may be 
derived from a blood-borne precursor. ~
I.ll(ii)b Chimera experiments
Chick-Quail chimeras have been used to study the origins of bone forming and 
resorbing cells (Kahn and Simmons, 1975; Jotereau and Le Douarin, 1978) based 
on morphological differences in the nuclei of the two species. Embryonic quail or 
chick long bones were grafted into the chorioallantoic membranes of the opposing 
species and the origin of the cell nuclei assessed. In experiments in which the grafts 
were implanted before the onset of myelogenesis the osteoblastic and osteocytic 
populations both demonstrated donor nuclei morphology. In contrast, the 
osteoclasts present demonstrated only host nuclei. If bone containing myeloid tissue 
was grafted, the osteoclasts initially demonstrated nuclei of both species. However, 
as the donor marrow in the graft was replaced with host marrow, so the osteoclasts 
began to demonstrate more nuclei of the host until, finally, all nuclei were of host 
origin. Similar experiments have also been carried out using embryonic mouse bone 
in a similar system to that described (Thesingh and Burger, 1983). Both groups 
demonstrate different origins for the osteoblastic and osteoclastic cells and point to 
a haemopoietic precursor for the latter population.
I.ll(ii)c Osteopetrosis
Osteopetrosis is a condition characterized by systemic skeletal bone accumulation 
caused by a deficiency in osteoclastic resorption (Marks and Walker, 1976; Marks, 
1983). In certain strains of mice this condition can be reversed either by parabiosis 
with a normal littermate (Walker, 1972; Walker, 1973) or by transfusion of normal 
bone marrow or spleen haemopoietic cells into irradiated mutants expressing the 
disease (Walker, 1975). The donor origin of the resultant osteoclasts has been
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demonstrated by utilising cells expressing characteristic structural markers such as 
the giant lysosomes of the beige mouse (Ash et al, 1980). Similarly, female 
osteopetrotic mice have been transfused with marrow from normal male siblings 
and Y-body analysis of the resultant osteoclasts has shown them to be of donor 
origin (Coccia etal, 1980; Sorell etal, 1981). These data provide direct evidence 
for a haemopoietic origin for the osteoclast.
1.11 (Hi) Osteoclasts and the monocvte/macrophage lineage 
Since the strongest evidence supports the theory that osteoclasts are derived from 
haemopoietic tissue it has been suggested from a number of observations and 
experimental findings that the most likely candidate for their precursors are stem 
cells of the monocyte/macrophage lineage (reviewed by Mundy and Roodman,
1987). Despite this evidence, however there are those who have suggested from 
their own observations that the osteoclast is not derived from cells of this lineage 
(Loutit etal 1981; Loutit and Nisbit, 1982; Chambers and Horton, 1984; Horton et 
al 1984; Chambers, 1985; reviewed by Chambers, 1989).
It has been observed that osteoclasts and monocytes are enzymatically very active 
cells with abundant acid hydrolases to fuel their catabolic activities (Doty and 
Schofield, 1972). Similarly, like osteoclast precursors, which form multinucleated 
cells in response to signals at the bone surface, monocytes are also capable of 
forming polykaryons in response to the appropriate stimuli. Amongst normal cells 
the ability to form polykaryons is almost unique to these two populations. Despite 
this similarity there are obvious functional differences between the osteoclast and 
the macrophage. For example, it has been demonstrated that unlike bone marrow 
transfusions, the infusion of mature macrophages alone were incapable of restoring 
bone resorption in osteopetrotic (ia) rats and (mi) mice (Loutit and Nisbet, 1982; 
Schneider and Byrnes, 1983). Similarly, while it has been shown that calcitonin is 
able to induce functional quiescence in osteoclasts, it has no detectable effect on
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monocytes or macrophages (Chambers and Magnus, 1982). The outstanding 
structural features of the osteoclast are the ruffled border and clear zone which are 
not demonstrable in either the monocyte or the multinucleated macrophage 
polykaryon. As a result these latter cells are incapable of forming Howship 
resorption lacunae on devitalised bone slices (Chambers and Horton, 1984). 
Conversely, unlike monocytes or macrophages, the mature osteoclast lacks 
receptors for either complement C3b or the Fc portion of IgG (Horton et a/,1984). 
To counter this argument, Mundy and Roodman (1987) suggest that the above data 
merely indicate that the osteoclast is not derived from mature macrophages.
Loutit et al (1981) reported that marrow from W/Wv mice, which are thought to 
have a haemopoietic stem cell deficiency, was capable of restoring normal 
osteoclastic activity when transfused into osteopetrotic mice. Again, Mundy and 
Roodman (1987) try to balance this argument and claim that the defect in this strain 
is predominantly one of erythroid precursors with decreased numbers of stem cells. 
However, blood counts indicate normal leukocyte and platelet parameters 
suggesting to these authors that the results of Loutit et al (1981) are insufficient to 
exclude an osteoclast precursor of monocyte/macrophage origin.
An association between osteoclasts and monocyte/macrophages has been suggested 
on the grounds of shared antigenic determinants as demonstrated by 
immunocytochemistry. Monoclonal antibodies raised against osteoclasts have also 
been shown to react with cells of the monocyte macrophage lineage. (Oursler et al, 
1985; Nijweide et al, 1985). Conversely, some antibodies raised against cells of the 
monocyte/macrophage lineage also demonstrate cross-reactivity with osteoclasts 
(Athanasou et al, 1986). However these data could be be interpreted to mean that 
the cells merely possess a number of shared structures or functions rather than 
shared ontogenic pathways.
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There are experimental data to suggest that osteoclasts may be derived from the 
monocyte lineage based on observations using labelled leukocytes. As far back as 
1962 Fischman and Hay showed that regenerating newt limbs were populated with 
osteoclasts formed from previously labelled blood leukocytes that histologically 
resembled monocytes. Consistent with this Jee and Nolan (1963) showed that intra- 
arterially injected carbon particles that were initially demonstrable in monocytic 
phagocytes were later detected in osteoclasts. Also, experiments have been carried 
out using either radio-labelled peripheral blood white cells (Tinkler et al, 1981) or 
those with identifiable Barr bodies (Stanka and Bargsten, 1983), and these markers 
have subsequently been detected in the osteoclast population. These data could be 
interpreted differently. For example, in the carbon uptake experiments of Jee and 
Nolan (1963) there was a 12 day time lag between detecting the particles in the 
macrophages and then the osteoclasts. The appearance of the particles in the 
osteoclasts could have been due to particle release from the macrophages and, 
phagocytic re-uptake by the osteoclasts. A similar theory could explain the 
parabiosis experiments of Gothlin and Ericsson (1973) in which a time period of 3- 
4 weeks elapsed before the detection of thorium in the callous osteoclasts. 
Macrophage release and osteoclast re-uptake could easily explain the presence of the 
label in these latter cells. Experiments using labelled leukocytes, in which the 
authors suggest monocytes as the potential source of osteoclast precursors could be 
interpreted differently. For example, although the experiments of Tinkler et al 
(1981) showed incorporation of ^ H-thymidine in osteoclasts after infusion of 
labelled leukocytes, the actual numbers were relatively low. In further work by this 
group, osteoclast numbers were induced to rise in animals in which 60% of the 
leukocytes were radiolabelled. However the amount of label detected in the 
osteoclasts was still as low as 4% (Tinkler et al, 1983).These results do not 
resemble the kinetics of monocyte emigration to an inflammatory site (Chambers, 
1989), and that the precursors do not immediately contribute to the osteoclast nuclei 
but rather there is a long maturational delay before they can be detected. Although
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the results from these labelled leukocyte experiments indicate that a cell type injected 
within the leukocyte population does eventually contribute to the formation of 
mature osteoclasts they do not give any indication of the cell type responsible for 
their formation. —
Other experimental data which have been used to establish a link between the 
osteoclast and macrophage lineages includes the dissolution of bone particles by 
this latter population (Teitelbaum, 1979). However, this procedure involves the 
phagocytic internalisation of the particles which is a totally different process to the 
extracellular excavation of bone which is the characteristic function of osteoclasts. It 
has already been noted that the monocyte/macrophage cells do not possess a ruffled 
border, which is a prerequisite for the successful excavation of bone.
In an in-vitro co-culture system, developed by Burger etal (1982, 1984), 
osteoclast formation could be detected when CSF- stimulated mouse bone marrow 
cells were subsequently co-cultured with periosteum-stripped mouse bone 
rudiments. This foetal bone was initially osteoclast-free but became populated with 
osteoclasts derived from cells with the histological appearance of immature 
monocytes. It could be argued, however that the small number of osteoclasts 
formed (100 polykaryonic nuclei) from a relatively large number of cells (5x10s 
per bone rudiment) may have been due to a minor contaminating population of cells 
within the immature mononuclear phagocyte population.
A direct link between monocytes and osteoclasts has also been suggested from a 
number of morphological studies in which the formation of osteoclasts is detected 
in bone sections. Histologically identifiable monocytes have been detected both 
before and during osteoclast formation and it is claimed that transitional cells, 
containing markers of both cell populations, can also be detected (Luk et a/,1974; 
Rifkin et al, 1979; Baron et al, 1986). The most recent of these studies by Baron et
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al suggest that prior to the formation of mature osteoclasts there are monocytes 
present expressing fluoride-inhibitable non-specific esterase, which is a known 
marker enzyme for this lineage. This is followed by the appearance of cells 
expressing both this enzyme and a marker enzyme for osteoclasts called tartrate- 
resistant acid phosphatase. Immediately prior to the formation of the mature 
multinucleated osteoclast there is an accumulation of cells only expressing the latter 
enzyme. This data would seem to imply a strong relationship between the two 
lineages and suggests that an immature cell of the mononuclear phagocyte lineage is 
indeed the osteoclast precursor.
An interesting serendipitous observation with regard to osteoclast function and their 
link to the monocyte /  macrophage lineage has been made regarding the c-src proto­
oncogene (Soriano et al, 1991). These authors recently demonstrated that targeted 
disruption of the gene encoding for this proto-oncogene leads to osteopetrosis in 
mice with impaired osteoclast function. This effect on osteoclasts was unexpected, 
although it has been demonstrated that differentiating monocytes show elevated 
levels of src activity (Bamekow and Gessler, 1986; Gee etal, 1986). The highest 
levels however are expressed in the central nervous system and in platelets, but no 
abnormalities were observed in these tissues. It was suggested that the overlap in 
function of different members of this family may explain why a malfunction of 
these tissues was not seen. Baron etal {1991) have shown by immunolocalization, 
using an m\\-c-src monoclonal antibody, that in the chicken and rat, osteoclasts are 
the only bone cells that express this proto-oncogene. They also demonstrated that 
expression of c-src was associated with the in-vitro differentiation of chick 
osteoclasts from bone marrow macrophages in the presence of 1,25 
dihydroxyvitamin D3.
The human long-term marrow culture system has been used to demonstrate that 
when non-adherent bone marrow cells are cultured with GM-CSF they yield
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committed progenitor cells (CFU-GM). If 1,25D3 is added to this there is an 
increased formation of cells that bind Mab 23C6 (Kurihara etal, 1990,1991)which 
binds to the vitronectin receptor and is selective for osteoclasts in bone (Horton et 
al, 1985; David et al, 1986). In addition these cells contract in response to calcitonin 
and approximately 20% will resorb pits in bone slices. These data would suggest 
that the osteoclast precursor is derived from the colony-forming unit-granulocyte, 
macrophage (CFU-GM). This is supported by the the work of Schneider and 
Relfson (1988) who observed that enriched populations of GM-colony forming 
cells (CFU-GM) from normal animals were effective in curing the osteopetrotic 
disease of ia rats. This effect was probably due to the formation of osteoclasts from 
the adoptive transfer of their precursors.
The evidence to date would suggest that although mature monocytes and 
macrophages cannot function or develop into osteoclasts they may share a common 
origin from the CFU-GM (Mundy and Roodman, 1987)
1.12 In-vitro models of osteoclast differentiation
In order to study and understand the steps involved in the differentiation and 
maturation of the multinucleated osteoclast it has been necessary to devise suitable 
in-vitro models in the absence of a suitable osteoclast cell line.
I.12(i) Isolation of osteoclasts
A number of methods have been devised to release osteoclasts from the long bones 
of chicks (Osdoby et al, 1982), rats (Chambers and Magnus, 1982) and rabbits 
(Chambers et al 1984). However, the viability of these cells is often poor. 
Zambonin-Zallone et al (1982) improved the situation by isolating medullary bone 
osteoclasts from hens maintained on a low-calcium diet. The osteoclasts were 
enriched further on albumin gradients and this yielded preparations containing 
approximately 95% osteoclasts that could be kept in culture for up to 3 weeks.
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Methods employing enzymatic digestion or selective digestion of rodent calvariae 
have also been used to try and improve the viability of isolated osteoclasts (Dziak 
and Brand, 1974; Wong et al, 1977; Peck et al, 1977). Cells fulfilling osteoclastic 
criteria were obtained in this way but many that do not were also present in these 
preparations. Recently, a method utilising magnetic beads coated with osteoclast- 
specific monoclonal antibody has been used to purify avian osteoclasts (Collin- 
Osdoby et al, 1991). This method yields 100-fold enrichment and greater than 90% 
purification of osteoclasts from subpopulations of either predominantly nonviable 
or viable osteoclasts. A potential drawback of this technique is that the binding of 
the plasma-membrane reactive antibody may cause antigen activation analogous to 
receptor-ligand responses. This may make studies of physiological responses of 
osteoclasts difficult on cells isolated in this way. Using osteoclasts derived from 
various sources, including human osteoclastomas (Horton et al, 1984) it has been 
possible to study the effects of various osteotropic hormones on osteoclastic 
function. However, little information concerning differentiation is obtained from 
osteoclasts isolated in this way.
I.12(ii) Organ culture systems
This system allows the study of the effects of various added agents on osteoclastic 
bone resorption (reviewed by Stem and Raisz, 1979). For example, 45Ca labelled 
calvariae from neonatal mice are placed on a wire mesh in medium containing the 
appropriate factor. The effect on resorption is calculated by measuring the amount 
of 45Ca released into the medium relative to the amount present in the bone 
fragments. This system has a number of potential drawbacks; although it has 
permitted the identification of various promoters and inhibitors of bone resorption it 
gives no information concerning osteoclastic differentiation, and the information 
derived from neonates may not reflect what occurs in the adult Because this system 
includes all the cell types present in the calvariae it is not possible to whether a 
factor works directly on the osteoclast or indirectly through a another cell.
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Burger etal (1982) developed a co-culture system which utilised bone rudiments 
stripped of their periosteal layer and putative osteoclast precursors to study 
osteoclast ontogeny. This has proven to be an excellent model, but has a major 
shortfall in that the evaluation of osteoclast formation is carried out on fixed paraffin 
embedded tissue.
I.12(iii) Bone marrow culture systems
A major breakthrough came in the early 1980s when the bone marrow culture 
system was developed and was used by Testa et al (1981) to demonstrate the 
formation of osteoclast-like cells using feline bone marrow cells. Other groups have 
since used this system to demonstrate osteoclast-like cell formation using other 
mammalian bone marrow sources such as baboon (Roodman, 1985), human 
(MacDonald et a l , 1987) and mouse (Takahashi et al, 1988).
Using the bone marrow culture system it is believed that mature osteoclasts form 
from their mononuclear progenitors under suitable conditions. The osteoclast-like 
cells demonstrate a number of characteristics which fulfil accepted criteria for 
mature osteoclasts such as the excavation of pits in dentine, tartate-resistant acid 
phosphatase activity and the induction of quiescence in response to calcitonin. In 
addition, these cells have exhibited reactivity with monoclonal antibodies selective 
for the osteoclast phenotype such as 23C6 (Horton et a l , 1985) and latterly KN22 
(Kukitaeftf/, 1989).
1.13 Requirements for osteoclast differentiation in in-vitro systems
The types of in-vitro systems described have been used extensively in recent studies 
to try to understand the origin and development of the mature osteoclast from its 
mononuclear precursor. However, rather than resolving the issue the results from 
these studies are often contradictory with regard to the requirements for the
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formation of osteoclasts. Some systems appear to support the formation of 
osteoclasts without the requirement of other cells (such as osteoblasts) while in 
others the presence of these cells is essential for osteoclast formation. The examples 
below illustrate this point. —
I.13(i) Co-culture systems
Burger et al (1982, 1984), who pioneered the co-culture system, demonstrated the 
formation of osteoclasts from mouse bone marrow-derived haemopoietic precursors 
when cultured on live bone rudiments. When they repeated these experiments using 
devitalised bone rudiments no osteoclast formation was observed. Thus, they 
hypothesized that living bone cells were an absolute requirement for osteoclast 
development.
In support of this hypothesis Kurihara et al (1989) showed that osteoclast-like cells 
could be formed from the haemopoietic blast cells derived from 5-fluorouracil 
treated mice (enriches the number of quiescent primitive stem cells in the spleen) 
that had been co-cultured with IL-3 or GM-CSF in the presence of 1,25D3. Despite 
the presence of TRAP activity and calcitonin receptors, these cells were incapable of 
excavating resorption pits in devitalised bone. When co-cultured on embryonic 
mouse calvariae the multinucleated cells demonstrated resorptive activity and the 
presence of a ruffled border and clear zone. In addition, this group have since 
demonstrated that the blast cell population possess receptors for both 1,25D3 and 
PTH (Hakeda et al, 1989).
I.13(ii) Human long-term marrow cultures
The human long-term marrow culture system has recently been further refined to 
allow the identification of the committed osteoclast precursor (Kurihara,1990,
1991). In this model isolated haemopoietic stem cells are cultured in the presence 
GM-CSF in semi-solid medium to form GM-CFUs. These putative osteoclast
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precursors are overlayed with bone resorbing agents such as la ,25 - 
dihydroxyvitamin D3, IL-1, IL-6 or PTH and following further culture produce 
late precursor cells with a distinct polygonal morphology. These cells differentiate 
into mature osteoclast-like cells upon further culture, demonstrating morphological 
and functional characteristics of osteoclasts.These observations raise points worthy 
of comment. First, the early precursors formed in this system were capable of 
differentiating into both osteoclast-like cells and macrophages while the late 
precursors only differentiated into the osteoclast-like cells. Osteoclast-like cell 
formation could be stimulated by 1,25D3, EL-ip and IL-6 in both the early and late 
precursors, but only the early precursors were affected by PTH. Finally, in contrast 
to the co-culture system, this model is capable of supporting the formation of 
osteoclast-like cells in the absence of osteoblastic cells.
I.13(iii) Human leukemic cell lines - HL-60 cells 
Other in-vitro systems have also been used to study human osteoclast ontogeny. 
Recently, Yoneda et al (1991) described the use of the human promyelocytic HL-60 
leukaemia cell line. Although at an arrested state of differentiation, under 
appropriate conditions the wild type HL-60s could be induced to differentiate into 
multinucleated cells with many of the accepted characteristics of mature osteoclasts. 
This model may have a number of advantages over other in-vitro systems, such as 
the availability of large numbers of human osteoclasts free of contamination with 
osteoblasts and stroma and also the ability to dissect and study cells at each step of 
their differentiation pathway.The major drawbacks are that complicated 
manipulations are required to induce osteoclast formation and only a small number 
of resorption pits are formed by these cells i.e 10 pits/105 cells (Yoneda et a l , 
1991). This model appears to be capable of supporting the differentiation of 
osteoclast-like cells without the requirement for osteoblastic cells.
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I.13(iv) Human leukemic cell lines - FLG 29.1 cells 
FLG 29.1 are cells derived from a human monoblastic leukemia that can be induced 
to form osteoclast-like cells in the presence of the phorbol ester 12-0- 
tetradecanoylphorbol 13-acetate (TPA). In their differentiated form these cells, 
express a number of osteoclastic characteristics, such as multinucleation, TRAP 
activity, calcitonin receptors and the ability to degrade 45C-labelled bone particles. 
They are however, devoid of ruffled border and clear zones and are thus unable to 
form resorption pits in dentine slices (Gattei et al, 1992). The formation of these 
osteoclast-like cells proceeds without the requirement of osteoblastic cells.
1.14 Monoclonal antibodies 
In 1975 Kohler and Milstein first described the in vitro production of monoclonal 
antibodies from the fusion of spleen cells, derived from immunized mice, and 
myeloma cells. This revolutionary discovery means that unlimited quantities of 
chemically, physically and immunologically identical antibody can be produced. In 
addition these molecules are unhindered by nonspecificity or cross-reactivity. The 
production of antibody of a desired reactivity is possible even if the antigen is only 
weakly immunogenic or is only a minor part of an antigenic mixture. The major 
requirement is for a screening protocol specific enough to detect the antibody 
reactivity required.
Researchers had strived for many years to produce homogeneous antibody of 
defined specificity and some success was achieved by screening myeloma 
immunoglobulin for reactivity (Potter, 1977). However, this was very cumbersome 
since the reactivity of the myeloma protein was predefined by the disease and not 
adaptable by the researcher. A general method was not available until the advent of 
hybridization to produce continuous cell lines secreting antibody of predefined 
specificity (Kohler and Milstein, 1975,1976).
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In their original experiments, Kohler and Milstein fused a hypoxanthine, 
aminopterin, thymidine (HAT)-sensitive variant of the MOPC-21 myeloma cells 
with spleen cells from mice immunized with sheep erythrocytes. The cell fusions 
were mediated by Sendai virus and were selected in HAT medium. This selection 
procedure (Littlefield, 1964) works by blocking the main pathway of guanosine 
biosynthesis using the folic acid antagonist aminopterin. There is an alternative 
salvage pathway in which the nucleotide metabolites hypoxanthine or guanine are 
converted, in the presence of hypoxanthine guanine phosphoribosyl transferase 
(HGPRT) into guanine monophosphate. If cells are selected, as were the MOPC- 
21 s, for a deficiency in the HGPRT enzyme then they will die in the presence of 
HAT which effectively blocks both pathways. However, if the HGPRT • cells fuse 
with an HGPRT + partner, such as the spleen cells, then they will survive in the 
presence of this selection medium. The overall effect is that unfused myeloma cells 
and myeloma/myeloma fusions will die because of their lack of HGPRT and the 
unfused spleen cells and spleen cell/spleen cell fusions will perish because they are 
incapable of survival in culture. Therefore the only cells to survive should be the 
myeloma/spleen cell hybrids. Since these first experiments the only major 
modifications are that polyethylene glycol has supercede Sendai virus as the fusing 
agent (Pontecorvo, 1976) and that non-immunoglobulin producing variants of 
myeloma cells are used.
The HGPRT_ cells are selected using 8-azaguanine or 6-thioguanine. These toxic 
base analogues are incorporated into the cellular DNA via the HGPRT enzyme thus 
causing the death of HGPRT + cells. Because the salvage pathway is not normally 
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Fig 1.3. This diagram illustrates the steps involved in the formation of hybridomas between 
mouse spleen cells and myeloma cells. The protocol involves the use of myeloma cells that 
do not synthesize their own immunoglobulin and lack the hypoxanthine phosphoribosyl 
transferase (HGPRT) enzyme. The fused hybrids are selected in HAT medium so that the 
unfused myeloma cells and spleen cells die out. The hybrids are cloned and antibody is 
produced in tissue culture or by ascites formation.
6 2
Ch I
1.15 Tissues used for the study
I.15(i) Osteoclastomas 
Because osteoclasts are rarely seen in normal bone an alternative source, containing 
suitable numbers of these cells, was required to obtain the appropriate number 
required for the immunization procedure. This was achieved using osteoclasts 
derived from giant cell tumours of bone or osteoclastomas. This type of tumour is 
defined by the WHO as:
"An aggressive tumor, characterized by richly vascularized tissue consisting o f 
rather plump spindle-shaped or ovoid cells and by the presence of numerous giant 
cells of osteoclast type, which are uniformly distributed throughout the tumor 
tissue."
These are rare neoplasms which most often occur in the third and fourth decades of 
life and most series in the literature show a slight female preponderance 
(Goldenberg et al 1970). Initially they were thought to be uniformly benign lesions 
but they are now known to represent a progressive, potentially malignant process 
that can recur in approximately 50% of cases. A great majority of these tumours 
(80 - 90%) occur near the end of long bones, most frequently at the lower and 
upper ends of the femur, and the upper ends of the tibia and humerus. Over half of 
them occur around the knee (Goldenberg et al 1970; Dahlin et al 1970.) but rarely 
they may occur in the skull, pelvis, small bones of the hands and feet and even 
within the patella.
Although these neoplasms are frequently localised within the ends of long bones 
they may also, rarely, affect the diaphysis. The lesion most often expands from 
the centre of the bone shaft and with this growth gradually causes a club-like 
deformity giving rise to the most common clinical complaints of pain, swelling, 
tenderness and impaired mobility.
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Macroscopically the tumour appears firm and friable with a grey/pink to yellowish 
brown colouration. Commonly there are foci of haemorrhagic necrosis and cystic 
softening. Fine spicules of calcification are also often seen within the soft tissue of 
the tumour, and these are often associated with bone cell activity such as the 
presence of osteoblasts and osteoclasts actively resorbing it.
At the light microscope level, these tumours are composed of mononuclear stromal 
cells which are irregularly interspersed with numerous multinucleated, osteoclast­
like, giant cells. The histogenesis of these latter cells is still unresolved and 
although some groups believe them to be osteoclasts there are still those who 
suggest that they may merely be a syncitial aggregation of the stromal cells and 
prefer the designation of giant cell tumour of bone (GCT).
Goldring etal, (1987) characterized the cells present in giant cell tumours according 
to a number of criteria and found they consisted mainly of three cell types. The 
mononuclear neoplastic cells had fibroblastic morphology and proliferated in 
culture. The second population expressed antigens characteristic of cells of the 
monocyte/macrophage lineage and were incapable of proliferation in culture. The 
final population of multinucleated giant cells expressed phenotypic characteristics of 
osteoclasts including responsiveness to calcitonin. This supported work carried out 
by Chambers etal (1985) who had previously described the calcitonin-induced 
morphological changes and decreased resorption capacity of giant cells cultured 
from giant cell tumours. Horton et al (1985) used human osteoclastoma derived 
giant cells to produce a panel of monoclonal antibodies reactive with a range of 
osteoclastic plasma membrane and cytoplasmic antigens. They demonstrated these 




Osteoclasts are present in normal bone in very low numbers and it has been 
estimated that at any given time approximately 80% of normal bone surfaces_are 
quiescent (Parfitt, 1984). In addition, the success of in-situ techniques such as 
immunocytochemistry have been impeded by the very nature of normal adult human 
bone. Its hard mineralised matrix makes it difficult to section for these techniques 
and this also prevents it from adhering successfully to glass microscope slides. 
Methods using harsh demineralization steps may introduce artifactual results. 
Therefore, in order to check the reactivity of the anti-osteoclast monoclonal 
antibodies against bona fide osteoclasts in human bone it was necessary to obtain 
tissue that expressed abundant numbers of this cell type and was technically easy to 
work with. Dodds and Gowen (submitted) describe, in detail, such a human model 
system that stems from the bony outgrowths characteristic of the osteoarthritic joint. 
Termed osteophytes (Hamerman, 1989) they grow at the margin of the disease 
damaged articular cartilage and consist of cancellous trabeculae and fatty bone 
marrow covered by fibrocartilage, periosteal connective tissue and/or inflammatory 
synovium (reviewed by Jaffe, 1975). They form at points where the remaining 
articular cartilage of the joint merges with the synovial membrane and the 
periosteum. This is an area where multipotential mesenchymal cells are grouped 
(Collins, 1966). Within the developing osteophyte all stages of bone formation and 
its subsequent remodelling can be observed. Using in-situ techniques such as 
immunocytochemistry (Walsh et al, 1991), in-situ hybridization (Dodds et al, 1992; 
Merry et al, 1992; Littlewood et al, 1992) and quantitative cytochemistry (Dodds et 
al, 1992) it has been possible to study bone cells and their differentiation in situ, in 
relation to tissue morphology.
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1.16 Metabolic bone diseases 
Osteoporosis is the most prevalent bone disease in the affluent western world. It is 
characterized by a loss of mineralized bone to such a level that fracture may occur in 
the absence of, or in response, to trivial trauma. There are a number of variants of 
these diseases including juvenile, senile and postmenopausal osteoporosis. The 
latter form is most prevalent in Caucasian women in whom it is estimated 30% will 
suffer at least one osteoporotic fracture in their lives. The scale of the problem is 
enormous. In the USA, for example, there are approximately 300,000 new cases of 
osteoporosis-related hip fractures reported each year, and as such it puts a huge 
financial burden on their health care service. This is exacerbated by the trend 
towards an aged population.
The increased bone loss linked to the menopause is attributed to failure of ovarian 
function and the resultant imbalance between bone formation and resoiption. This 
may result in osteoclasts resorbing more bone than occurs in the normal situation, 
the osteoblast failing to refill the lacunae, or a combination of both events.
Another prevalent erosive bone diseases is rheumatoid arthritis (RA). RA is an 
autoimmune disease of unknown aetiology which is characterized by joint erosion 
in which the architecture of the joint is damaged and there is systemic bone loss. 
Osteoarthritis, in contrast, is characterized by sclerotic bone changes in the joints 
and the formation of osteophytes These are examples of diseases that are 
characterized by aberrant bone cell function in which the osteoclast may be playing 
a major role. It was felt that this study may add to the understanding of osteoclastic 
activity, by providing reagents that recognize functionally important antigens and 
also provide us with the tools for isolating osteoclast precursors. This may provide 
two potential targets for therapy in these diseases; blocking of antigenic function 








The methods described in this chapter are those which have been used extensively 
in more than one section of this work. The recipes for solutions, media etc are 
given in the section at the end of the chapter.
II.l(i) Giemsa.
This was performed using the Diff-Quik slide-immersion technique, normally used 
for the rapid staining of blood smears. The manufacturers claim that the results 
obtained on these preparations are comparable to those of the Giemsa-May- 
Grunwald technique. It was found that apart from cell preparations excellent results 
were also obtained for tissue sections of osteoclastoma and osteophyte.
Air dried preparations of either tissue or Cytospin immobilised cells were repeatedly 
immersed in the methanol based fixative for 5 seconds. Excess fixative was briefly 
drained from the slide onto an absorbent tissue before immersing it, repeatedly, in 
the eosin G-based stain for 5 seconds. After draining the slide, as before, it was 
immersed in the final thiazine stain for a further 5 seconds, drained, rinsed in tap 
water and mounted in a glycerol-based aqueous mountant.
II. l(ii)Tartrate-resistant acid phosphatase (TRAP).
This technique was carried out according to the manufacturers instructions. Tissue 
and cell preparations were fixed in the 0.38 M citrate buffer /  acetone fixative for 30 
seconds, rinsed twice in distilled water and air dried for at least 15 minutes at room 
temperature. Duplicate preparations were screened so that one was placed into 
substrate without tartrate (total acid phosphatase) and one into substrate in the 
presence of tartrate (TRAP). These were incubated at 37°C for 1 hour after which 
time the reaction was terminated by washing the preparations in deionised water for 
3 minutes. The preparations were couterstained with Mayers haematoxylin for 5 
minutes and the colour developed in tap water for a further 2 minutes. The reactivity
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was observed by light microscopy. For culture dishes an inverted microscope was 
used. The presence of acid phosphatase was demonstrated by the presence of a 
maroon precipitate.
Il.l(iii) Preparation of tissue for immunocytochemistry.
Tissue blocks were chilled by precipitate immersion in n-hexane and stored dry at - 
70°C until required. This form of chilling is superior to crack freezing directly into 
liquid nitrogen since it provides better preservation of the tissue histology. Ice 
damage caused by the formation of ice crystals is kept to a minimum by this 
immersion technique. The chilling bath was prepared by placing a beaker of n- 
hexane in a bath of absolute ethanol cooled by the addition of solid CO2. Excised 
tissue was immersed in the hexane to allow complete chilling and then placed in 
glass universal containers for storage at -70°C. When required, 8pm sections of the 
tissues were cut on a Bright's cryostat and placed onto either 4 or 10 well multi­
spot slides. The sections were dried for approximately 15 minutes at room 
temperature, fixed in acetone and the histology of the tissue checked using the 
Giemsa staining method (vide supra). Suitable tissue was wrapped in foil and 
stored at -70°C until required.
Il.l(iv) Indirect immunofluorescence.
A standard indirect immunofluorescence method was performed (Johnson, 1981) 
using PBS / 2% FCS as the washing buffer .The sections or cytospin preparations 
were rehydrated for 20 minutes in washing buffer. This acted as a blocking step to 
prevent non-specific binding. The excess buffer was removed and the wells were 
overlayed with primary antibody. After 30 minutes the washing step was repeated 
followed by a further 30 minutes incubation with an FITC goat anti-mouse 
conjugated second antibody. After a final wash in PBS alone the sections were 
counterstained for 30 seconds by immersion in 0.002% (W/V) ethidium bromide in 
PBS which intercalates with DNA to gives a red nuclear stain. This was washed
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off with PBS and the slides were mounted using 90% glycerol in PBS (V/V). 
Positivity was detected using a Leitz SM-Lux microscope with epi-fluorescence. 
Positive and negative controls (23C6 and culture supernatant respectively) were set 
up in parallel with each screening.
II.l(v) Alkaline phosphatase anti-alkaline phosphatase (APAAP)
This was carried out according to the manufacturers instructions. Acetone fixed 
sections of tissue or cell preparations were overlayed with optimally diluted 
antibody in 0.05 M TRIS buffered saline (TBS, pH 7.6) and incubated in a moist 
chamber for 30 minutes at room temperature (RT). This was rinsed off with TBS 
and the slides washed in fresh buffer for 1-2 minutes. Excess buffer was removed 
and the sections incubated for a further 30 minutes with rabbit anti-mouse 
immunoglobulins diluted 1:25 in TBS. The slides were washed as described, 
overlayed with the APAAP complex (diluted 1:50 in TBS) for 30 minutes and then 
washed off with fresh buffer. Freshly prepared substrate was filtered directly onto 
the slides and the colour reaction allowed to develop for 15-20 minutes at RT. 1 
mM Levamisole was added to the substrate to block endogenous alkaline 
phosphatase activity. The reaction was stopped by immersing the slides in TBS 
then tap water and the sections lightly counterstained in Mayers haematoxylin for 45 
seconds. Excess stain was removed with tap water and the slides mounted in the 
glycerol mountant described above.
n .l(v i) Cell enrichment using Dynabeads.
Dynabeads are a commercially available product that consist of magnetisable 
polystyrene beads of 4.5 pm diameter. This particular product has goat anti-mouse 
immunoglobulins covalently bound to their surface which recognize all mouse IgG 
subclasses. If a mouse antibody that recognises a cell surface determinant is bound 




The Dynabeads were resuspended by gentle shaking and tissue culture supernatant 
was added at a ratio of approximately 1 mg of beads to 0.2 - 2 pg of monoclonal 
antibody. The suspension was mixed by rotation for 2 hours at 4°C and the beads 
were collected on the side of the tube using a strong magnet. While the beads were 
immobilised the supernatant was removed by aspiration using a pasteur pipette. The 
tube was removed from the magnet, the beads resuspended in PBS / 0.1% BSA 
and washed by rotation at 4°C. This washing step was repeated 3 more times and 
the beads were finally resuspended and stored at 4°C in PBS / 0.1% BSA 
containing 0.01% thimerosal as preservative.
Il.l(vii) Preparation of poly-l-lysine coated slides
Poly-l-lysine coated slides were prepared by overlaying sterile 4-well multispot 
slides with 150 pi / well of poly-l-lysine (50-150xl03 molecular weight) diluted to 
50 pg / ml in sterile distilled water. Following incubation at room temperature for 
30 minutes the excess was removed by aspiration, the wells washed x2 in distilled 
water and the slides left to dry. These could be used immediately or stored at room 
temperature until required.
Il.l(viii) Human long-term marrow cultures.
Normal human bone marrow was obtained by either aspiration from the posterior 
iliac crest or from rib samples removed during lung resection. For aspirates, the 
marrow was collected into a-MEM containing 5% FCS and 100 U/ml heparin. The 
sample was diluted 1:2 with medium, overlayed onto Ficoll density gradient 
medium (Boyum, 1968) and centrifuged at lOOOg for 15 minutes at room 
temperature. For rib-derived marrow, the sample was transported aseptically in 
serum-free a-MEM medium and transferred to a 10 cm Petri dish for preparation. 
The rib was split longitudinally with a sterile scalpel blade and the marrow cells 
flushed out using serum-free medium from a 20 ml syringe fitted with a 20 gauge
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needle. Isolated cells were decanted into a sterile 50 ml tube and pelleted by 
centrifugation at 400 g for 5 mins. The cells were resuspended in fresh medium, 
overlayed onto Ficoll and separated as described above. The mononuclear cells 
from both preparations were harvested from the medium / Ficoll interface and 
washed x3 in medium at 400g for 5 minutes.
(i! Plate cultures
The cell number was determined using a haemocytometer and the density was 
adjusted to lxlOfyml in a-MEM supplemented with 20% horse serum and 100 
pg/ml of GM-CSF. 0.5 ml of cell suspension was dispensed into the 24-well 
plates and incubated at 37°C in an atmosphere of 90% air buffered with 5% CO2 
for 7 days. The medium was replenished after 7 days by removing it and replacing 
it with the same volume of fresh medium supplemented with 10'8 M 1.25D3. After 
approximately 21 days in culture the confluent cells were fixed in methanol, air 
dried and probed with the antibodies.
(iil Slide cultures
The medium used was the same as above. 150 pi of the cell suspension containing 
105 cells was dispensed onto each well of a poly-l-lysine coated 4-well multispot 
slide. The slides were placed into sterile plastic dishes and cultured as described 
above. To prevent the loss of medium by evaporation, Bijou bottle tops containing 
sterile PBS were placed in the dishes The medium was changed every two days by 
removing 75 pi and replacing it the same volume of fresh medium containing the 
appropriate osteotropic factor. After completion of the the culture period the slides 
were washed in warm PBS, the excess drained off and fixed in acetone for 10 
minutes. The glass slides were air dried and stored at -20°C, wrapped in foil.
Il.l(ix ) Preparation of Cytospin cell suspensions.
This technique was used on cell suspensions derived from cultured cell lines. These
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preparations were washed by centrifugation at 400g for 5 minutes in PBS to 
remove any serum. They were resuspended in fresh PBS and their density adjusted 
to 5x10s / ml in PBS. 200 pi of this was dispensed into the Cytospin sample 
chambers and spun at 500 rpm for 1 minute to immobilize the cells onto glass 
slides. These were removed from the Cytospin, air dried for approximately 15 
minutes and fixed in acetone for 10 minutes at room temperature. The preparations 
were wrapped in foil and stored at -70°C until required.
(II. 1 (x) Cell culture
1. Hvbridomas - These were maintained in RPMI / 10% FCS supplemented with 
HT medium. When confluent, the supernatant was removed and the cells were 
pelleted by centrifugation at 400 g for 5 minutes. The supernatant was decanted into 
a sterile container and stored at 4°C until tested for reactivity by IF on 
osteoclastoma tissue. Positive supernatants were stored according to their isotype. 
IgG Mabs were frozen at -20°C in 1 ml aliquots and IgM Mabs were stored at 4°C 
supplemented with 0.01% thimerosal. The cells were prepared for storage by 
adjusting their density to lxlO6 / ml in freezing mixture (vide infra) and aliquoting 
them into 1.8 ml cryotubes ( 1ml / tube). These were placed into a sealed 
polystyrene igloo, containing cotton wool and placed at -70°C overnight. The 
tubes were then stored in liquid nitrogen until required.
2. U937 and HL60s These were maintained in RPMI / 10% FCS in 75 cm2 culture 
flasks. When the cells were confluent they were split at a 10:1 ratio with fresh 
medium. The spare cells were either prepared for freezing to maintain stocks, as 
described above, or discarded.
3. DX3 melanoma cells This adherent cell line was also maintained in RPMI / 10% 
FCS, in 25 cm2 culture flasks. When confluent the medium was removed and 
excess serum washed off with warm PBS x3. This was replaced with 1 ml trypsin
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solution (0.25% trypsin / 0.2% EDTA) and the flask placed at 37°C for 
approximately 5 minutes until the cells were displaced from the flask. Medium 
containing FCS was dispensed onto the cells and these were transferred to a sterile 
15 ml centrifuge tube and the cells pelleted by centrifugation at 400 g for 5 minutes. 
A tenth of the original cells were returned to the flask and placed at 37°C. The 
remainder were either cryopreserved or discarded.
II.2 MATERIALS
Cell culture media were obtained from GIBCO (Paisley, Scotland), cell culture 
plastics from NBL (Cramlington, Northumberland) and foetal calf serum from 
Imperial Laboratories (Andover, Hants). Percoll and low molecular markers for 
Western Blotting were purchased from Pharmacia (Milton Keynes, Bucks). 
Osteosorb bone wafers were from ICN (High Wycombe, Bucks). Diff-Quik was 
from Baxter. The mouse monoclonal isotyping kit was purchased from Serotec 
(Kidlington, Oxford). Histopaque (1.077), Poly-l-lysine, FITC and peroxidase- 
conjugated goat anti-mouse immunoglobulins, collagenase (type I), the enzymes for 
the dot blots and the acid phosphatase detection kit were obtained from Sigma 
Chemicals (Poole, Dorset). APAAP was performed using anti-mouse 
immunoglobulins and APAAP complex supplied by Dakopatts (High Wycombe, 
Bucks). 10-well multispot slides were supplied by Henley Ltd (Loughton, Essex). 
Goat anti-mouse IgG coated magnetic beads were from Dynal (Wirral,
Merseyside). Polyethylene glycol (PEG 1500) and IL-6 were supplied by 
Boehringer Mannheim (Lewes, East Sussex). The recombinant human preparations 
of IL-3 and GM-CSF were from Glaxo (Greenford, Middlesex). FM-85 was a 
kind gift from Winthrop, U.K. The monoclonal antibodies 23C6 and 13C2 and 
DX3 cells were kindly donated by Dr M.A. Horton and the Sperm whale dentine 





Tungsten-tipped steel knife - 
Cytospin 3 -
SM-LUX fluorescence - 
microscope with epi-fluorescence.
Wilovert inverted phase microscope
Isomet low speed saw -
Western blotting equipment -
Magnetic bead concentrator - 
(MPC-1 magnet for Dynabead 
separation)
Bright Instrument Co; Huntingdon, 
Cambridgeshire.
ARP; Cheshire.
Shandon Southern Products Ltd; Runcorn 
Cheshire.
Leitz Instruments; Luton, Beds.




Facstar plus cell analyser /  sorter - Becton Dickinson; Cowley, Oxford.
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II.4 SOLUTIONS AND BUFFERS
11.4(0 Media for cell culture
RPMI-1640 / 10% FCS - For the culture of hybridomas, U937, HL-60, DX3. 
MEM / 10% FCS - For bone resorption assays.
To 733 ml of deionised distilled water add 100 ml RPMI-1640 or MEM xlO 
concentrates, 20 ml penicillin (100 IU/ml) and streptomycin (100 pg/ml), 20 ml L- 
glutamine (2mM) and 27 ml 7% sodium bicarbonate. Mix, filter sterilise into two 
500 ml Duran bottles and add 50 ml sterile, heat inactivated FCS per bottle. For 
hybridoma cloning add 100 units / ml of IL-6 and HT medium (vide infra) and for 
the routine production of hybriboma supernatants add HT but not IL-6. Store at 
4°C.
a-MEM - For osteoclastoma (supplemented with 10% FCS) and bone marrow 
cultures (supplemented with 20% DHS).
Osteoclastoma cultures Bone marrow cultures
(1 litre) (1 litre)
a-MEM formulated 
powder
10 grams 10 grams
Penicillin /  streptomycin* 20 ml 20 ml
L-glutamine* 20 ml 20 ml
7% sodium bicarbonate 27 ml 27 ml
FCS 100 ml -
DHS - 150 ml
Distilled / deionized 
water
833 ml 783 ml
*Same final concentrations as given for RPMI and MEM.




II.4(ii) Liquid nitrogen freezing mixture for the cryopreservation of 
cells
To 40 ml of sterile RPMI-1640 medium was added 50 ml of FCS and 10 ml of 
dimethylsulphoxide. The density of cells for cryopreservation were adjusted to 
approximately lxlO6/ ml in freezing mixture and dispensed into cryotubes in 1 ml 
aliquots. The initial freezing procedure was carried out overnight at -70°C in a 
polystyrene igloo filled with cotton wool. The vials were then stored in liquid 
nitrogen.
II.4(iii) Aqueous mountant for IF and Giemsa
To 90 ml of glycerol was added 10 ml of PBS (pH 7.3) and 2.5 g (W/V) of 1,4- 
diazobicyclo-(2,2,2)-octane (DABCO). The DABCO reducing agent was added to 
retard photobleaching of the fluorescent dye during screening of the antibodies by 
the indirect immunofluorescence technique (Johnson etal, 1981).
II.4(iv) Ethidium bromide for IF counterstain (THIS IS A 
CARCINOGEN).
Wearing gloves add 0.1 g of ethidium bromide to 50 ml of PBS (pH7.3). Mix until 
dissolved, aliquot into 1m l volumes and store at -20°C until required. When 
required add one 1 ml aliquot to 99 ml of PBS and mix.
II.4(v) Erythrocyte lysing solution.
Stock solution: 8.26 g Ammonium chloride.
1.00 g Potassium bicarbonate.
0.37 g Ethylenediaminetetraacetic acid (disodium salt).
Make up to 100 ml with distilled water (pH 7.2-7.4).
W orking solution: Dilute the stock xlO and add to the cell pellet. Mix by 




Fixative: 40 ml of 0.38 M citrate buffer pH 5.4 was added to 60 ml acetone and 
was used immediately.
Beaker A (ml) Beaker B (ml)
Water (prewarmed to 37oC) 46 44
Acetate solution 2 2
Naphthol AS-BI phosphoric acid 2 2
Tartrate solution - 2
15 mg of Fast Garnet GBC salt was added to each beaker and stirred for 
approximately 1 minute. Once filtered into labelled coplin jars the solutions were 
ready for use.
II.4(viil Immunisation reagents
II.4(vii)a Preparation of HAT and HT media.
These were prepared by the addition of concentrated stock solutions to standard 
medium.
xlOO HT stock solution.
136 mg hypoxanthine.
39 mg thymidine.
To 100 ml of deionized distilled water, warmed to 70-80°C were added the above 
ingredients. This was filter sterilised and stored in 1 ml aliquots at -20°C.
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xlOO HAT stock solution - (lOmM hypoxanthine, 4xlO’5M 
am inopterin, 1.6mM thymidine).
1.8 mg of aminopterin was added to 100 ml of HT medium and a few drops of 1 
M NaOH were added to help dissolve it. This was filter sterilized, aliquoted into 1 
ml volumes and stored at -20°C in the dark until required. Aminopterin is light 
sensitive, and may deteriorate, resulting in the failure of HAT selection and growth 
of unfused myeloma cells.
The HT and HAT concentrates were tested for toxicity and effectiveness prior to 
use. The myeloma cells should grow normally in HT medium, but should die 
within 1-3 days in HAT medium.
II.4(viiil APAAP reagents
II.4(viii)a Substrate
Naphthol AS-MX Phosphate 2 mg.
Dimethylformamide (DMF) 0.2 ml
0.1MTRIS buffer pH 8.2 9.8 ml
1M Levamisole (4 M for bone sections) 10 ml
Fast-Red TR salt 10 mg
Prepare by dissolving the Naphthol AS-MX phosphate in DMF in a glass tube. 
Dilute to 10 ml with the TRIS buffer pH 8.2. Add levamisole to block endogenous 
alkaline phosphatase activity (can be stored at 4°C for several weeks, and for a 
longer time at -20°C).
Immediately before staining, dissolve the Fast-Red salt in the substrate solution and 
filter directly onto the slides.
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Dilute stock solution 1:10 in 0.15M saline.
II.4(ix) Western blotting / dot blotting reagents
II.4(ix)a 5% milk in PBS (PBSM, pH7.3)
Add 50 g of fat-free milk powder to 1 litre of PBS, mix well and adjust pH to 7.3 
with 1 M sodium hydroxide.
II.4(ix)b 2% Amido Black stain for molecular weight markers.
To 50 ml of methanol add 1 g of amido black 10B and allow to dissolve. Add 10 ml 
glacial acetic acid and 40 ml distilled water. Filter before use and destain using 50% 
methanol, 10% acetic acid and 40% distilled water.
II.4(ix)c Peroxidase substrate.
i). Stock substrate - To 100 ml of dimethylformamide add 0.4 g 3-amino-9-ethyl 
carbazole and 5 mg of thimerosal. Store at 4°C.
ii). 1 M Sodium acetate - Add 8.2 g of sodium acetate to 100 ml of distilled water 
and adjust the pH to 5 with glacial acetic acid. Store at 4°C.
For use dilute the sodium acetate 1:20 in distilled water (i.e. 10 ml + 190 ml) and 










This chapter describes the steps involved in the production and screening of a panel of 
murine monoclonal antibodies reactive with human osteoclasts. These were produced by 
in vivo immunizations using osteoclast enriched fractions, derived from human 
osteoclastomas, as the antigen source. The giant-cells in these neoplasms have been 
studied and shown to express a number of osteoclastic characteristics, such as 
multinuclearity, TRAP activity and the ability to resorb pits in devitalised cortical bone 
slices.
Antibody producing hybrids were obtained from the fusion of spleen cells, derived 
from immunized mice, with non-immunoglobulin secreting mouse myeloma cells. The 
original 1213 antibodies produced from these fusions were rapidly screened by indirect 
immunofluorescence on acetone-fixed sections of tumour and tumour prints. The cells 
producing antibody of the desired reactivity were cloned twice by limiting dilution to 
achieve monoclonality. Their selectivity for osteoclasts was confirmed by screening on 
undecalcified cryostat sections of adult human bone. This novel human model, derived 
from developing osteophytes from the osteoarthritic femoral head, demonstrated all 
stages of bone formation and remodelling and consequently osteoclasts at different 
stages of activation and differentiation. It thus provided an ideal substrate for the 




In an attempt to resolve the problem of osteoclast ontogeny several groups have used 
monoclonal antibody technology to produce biological probes that may assist in 
delineating the differentiation pathway of these intriguing cells. Avian osteoclasts have 
been used in in vivo immunization protocols to produce murine monoclonal antibodies, 
since osteoclasts are present in these species in the large numbers required for these 
techniques (Nijweide et al, 1985; Oursler et al, 1985). However, the production of 
antibodies reactive with human osteoclasts has been hampered by the small numbers of 
osteoclasts present in normal bone. Some groups have attempted to overcome this 
problem by using giant cells derived from human osteoclastoma neoplasms as the 
immunogen (Horton et al, 1985; Nelson et al, 1991). It has been demonstrated that 
these cells exhibit a number of osteoclast characteristics such as the ability to resorb 
bone and the induction of cytoplasmic quiescence with calcitonin. Using this approach 
these groups have produced a number of osteoclast-reactive Mabs, and verified their 
reactivity using a variety of neoplastic and normal substrates, including human foetal 
bone.
In agreement with these studies the production of a panel of Mabs is described, using 
phenotypically defined human osteoclastoma-derived osteoclasts as the immunogen. In 
contrast to these studies, however the selectivity of the antibodies for human osteoclasts 
was demonstrated by immunocytochemical techniques on cryostat sections of 
undecalcified adult human bone. These sections were cut from young developing 
osteophytes obtained from osteoarthritic femoral heads removed from patients 




III.3(D Characterization of the osteoclastoma giant cells 
In order to verify that the giant cells from the tumour tissues demonstrated an 
osteoclastic phenotype they were checked for multinuclearity, TRAP reactivity and the 
ability to resorb pits in devitalised bone slices.
III.3(i)a Osteoclastoma tissue culture for the demonstration of 
multinuclearity and TRAP activity
All cultures described in this thesis were carried out at 37°C in a CO2 incubator (5% 
C 02 / 95% air).
Osteoclastoma tissue was obtained by curettage from in-patients at the Royal 
Orthopaedic Hospital, Northfield, Birmingham. The tissue for culture was transported 
in serum-free a-MEM medium and under sterile conditions was cut into small pieces of 
approximately 0.5 x 0.5 cm. Upto twelve of these pieces were placed into individual 10 
cm Petri-dishes and cultured in a-MEM supplemented with 10% FCS. The cell growth 
from the tissue pieces was monitored daily using inverted phase microscopy. When a 
sufficient number of osteoclasts were observed the tissue was removed, the medium 
aspirated and the cultures washed x3 in fresh PBS. The cells were fixed according to 
the assay being performed; for TRAP, 0.38 M citrate buffer / acetone was used and for 
Giemsa a methanol-based fixative was used. Following a brief wash in distilled water 
they were air dried and assessed for multinuclearity with Giemsa stain . The presence 




III.3(i)b Resorption assay using devitalised bovine cortical bone slices
The Osteosorb product consists of sterile slices of bovine mid-shaft cortical bone. They 
are designed for use in bone resorption assays in which cultured osteoclasts will 
excavate resorption lacunae in the substrate. The assay was performed according to the 
manufacturer’s protocol.
Osteoclastoma tissue was cultured in the presence of the bone slices in 24-well tissue 
culture plates containing MEM medium supplemented with 10% FCS. The slices were 
incubated for 72 hours before fixation and staining. Fixation was performed by 
washing the wafers in warm PBS and then placing them in 4% gluteraldehyde in 0.2 M 
sodium cacodylate (pH 7.2) for 5 minutes at 37°C. The wafers were washed in fresh 
PBS and stained for approximately 2 minutes in 1% toluidine blue in 0.5% borax. The 
intensity of staining was adjusted by washing the wafers rapidly in 70% alcohol and 
then washing them in distilled water. After air drying the resorption lacunae could be 
observed by light microscopy.
III.3(i)c Sperm whale dentine
In addition to these studies, collagenase isolated osteoclastoma cells (vide infra) were 
also tested for osteoclastic activity using sperm whale dentine slices as the substrate. 
This substrate is generally believed to be far superior to cortical bone slices since its 
unblemished surface reduces the risk of artefactual results. To optimize the culture 
conditions and to find out if cryopreserved cells were capable of resorption, the assay 
was performed in two ways. Firstly, the cell suspension was incubated on duplicate 
dentine slices for the whole 24 hour culture period and in the second, the cells were 
only left to adhere for 1 hour before the slices were removed, washed in warm PBS 
and placed into fresh medium for the remainder of the culture period. The presence of 
osteoclasts was demonstrated by staining for TRAP activity, followed by staining with 
toluidine blue for the presence of resorption pits. The viability and functional capacity 
of the osteoclasts was also tested by repeating the above experiments using samples of
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cells that had been stored in liquid nitrogen. These were warmed rapidly in a 37°C 
waterbath, washed by centrifugation at 400 g for 5 minutes to remove DMSO- 
containing freezing mixture and resuspended in fresh medium for use in the assay. The 
cells for both studies were derived from the same tumour.
III.3(ii) Preparation of osteoclastoma tissue for the immunizations
III.3(ii)a Percoll density gradient isolation of osteoclastoma giant cells
The procedure used was a modification of that described by Oursler et al (1985). 
Osteoclastoma tissue was teased through a wire mesh using a scalpel blade in a 10 cm 
petri dish containing sterile PBS. The cell suspension was aspirated into sterile 50 ml 
tubes and allowed to stand for 2 minutes to allow sedimentation of large tissue 
fragments. The single cell suspension was carefully decanted into fresh 50 ml tubes and 
pelleted by centrifugation at 400g for 5 minutes at room temperature. The cells from 
each tube were mixed and the erythrocytes lysed for approximately 3 minutes using the 
lysing solution (see chapter n, section II.4(v)). The lysis was terminated by topping up 
the tube with fresh serum-free medium and pelleting the cells by centrifugation as 
before. The supernatant was removed by aspiration and the pellet resuspended in 40 ml 
of 50% Percoll. 4 ml of this suspension was carefully layered onto discontinuous 
Percoll gradients in each of ten sterile 15 ml centrifuge tubes . The tubes contained 2 ml 
each of 50,40, 30, 20 and 10% Percoll, layered on top of each other. These were 
centrifuged at 400g for 20 minutes at room temperature to separate the cells. Each tube 
demonstrated 4 distinct bands, one at each interface of the Percoll gradient and a pellet 
of cells at the base. The cells at each interface were harvested by aspiration into separate 
15 ml centrifuge tubes and washed x3 in fresh serum-free medium by centrifugation at 
400g for 5 minutes at room temperature. The cells were observed by light microscopy 
and in accordance with the observations of Oursler et al (1985) it was found that many 
osteoclasts were separated at the interface between the 10 and 20% gradients. 
Unfortunately, the viability of the osteoclasts in these upper layers, as demonstrated by 
trypan blue exclusion, was often very low (usually between 10 and 20%). However,
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when the cells were examined in the pellet at the bottom of the tube from one sample 
they demonstrated the presence of large numbers of osteoclasts, the majority of which 
were viable (70-80%). Although cells from each interface were prepared for storage in 
liquid nitrogen it was the cells from this pellet that were used for the majority of the 
immunizations.
III.3(ii)b Collagenase treatm ent of osteoclastoma tissue
Because of the poor viability and inconsistency of the Percoll technique in our hands, 
an alternative method was employed using collagenase treatment of the tissue. This 
gave excellent preparations of viable cells that could be stored in liquid nitrogen until 
required for culture (see chapter II, section II.4(ii)).
Osteoclast curettage samples were chopped up finely in a 10 cm petri dish and placed in 
a 50 ml centrifuge tube with 25 ml of collagenase (type I) at 3 mg / ml in serum-free 
medium. The tube was placed in a 37°C water bath and incubated for 1 hour with 
frequent mixing. The suspension was left to stand for 2 minutes to allow the tissue 
debris to sediment, the supernatant decanted into a fresh tube and the cells pelleted by 
centrifugation at 400g for 5 minutes at room temperature. Following three washes in 
serum-free medium the cells were prepared for storage in liquid nitrogen.
III.3(mI Immunization procedure
III.3(iii)a Osteoclast preparation
Cells are highly immunogenic and therefore do not require the use of adjuvants to 
produce the desired immune response. The osteoclast fractions were removed from 
liquid nitrogen and thawed rapidly in a water bath at 37°C. The cells were diluted in 
RPMI-1640 medium supplemented with 10% FCS and washed by centrifugation at 
400g for 5 minutes. The supernatant was removed and the cells were washed three 
times in PBS. After the final wash the cells were resuspended in fresh PBS at a density 
of between 4-25xl06/ml. 0.5 ml of this suspension was injected intra-peritoneally into
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6 week old female BALB/C mice. This was repeated twice and a final booster was 
injected 2-4 days before fusion, giving a total of four immunizations per mouse.
III.3(iii)b Preparation of mouse thymocytes ("feeder cells")
The problems of poor viability that are encountered when cells are plated out at low 
density can be overcome by culturing them in the presence of a slow or non-growing 
population of cells. Although the mechanism of support is unknown, these feeder cells 
may function by providing the hybrids with essential growth factor(s). The type of 
cells used as the feeder population include thymocytes (Lemhardt et al, 1978), spleen 
cells (Galfre and Milstein, 1981) and peritoneal cells (Hengartner etal, 1978).
The mouse thymocytes were prepared the day before the fusions. Two mice were 
killed, and prepared for dissection as described for the preparation of spleen cells (vide 
infra). The thymus was removed from each mouse via an incision in the thorax and the 
cells were prepared as described below. The washed cells were resuspended in RPMI- 
1640/10% FCS, plated out in 50 pi aliquots at a density of 105 cells / well in flat- 
bottomed 96-well tissue culture plates and placed in a CO2 incubator at 37°C overnight.
III.3(iii)c Preparation of spleen cells
The mouse spleens were removed using medium sized and fine scissors and fine 
forceps. These were sterilised by boiling in water for 5 mins and placing them in 70% 
ethanol until required. The animals were killed by decapitation and a blood sample was 
saved for screening to test for immunoreactivity. To remove the spleens the animals 
were initially swabbed in 70% ethanol, the superficial skin over the left side of the 
abdomen was pinched up using forceps and a small cut was made over the spleen. The 
skin was tom back to reveal the abdominal muscles, through which the spleen was 
visible. The abdominal wall over the spleen was pinched up with the fine forceps and a 
small incision made with the fine scissors taking care to avoid the gut. After cutting the 
surrounding mesentery the spleen was carefully removed via the incision and placed in
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a 10 cm petri dish. A single-cell suspension was made by gently teasing the spleen with 
flat-nose forceps into serum-free RPMI-1640. The cells were harvested by 
centrifugation at 400g for 5 mins, washed twice in medium and counted in an improved 
Neubauer haemocytometer. The red cells were omitted from the suspension by using 
3% acetic acid as the counting diluent. A typical yield of nucleated cells from these
o
spleens was approximately 10 .
III.3(iii)d Preparation of myeloma cells
X63-Ag 8.653 (X63) myeloma cells were chosen as the spleen fusion partners since 
they are HAT sensitive (vide infra) and have lost the capacity to synthesize endogenous 
immunoglobulin. They were maintained in culture in RPMI-1640 medium 
supplemented with 10% FCS. The FCS was batch tested to check its capacity to 
support the growth of these cells in culture. When required for fusion the myeloma 
cells, in exponential growth, were washed by centrifugation in serum-free medium . 
The cells were counted in a haemocytometer and the number was adjusted to give a 
ratio of 1 myeloma cell to 10 spleen cells.
III.3(iii)e Fusion
Hybridomas produced using polyethylene glycol were originally described by Galfre et 
al (1977). There are a number of important variables in this technique which can 
directly affect the success of the fusion step. One of these is the concentration of PEG 
used to induce fusion. It has been demonstrated that using less than 30% PEG will 
produce very few hybrids, while 50% PEG will be too toxic for the cells. Similarly the 
purity of the PEG appears to be important in cell survival. A contaminant in the PEG 
appears to be essential for cell fusion, but some batches are too toxic. The success of 
the fusion is also dependent on the pH of the PEG mixture. Sharon et al (1980) showed 
that fusion occurs optimally at a pH of between 8.0 and 8.2. The duration of exposure 
to the PEG mixture can also play an important role in the outcome of the fusion step. 
Fusion frequency but also the toxicity increases with the time of exposure to PEG.
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Lower concentrations of PEG (30-35%) can be tolerated for longer times e.g. 7 mins, 
than higher concentrations (50% PEG for no longer than 1-2 mins). Finally it has been 
demonstrated that factors such as temperature and cell numbers can also affect this 
fusion step. The optimal fusion temperature lies between 27° and 37°C and the optimal 
cell numbers required for a fusion is best calculated by running dummy fusions using 
varying ratios of fusion partners prior to the critical fusion.
The spleen cells from the immunized mice were mixed at a ratio of 10:1 with the X63 
myeloma cells in a 50 ml tube and a common pellet formed by centrifugation at 400g 
for 5 mins at room temperature. All the supernatant was carefully removed from the 
cells to prevent subsequent dilution of the PEG. The cell pellet was dislodged by gentle 
tapping and 1 ml of 50% PEG (Mwt 1500) solution was added over a 1 min period 
with constant shaking. The tube was transferred to a beaker containing water at 37°C 
and shaken for a further 90 seconds. The PEG was diluted with PBS, 1 ml was added 
over the first 30 seconds, 3 mis over the next 30 seconds and 16 mis over 1 minute.
The tube was finally topped up to 50 ml with PBS and centrifuged for 10 mins at 400g. 
All the supernatant was carefully removed and the pellet taken up gently in a small 
volume of RPMI/10% FCS and placed in a sterile 100 ml bottle. Medium was added to 
the cell suspension until the desired volume was reached and the cells were aliquoted at 
a density of 105 cells / well in 50 pi volumes to the wells containing the feeder cells.
The plates were then placed in the 37°C CO2 incubator overnight. The following day 
100 pi /well of x2 HAT selection medium was added and cultured for approximately 
one week until non-fused and unwanted fusions had died.
III.3(iii)f Termination of HAT selection
After 1 week it is safe to assume that all myeloma cells are dead and any growing cells 
will be hybrids. HAT selection is terminated at this point. This can be done by culturing 
the hybrids in HT medium which provides the necessary components for the utilization 
of the salvage pathway .
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It should be noted that aminopterin is metabolized very slowly and the main route of 
elimination in man is by urinary excretion and catabolism does not appear to occur to 
any significant degree. In cultures, the aminopterin is eliminated by dilution. Therefore 
one has to remove as much of the HAT medium as possible prior to feeding with HT 
medium. It has been demonstrated by Zola and Brooks (1982) that some hybrids died 
when taken out of HT medium, and suggested that the cells be grown in HT medium 
permanently.
III.3(iii)g Removal of supernatants
The fusions were initially fed by carefully removing the majority of HAT medium using 
a multipipette with sterile disposable tips, and replacing it with an equal volume of HT 
medium via an Eppendorf dispenser. In subsequent feeding steps, half the medium was 
removed from the wells and replaced with a similar volume of fresh HT medium.
III.3(iii)h Cloning of positive cells
Wells of the tissue culture plates were regularly checked by eye for growth of cell 
colonies. When the medium had turned yellow, 200 jul was removed from the wells and 
replaced with a similar volume of fresh medium. The hybridoma supernatants were 
selected for their reactivity against osteoclasts on fixed cryostat sections of tumour and 
undecalcified adult human bone by an indirect immunofluorescence technique (vide 
infra). Cells producing supernatants that fulfilled our pre-defined criterion of 
demonstrating reactivity against osteoclasts in the osteoclastoma tissue underwent 
primary cloning. The cloning was performed, ultimately, to achieve clonality of the 
cells so that the antibody produced was the product of a single clone of cells. The 
cloning was performed by limiting dilution. The density of the cells was adjusted so 
that one cell was delivered per well of a flat-bottomed 96-well tissue culture plate in 200 
pi of HT medium supplemented with 100 units/ml of IL-6. The IL-6, also called 
hybridoma growth factor, was used instead of the feeder cells to support the growth of
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the low density plated hybrids. For each positive clone, three tissue culture plates were 
set up containing one cell per well and one plate with five cells per well. This latter plate 
was used as a back-up in case growth did not occur in the one cell per well plates. The 
cells from this plate were grown up and if the supernatants demonstrated the desired 
reactivity they were stored in liquid nitrogen. The supernatants from the one cell per 
well plates were also screened and if reactivity was detected, the cells from these wells 
were cloned by limiting dilution for a second time to ensure clonality of the hybrids. If 
the cells from these second clonings produced anti-osteoclast reactive antibody they 
were considered clonal and their antibody product monoclonal. The antibody from 
these second clonings were used for all subsequent characterization work.
III.3(ivl Screening of hvhridomas
III.3(iv)a Indirect immunofluorescence (IF) on tissue sections and imprint 
preparations
(i) Tissue sections
Tissue was prepared for cryostat sectioning as described in chapter II. When required, 
8pm sections of the tissues were cut on a Bright's cryostat and placed onto either 4 or 
10 well multi-spot slides. The sections were dried for approximately 15 minutes at 
room temperature, fixed in acetone for 10 minutes at room temperature and the 
histology of the tissue checked using the Giemsa staining method. Suitable tissue was 
wrapped in foil and stored at -70°C until required.
(ii) Tissue imprints
Fresh pieces of tumour were dabbed onto individual wells of 4-well multispot slides 
and the cells were allowed to air dry for at least 15 minutes. The presence of osteoclasts 
in the preparations was checked by staining with Giemsa and the remaining slides were 




III.4(i) Characterization of the giant cells ~
The Giemsa stain in the fixed culture preparations clearly demonstrates the 
multinucleated morphology of the osteoclasts compared to the mononuclear appearance 
of the surrounding stromal cells (Fig M.l). The intense maroon precipitate in the 
multinucleated osteoclasts indicates their strong TRAP activity while the stromal cells in 
the cultures failed to express any activity (Fig III.2). In one culture there were 
numerous TRAP positive mononuclear cells whose morphology was subtly different 
from the abundant stromal cells, in that they had a much more rounded cytoplasm. 
These cells often formed foci immediately beneath a piece of cultured tumour and were 
often associated with multinucleated osteoclasts (Fig III.3). Although it would be 
tempting to suggest that these may represent a precursor population, the idea is 
tempered by the fact that TRAP activity has also been demonstrated in macrophages 
(Efstratiadis and Moss, 1985).
In the resorption experiments, the bone slices cultured with the osteoclasts were 
characterized by the presence of pits which were clearly visible by reflected light 
microscopy. Their visualization, however was enhanced by the use of digital imagery. 
The information from the slices was processed and presented by the computer 
so that the pits were represented as a different colour to that of the flat bone surface (Fig 
in.4). This was in contrast to the negative control slice whose surface was 
unblemished by resorption and was therefore represented as one colour on the digital 
image (Fig III.5) These results confirm those of Horton et al (1985). The experiments 
with the whale dentine showed it to be of greatly superior quality for these studies 
when compared to the cortical slices. The surface of the dentine was smooth with no 
evidence of cutting cones or other artefactual blemishes (Fig III.6). The fresh 
collagenase digests that were only cultured with the slices for 1 hour, proved to be the
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Characterization of osteoclastoma giant cells. 1. Giemsa
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Fig rn.l. The cells cultured from osteoclastoma tissue were fixed and stained using the 
Diff-quik technique. Multinucleated osteoclasts (OC) are seen surrounded by 
mononuclear stromal cells (SC). Giemsa xlOO.
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Characterization of osteoclastoma giant cells. 2. TRAP
*
JBif  A
'  > w
-  S >
> »
m
Fig III.2. A similar culture to the one above was fixed and stained to demonstrate the 
presence of tartrate-resistant acid phosphatase. The negative stromal cells (S) are in 
sharp contrast to the positive osteoclasts (OC) which show the presence of a deep 
maroon precipitate, characteristic of this technique. TRAP x200.
Fig III.3. This photograph demonstrates TRAP reactivity in a population of 
mononuclear cells (M) and osteoclasts (OC) in the osteoclastoma cultures. These 
rounded cells are morphologically different to the negative stromal cells which appear 
flatter and more fibroblastic in appearance. TRAP xlOO.
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Characterization of osteoclastoma giant cells. 3. Bovine cortical bone
resorption
Fig III.4. The resorption of pits produced by the osteoclasts are demonstrated by this 
colour enhanced digital image. The bone surface is shown in green and the resorption 
pits in blue. Areas in which stromal cell growth occurred are represented in yellow.
Fig m.5. In contrast to the above image this negative control shows no pits. Almost the 
entire surface of the bone is represented by an even green colour. The yellow 




QmracterLfsation of osteoclastoma slant cslls, 4, Sperm whale denting 
resorption
Fig III.6. The superior quality of dentine slices was apparent since the surface was 
smooth and free from possible artefactual blemishes that may be mistaken as resorption 




Fig III.7. The resorptive activity of fresh collagenase-isolated osteoclasts is 
demonstrated in this photograph. The osteoclasts appear healthy and active after 24 
hours culture on this substrate, as demonstrated by the presence of numerous 
resorption pits (RP). Toluidine blue xlOO.
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Characterization of osteoclastoma giant cells. 4, Sperm whale dentine 
resorption
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Fig III.8. The osteoclasts in this preparation were derived from the same tumour as 
above, but were thawed from liquid nitrogen storage. In contrast to the fresh 
preparation the osteoclasts on this slice look morphologically less healthy . They appear 




best for these studies. The osteoclasts looked much plumper and and the number and 
size of pits was increased (Fig III.7) when compared to the cells from liquid nitrogen 
storage (Fig IIL8). The slices that were cultured for the whole 24 hours in the presence 
of the cell suspension were covered in a confluent mat of stromal cells and it was not 
possible to detect osteoclastic activity (data not shown).
III.4(ii) Monoclonal antibody production and initial screening
From the two fusions a total of 3336 wells of 96-well tissue culture dishes were plated 
out with the required ratio of spleen and myeloma cells. After selection in HAT 
medium, 1213 wells (36% of the total) demonstrated growth of hybridomas from 
which the supernatants were removed and screened for antibody reactivity on 
osteoclastoma substrate. 35 (2.8% of the growing hybridomas) supernatants 
demonstrated anti-osteoclast reactivity and were cloned. Following a further screening 
of the supernatants on adult human bone sections 11 hybridomas (0.9% of the growing 
hybridomas)were finally cloned for a second time to ensure monoclonality. These 
statistics are summarised in table III.2.
III.4(iii) Screening of hybridomas on osteoclastoma tissue and imprints
The supernatants from all 1213 hybridomas that demonstrated growth were screened on 
osteoclastoma tissue (Fig III.9) by indirect immunofluorescence. This provided a quick 
and selective technique that enabled us to clone positive hybrids on the same day as the 
assay, thus minimising the risk of cell death by over-growth. Initially, screening was 
performed on osteoclastoma sections (Figs III. 10-11) and imprints (Fig 111.12). 
However it was apparent that these latter preparations did not add any further 
information regarding the reactivity of the antibodies so they were dropped from the 
screening program. In addition, they were tedious to prepare and the quality of the final 
preparations was inconsistent compared with the excellent quality of the cryostat 
sections. The usefulness of the EF technique was further increased by the use of the
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IMMUNIZATION NUMBER OF DAY OF
SERIES CELLS/IMMUNIZATION IMMUNIZATION
ONE a 2 x 106 1
b 6 x  106 21
c 6 x 106 103
d 12.5 x 106 131
134 FUSION










Number of spleen 
cells used
Number of wells 
plated
Number of wells 
positive for growth
Number positive on 
osteoclastoma
Number cloned once 
by limiting dilution
Number cloned 
twice by limiting 
dilution
1 2.2 x 108 1632 310 (19%) 17 (5.4%) 15 (4.8%) 5 (1.6%)
2 3.2 x 10» 1704 903 (53%) 18 (2%) 18 (2%) 6 (0.7%)




Screening of hybridom as. 1. O steoclastom a tissue sections
Fig ni.9 The histology of the osteoclastoma is demonstrated using the Diff-Quik 
technique. It demonstrates the classical appearence of this tissue with mononuclear 
stromal cells (S) interspersed with numerous multinucleated osteoclasts (OC). Giemsa 
x200.
Fig III. 10. Osteoclastoma sections proved to be ideal for the screening protocol 
especially when the nuclear counterstain, ethidium bromide was used. This gave an 
idea of the localization of reactivity of the antibody with some regard to the surrounding 
tissue histology. This shows the reactivity of a cytoplasmic reactive antibody, later 
designated C27. The osteoclasts (OC) demonstrate strong binding of the antibody as 
do the majority of surrounding mononuclear cells (M). The nuclei are counterstained 
with ethidium bromide which fluoresces red. FITC x400.
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Fig III. 11. In contrast, this photograph demonstrates the reactivity of a plasma 
membrane reactive antibody (C22), which shows selective staining of the osteoclasts 
(OC) present in the section. FITC x900 (water).
Screening of hvbridQmas, 2. Osteoclastoma imprints
O C
i
Fig III. 12. Although tissue imprints were used extensively in the initial stages of the 
screening, they were later superceded completely by tumour sections. This latter 
substrate was easier to prepare and was always of good quality. The reactivity of an 
antibody (Cl 8) reactive against a cytoplasmic osteoclast (OC) antigen is shown, using 
ethidium bromide as the counterstain. FITC x400.
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nuclear counterstain, ethidium bromide. This gave some information regarding both the 
histology of the tissue and the localization of positive staining.
III.4(iv) Secondary screening on osteophyte tissue
The positive clones were screened a second time by IF, this time on the osteophyte 
tissue (Fig 111.13). This gave information regarding the selectivity of the antibody 
staining for osteoclasts in the bone environment (Fig III. 14). For example it would 
indicate whether there was reactivity against other bone cells such as osteoblasts or 
osteocytes or against the haemopoietic marrow. If totally non-selective on this tissue the 
clone was discarded and only those that demonstrated a degree of selectivity were 
cloned a second time. The technique for screening on bone was further enhanced by 
using white light in conjunction with the IF (Fig III. 15). This gave important 
information regarding the position of positive osteoclasts in relation to the bone surface, 




Screening of hybridomas. 3. Osteophyte.
Fig 111.13. A typical histology of the young developing osteophyte is shown. This 
demonstrates the presence of numerous osteoclasts (OC) both on and away from the 
bone surface (BS), illustrating its importance as a substrate for the screening of the 
Mabs. Giemsa x200.
Fig III. 14. The antibodies were screened on undecalcified sections of adult human bone 
using indirect immunofluorescence to check their selectivity for bone-derived 
osteoclasts. Even using ethidium bromide as the counterstain it was sometimes difficult 
to ascertain where the positive osteoclasts were situated in relation to the bone surface. 
This shows the reactivity of plasma membrane reactive C22. A positive osteoclast (OC) 
is seen just away from the bone surface (BS). FITC x400.
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Fig m.15. To emphasize the point about localizing positively stained osteoclasts in 
relation to their position in bone, this photograph demonstrates the use of combining 
white light with IF to alleviate this problem. The positive green osteoclasts (OC) stained 





Osteoclasts are the principal cells responsible for bone resorption and are involved in 
remodelling and calcium homeostasis. However, despite this knowledge regarding their 
function, the cellular origin of the osteoclast is still a matter for conjecture. Since these 
cells are present in normal bone in such low numbers it was necessary to find an 
alternative source containing large numbers of normal osteoclasts. It is generally agreed 
that the numerous giant cells present in human osteoclastomas fulfill this criterion. The 
concensus is that the stromal fraction of these tumours constitutes the neoplastic 
element and that the osteoclasts are the immigrant population (Chambers, 1978; 
Chambers et al, 1985). Since the osteoclasts are present in such increased numbers in 
these lesions it seems salient to suggest that as their precursors pass through this highly 
vascularised tissue they are induced to differentiate into mature multinucleated 
osteoclasts by as yet unidentified factor(s). In agreement with observations made by 
other groups it has been demonstrated in this study that the giant cells in the 
osteoclastomas show morphological and functional characteristics of normal bone- 
derived osteoclasts. In addition to their multinuclear appearance, TRAP activity and 
bone resorptive capabilities it has been demonstrated by others that they respond in a 
characteristic way to calcitonin (Chambers et al, 1985). As a result of these 
observations it was concluded that these cells were a suitable source of antigen for the 
production of a panel of anti-human osteoclast reactive monoclonal antibodies.
The original technique chosen to isolate the osteoclasts from the tumour was adapted 
from the protocol of Oursler et al (1985). This method relied on separating the cells by 
centrifugation, on a discontinuous Percoll density gradient. The highest density of 
osteoclasts was found between the 10 and 20% gradients but unfortunately, the 
viability of these cells was very low, as demonstrated by trypan blue exclusion 
staining. On one occasion a high viability sample was obtained but these cells were
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found in the pellet at the bottom of the tube. It was felt that the technique was too 
inconsistent and too harsh for these cells, both at the initial stage where the osteoclasts 
were forced through a sieve, and later when they were exposed to shearing forces when 
separated through the Percoll. Consequently, a collagenase digest method was adopted 
which gives high yields of viable osteoclasts that can be cryopreserved and can now be 
isolated using one of the membrane reactive antibodies (see chapter III, section m(ii)b).
The success of raising monoclonal antibodies rests on the efficiency of the screening 
protocol employed. Unless this step can cater for the large numbers of supernatants 
produced and be performed at a reasonable speed and with a minimum of effort, the 
production of the hybridomas is likely to fail (Goding, 1986). With these criteria in 
mind it was decided that an indirect immunofluorescence technique would suffice, 
using fixed osteoclastoma tissue and imprints as the substrate. Using this approach it 
was possible to optimize the technique before the fusions were carried out and it 
permitted the use of substrate that had been used as the source of the immunizing 
antigen. The reactivity could then be compared with tissue derived from different 
osteoclastomas in an effort to detect differences in reactivity.
In contrast to the work described by other groups, who have attempted to raise Mabs 
reactive against human osteoclasts, it was possible to verify the reactivity of the 
antibodies on undecalcified cryostat sections of adult human bone. Previous work in 
this area has been limited to the use of human foetal bone for the verification of the anti- 
osteoclastic activity of antibodies (Horton etal, 1985; Nelson etal, 1991). Histological 
(Dodds and Gowen, submitted), histochemical (Dodds, 1992), and 
immunocytochemical (Walsh et al, 1991) studies of the developing osteophyte have 
demonstrated the presence, in this ex vivo human model, of all the cellular elements 
required for the formation and remodelling of bone. Consequently it provided an ideal 
substrate for this study since osteoclasts in various states of activation and 
differentiation were present. This secondary screening phase not only indicated if the
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Mabs were reacting with osteoclasts, but also demonstrated whether they reacted with 
other bone elements. In this way it was possible to to reject non-selective antibodies 
from the first screen and only retain the most selective antibodies for the third screening 
phase. Using this protocol the group of 33 hybrids cloned from the first phase was 





CHARACTERIZATION OF THE TISSUE AND CELLULAR





From the 1213 antibodies that were initially screened for anti-osteoclast reactivity, 11 
were chosen for further characterization against an extensive panel of human tissue and 
blood cell substrates. This was performed in order to find out how selective the 
reactivities of the Mabs were for osteoclasts and also as a pointer to the antigens 
responsible for their reactivities. In addition, cryostat sections from animal long-bone 
samples were probed with the antibodies to demonstrate whether the antigens were 
conserved through these species or whether they were selective for human osteoclasts. 
Each of the antibodies exhibited unique reactivities across this range of human 
substrates and three in particular demonstrated distinctive reactivities; C35 was highly 
selective for bone osteoclasts, C27 showed selective reactivity for osteoclasts, tissue 
macrophages and blood-borne monocytes, and C22 showed selective membrane 
staining of osteoclasts. Consequently C22 has been used to coat Dynabeads to affinity 
purify viable human osteoclasts from osteoclastoma derived cell suspensions.
Immunocytochemical staining of inflammatory osteoarthritic synovium / granulation 
tissue demonstrated positivity in the majority of giant cells with Mabs C22 and C27. In 
contrast C35 reacted with only very occasional giant cells. Furthermore, multinucleated 
cells formed in human long-term bone marrow cultures demonstrated similar selective 
staining. C27 stained all giant cells and the majority of mononuclear cells. C22 
detected only a small proportion of giant cells. In contrast to its staining on bone 
osteoclasts, C22 demonstrated granular cytoplasmic staining in cultured giant cells.
C35 stained no cells at all in these cultures.
These Mabs may therefore distinguish between giant cells of various origins and 
authentic mature osteoclasts. Alternatively they may recognise antigens expressed at 
different stages of osteoclast differentiation and therefore provide an excellent tool for 




The usefulness of monoclonal antibodies may not be diminished by the fact that the 
identity and structure of the antigens with which they react are not known. Such 
antibodies may be used successfully as probes to identify and classify cell populations 
on a purely empirical basis. However, it is important to be aware of the short-comings 
of such an approach. The initial impression that an antigen, recognised by a particular 
monoclonal antibody, is confined to a particular cell lineage may be disproven by a 
more extensive tissue screening program. With regard to the osteoclast-reactive Mabs, 
for example, the term osteoclast-specific cannot be used unless the antibodies have been 
screened on a wide range of tissue substrates and found to be negative. The importance 
of this point cannot be overemphasized and is aptly illustrated by a recent publication on 
the production of a monoclonal antibody with putative reactivity against osteoclast 
precursors (Kukita and Roodman, 1989). Screening results for the reactivity of the 
antibody were limited to cells of the blood and bone marrow, with no mention made of 
other tissue substrate reactivities. Subsequent analysis of this antibody in our laboratory 
against a panel of human tissue and blood cell substrates showed it to react with almost 
all of them, thus refuting the original claim of the authors. The importance of screening 
Mab reactivities is further illustrated by the work of Athanasou et al (1987, 1988,1990) 
who have spent a great deal of time phenotyping the human osteoclast with regard to its 
reactivity with antibodies against other haemopoietic elements, such as cells of the 
monocyte/macrophage and megakaryocyte/platelet lineages. In a similar way they have 
also tested the reactivity of putative osteoclast-selective antibodies (23C6 and 13C2) on 
a panel of normal and pathological tissues to define the distribution of the antigens and 
suggest that the term osteoclast-reacting is a better term to describe their reactivity 
(Athanasou et al, 1990).
In this chapter the reactivities of the panel of osteoclast-reactive antibodies is described, 
using a comprehensive range of techniques including immunocytochemical screening
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on a large selection of human tissue and blood cell substrates. In addition the reactivity 
of the Mabs on bone derived from animal species is tested and also the effects of 




IV.3(i) Monoclonal antibody isotyping
The isotyping of the Mabs is important since it provides important information 
regarding purification strategies, potential uses in immunocytochemical techniques and 
even storage. If the Mabs are of certain IgG subclasses (IgG2a, IgG2b and IgG3), for 
example, they can be efficiently purified using protein A columns whereas other Mab 
isotypes and the other IgG subclass (IgGl) cannot. In the APAAP technique used in 
this study IgM antibodies are not detected. Also, antibodies of this isotype are often 
more efficiently stored at 4°C than at -20°C.
The commercially available kit used for isotyping worked on the principal of reversed 
passive haemagglutination. Each vial in the kit consisted of sheep erythrocytes 
sensitized with a rat monoclonal antibody directed against the heavy chain portion of 
mouse immunoglobulin. A positive agglutination result was achieved when the rat 
antibody on the cells bound specifically to mouse immunoglobulin in the supernatants, 
thus causing cross-linking of the erythrocytes. The kit also provided positive and 
negative controls. The former consisted of erythrocytes sensitized with a polyclonal 
antibody directed against mouse immunoglobulins and the latter of an irrelevant 
antibody bound to the erythrocytes.
The freeze dried reagents consisting of erythrocytes coated with rat anti-mouse IgGl, 
IgG2a, IgG2b, IgG3, IgA and IgM together with the positive and negative controls 
were reconstituted by adding 1 ml of the reconstitution diluent. The cells were gently 
mixed and placed at 4°C overnight. The tissue culture supernatants were diluted 1:5 and 
1:50 in PBS and 30 pi of these were dispensed into each of eight wells across a 96-well 
U-bottomed microtitre plate. The sensitized erythrocyte reagents were gently 
resuspended by inversion and 30 pi was added to the relevant wells. The plate was
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covered, the reagents were mixed by gentle tapping and left to incubate at room 
temperature for 1 hour. Positive agglutination was observed as a carpet of cells in the 
wells and a negative result as a buttoning of the cells.
IV.3(ii) Alkaline Phosphatase Anti-Alkaline Phosphatase (APAAP) on 
osteophyte tissue
Acetone fixed sections of osteophytic bone were overlayed with optimally diluted Mabs 
(determined by dilution on osteoclastoma tissue sections) in 0.05 M TRIS buffered 
saline (TBS, pH 7.6) and a standard APAAP method was performed according to the 
method in chapter II (section n.l(v)), with one minor alteration. Although 1 mM 
levamisole was sufficient to block endogenous alkaline phosphatase in most tissues it 
was observed that a final concentration of 4 mM levamisole (v/v) was needed in the 
substrate to block endogenous alkaline phosphatase activity in bone. Therefore this 
concentration was routinely used in this study. Osteoclastoma was used as a positive 
control tissue in all the immunocytochemical staining protocols where the osteoclast- 
reactive Mabs were used.
IV.3(iii) APAAP staining of cultured human bone marrow giant cells and 
synovial tissue
Human bone marrow derived mononuclear cells were harvested and placed in culture 
according to the method of MacDonald et al (1987) and as described in chapter II 
(section II.4(viii)). When the initial experiments were performed they were carried out 
in 10 cm Petri dishes and after the 14 days culture period the cells were fixed for 5 mins 
with methanol, rinsed with distilled water and air-dried. The fixation was initially 
carried out using methanol because the acetone fixative destroyed the plastic of the Petri 
dishes. Subsequently it was demonstrated that methanol completely ablated the 
reactivity of some of the antibodies so the experiments were repeated using cells that 
had been cultured on poly-l-lysine coated 4-well multi-spot slides. This treatment 
facilitated the attachment of the cells to the surface of the slide. Throughout the culture
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period the level of medium (200 pi / well) was maintained by gently removing half the 
volume and replacing it with fresh medium. The teflon-type coating between the wells 
of the slide prevented the medium from flooding from the individual wells. The 
APAAP technique was performed, as described in chapter II (section II.l(v)) with 
Mabs C22, C27, C35 and a negative control (culture medium).
Fixed cryostat sections of human synovial / granulation tissue which contained 
numerous giant cells as shown by routine histochemical techniques were also processed 
for the APAAP method using the above Mabs and controls. This tissue was associated 
with sites of active bone resorption by osteoclasts.
IV.3(iv) Characterization by indirect IF on human tissues and blood cells
Post-mortem specimens of human kidney, spleen, liver and muscle, and tonsil from 
tonsilectomy were prepared for IF by precipitate immersion in n-Hexane as outlined in 
chapter II (section n.l(iii)).
Normal donor neutrophils (PMNs), mononuclear cells (monos) and erythrocytes 
(RBCs) were isolated from 20 ml of heparinized (10 IU/ml) whole blood taken by 
venepuncture. This was overlayed onto 15 ml of FM-85 density gradient medium and 
the cells were separated by isopycnic centrifugation for 30 mins at 1500 rpm. Three 
populations of cells were obtained ; an upper band of monos, a lower band of PMNs 
and a pellet of RBCs. These were harvested, washed twice by centrifugation in PBS 
and the cell densities adjusted to lx l06/ml in fresh PBS. Poly-l-lysine-coated slides 
were overlayed with 50 pi / well of the cell suspensions, incubated for 30 mins at RT to 
allow cell adherence followed by fixation in acetone for 10 minutes. The slides were air 
dried, wrapped in foil and stored at -70°C until required.
Platelets were isolated from acid-citrate-dextrose treated whole blood (5 ml/20 ml 
blood) and treated as described in chapter V (section V.3(i)a).
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Because of the proposed link between the osteoclast cell lineage and that of the 
monocyte / macrophage an experiment was performed in which mononuclear cells were 
cultured in RPMI-1640 / 10% FCS at 37°C over a period of 24 hrs. At time points 0, 6 
and 24 hrs an aliquot of cells was removed from culture and prepared for IF as outlined 
above. In addition cultured cell lines were also prepared in order to check for any 
shared reactivity. The cell lines used were ROS 17/2.8 (rat osteosarcoma cell line), 
K562 (human erythroblastoid cell line) and HEp2 cells (human laryngeal carcinoma cell 
line).
IF was performed as outlined, with the following modifications. The cells were pre­
incubated for 20 mins with normal rabbit serum (1:5 in PBS) to block Fc receptors. 
Second, the FITC conjugate was supplemented with 1% AB serum and was pre­
absorbed with a mixture of the isolated PMNs and monos to prevent non-specific 
binding.
IV.3(v) Characterization on rat, rabbit and marmoset bone
Fresh tissue was obtained from the long bones of one day old animals and was frozen 
and prepared for screening by APAAP and indirect IF (depending on the isotype of the 
antibody) as described in chapter II (section II.l(v) and Il.l(iv) respectively).
IV.3(vi) The effects of fixation on the reactivity of the Mabs 
It had been noted that a number of the antibodies did not react with formalin-fixed, 
paraffin embedded osteoclastoma tissues (Dr Starkie, personal communication). Since 
this may have implications regarding the success of other assays, such as Western 
blotting, other methods of fixation were assessed. Osteoclastoma tissue was processed 
for cryostat sectioning as previously described. The air dried sections were then fixed 
for 10 minutes either in methanol, 4% paraformaldehyde, 2% gluteraldehyde in 0.2% 
sodium cacodylate and the acetone/citrate buffer used for the TRAP assay. These types
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of fixation were directly compared with unfixed and acetone-fixed sections using the 
APAAP technique. In addition, a time course was carried out to see how quickly 
methanol destroyed the reactivity of the antigen recognised by Mab C35. This was 
performed using slides of osteoclastoma tissue that had been fixed in methanol for 10, 
20, 30 seconds and 1,5, 10 minutes.
IV.3(vii) Western blotting
The techniques involved are described in detail elsewhere (Burnette, 1981; Gershoni 
and Palade, 1983). An osteoclastoma tissue lysate was prepared as the antigen source 
by disrupting and boiling the tissue in SDS sample buffer for 5 minutes. The protein- 
rich supernatant was aliquoted and stored at -70°C until required. To assess optimal 
protein loading the lysate was used at concentrations ranging from neat to 1:32 in 
sample buffer. These were loaded onto a gel, separated electrophoretically and stained 
in Coomassie blue. An optimally diluted aliquot was loaded onto a 10% 
polyacrylamide gel and separated electrophoretically at 20 mA / gel. The proteins were 
transferred to a nitrocellulose sheet by overnight electrophoresis at 150 mA constant 
current. The sheet was removed from the gel and blocked for 2 hours in 5% milk 
powder in PBS (PBSM, pH 7.3. See section II.4(ix)a)) to prevent non-specific binding 
of antibody and conjugate. This blocking step and all subsequent incubations and 
washes were carried with gentle agitation on a rocking table. The gel was stained with 
Coomassie blue to check that all the protein had transferred to the nitrocellulose. The 
nitrocellulose sheet was cut into representative strips and placed into individual troughs 
of an incubation tray. These were incubated for 2 hours at room temperature with either 
5 ml of neat Mab supernatants or a similar volume of supernatants diluted 1:5 and 1:50 
in PBSM. The excess antibody supernatant was removed and the nitrocellulose strips 
were washed for 30 minutes in fresh PBSM. This was replaced with 5 ml / well of 
peroxidase conjugated goat anti-mouse IgG or IgM, optimally diluted in PBSM. This 
was incubated for 1 hour at room temperature, replaced with fresh PBS only and 
incubated for a further 1 hour at room temperature. The binding of antibody was
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detected by adding the chromogenic substrate (see section II.4(ix)b). This consisted of 
0.4% 3-amino-9-ethyl carbazole in dimethylformamide made up in 1 M sodium acetate 
(pH 5) and just before use 1 pi / ml of hydrogen peroxide (30 vol) was added. After 
incubating this on the strips for 30 minutes the reaction was terminated by replacing the 
substrate with distilled water. Molecular weight markers were run in parallel with the 
lysate and stained with 1% amido black to provide a standard curve from which the 
weights of the unknown proteins could be determined.
IV.3(viii) Enzyme dot blots
The majority of Mabs reacted with cytoplasmic elements of the osteoclasts, which are 
known to be enzymatically very active cells. Consequently a number of commercially 
available enzymes known to be present in osteoclasts or involved in matrix degradation 
(Vaughan, 1975; Baron et al, 1986) were utilized in a dot blot assay. These were 
carbonic anhydrase II, cathepsins B,C and D and ATPase (sodium and potassium 
activated).The assay was optimized using human carbonic anhydrase II (CAB) and a 
polyvalent sheep anti-human CAB. 5 pi of the enzymes was dried onto small discs of 
nitrocellulose (5 pg /  disc). The discs were then blocked for 1 hour at RT in PBS 
containing 5% milk powder (PBSM). Each Mab was diluted 1:5 and 1:50 in PBSM 
and placed onto the discs for 1 hour, washed for 30 mins in fresh PBSM and then 
overlayed for a further 1 hour with peroxidase labelled goat anti-mouse 
immunoglobulins diluted 1:1000 in PBSM. Following washing for 30 mins in PBS 
alone, the discs were overlayed with a chromogenic substrate (0.4% 3-amino-9-ethyl 
carbazole in dimethylformamide) and after 30 mins the reaction was stopped with 
distilled water.
IV.3(ix) Enrichment of osteoclasts from tumour with Dynabeads
The procedure was performed using collagenase isolated cells from osteoclastoma 
tissue as described in chapter III (section BI.3(ii)b). Magnetic beads have been used 
previously to isolate cells from human tissue (Nilsson et al, 1987) and more recently
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osteoclasts have been isolated from heterogeneous cell populations derived from chick 
long-bones (Collin-Osdoby et al, 1991). In this study 4xl07 goat anti-mouse IgG 
coated Dynabeads were incubated with culture supernatant from the membrane reactive 
Mab C22 as described in chapter II (section Il.l(vi)). The labelled beads were 
resuspended in 200 pi of fresh buffer and 25 pi was added to a thawed tumour cell 
fraction from the liquid nitrogen store, to give a bead to osteoclast ratio of 
approximately 10:1. After 30 mins incubation at 4°C with constant mixing, the 
bead/cell rosettes were enriched by placing the tube on the magnet. After discarding the 
supernatant the rosettes were washed x3 with fresh cold buffer and the purified cell 
suspension dispensed into a 3 cm Petri-dish. These were cultured overnight in MEM 
medium supplemented with 10% FCS to allow the cells time to adhere. The following 
day the medium was removed by aspiration and the adherent cells were fixed for the 
demonstration of TRAP activity (see chapter II, section II. 1 (ii)).
In repeat experiments the isolated cells were settled onto dentine slices and cultured as 
described in chapter III (section IH.3(i)c). The slices were washed, fixed and stained in 




IV.4(i) Reactivity of Mabs with human osteoclasts in bone sections"
All 11 antibodies reacted with osteoclasts but not osteoblasts in sections of 
undecalcified adult human bone (Table IV. 1). Of these, 9 were reactive against 
cytoplasmic components of the osteoclasts and the remaining 2 with plasma membrane 
antigens. 6 were of the IgGl isotype, 1 of the IgG2a and 4 of the IgM isotype.
Examples of three antibodies, C22, C35 and C27 are shown (Figs IV. 1-4). C22 is a 
membrane reactive Mab which reacted strongly with all osteoclasts in the sections of 
bone tested from different donors. C27 is a cytoplasmic reactive Mab which stains all 
the osteoclasts in the bone sections and also a population of mononuclear cells in the 
marrow space. C35 is also cytoplasmic reactive and appears to be extremely specific for 
osteoclasts in the sections of bone. However, unlike C22 and C27 it did not react with 
all osteoclasts in all the sections of bone tested. Indeed there were qualitative 
differences in staining not only on sections from different donors but also on sections 
from different sites derived from the same donor. This differential staining 
phenomenon was also evident with other Mabs tested, particularly C20 and C26 (Table
IV.2).
IV.4(ii) Characterization on cultured bone marrow and inflammatory giant 
cells
Mab C27 stained all of the giant cells and the majority of mononuclear cells in the bone 
marrow cultures (Fig IV.5). C22 demonstrated reactivity against a small proportion of 
giant cells. However unlike the membrane staining seen on bone osteoclasts, a granular 
cytoplasmic pattern was detected (Fig IV.6). C35 was negative on all cells (Fig IV.7). 
The staining in the inflammatory synovium tissue from the osteoarthritic femoral head 
showed the following patterns; C27 stained all giant cells and the majority of associated
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T ab le  IV . 1. C haracterization  o f  the m on oclon a l an tib od ies bv indirect im m u n o flu o rescen ce  on  a 
panel o f  hum an tissu e  substrates.
T h e table in d ica tes the in ten sity  o f  sta in in g  on  a variety  o f  hum an tissu es  in c lu d in g  b o n e , - =  
n eg a tiv e , + /-  =  w eak  sta in in g , + + +  =  strong sta in in g , m acros =  m acrop h ages. T h e pattern o f  
sta in in g  ob served  in  the o steo c la sto m a  tissu e  w as iden tica l to that o b serv ed  in bone.
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Reactivities of Mabs C22. C35 and C27 against osteoclasts in 




Fig IV. 1. The plasma membrane reactive antibody C22 is shown reacting with two 
osteoclasts (OC) apposed to the bone surface (BS). Mononuclear cells (M) in the bone 
marrow space exhibit no staining. APAAP x200.
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Fig IV.2. Less selective staining is demonstrated by C27 which in addition to its strong 
osteoclast (OC) reactivity, also reacts against a population of mononuclear cells (M) in 




Fig IV.3. The strong and very selective cytoplasmic reactivity of C35 is shown on three 
osteoclasts (OC) immediately apposed to the bone surface. The mononuclear cells (M) 
in the marrow space showed no reactivity with this antibody. APAAP x200.
Fig IV.4. The negative control shows no reactivity against the osteoclast (black arrows) 
on the bone surface (open arrow) or any other cells in the section. The addition of 4 
















C3 + occasional OC ++ + ++ ++ + occasional OC
C4 + + ++ ++ + ++
C8 N.D. N.D. N.D. N.D. N.D. +/- occasional 
OC
C13 ++ + ++ + ++ N.D.
C20 N.D. N.D. + N.D. ++ occasional 
OC
+/ . occasional 
OC
C22 ++ ++ ++ ++ ++ +++





C27 ++ ++ +++ +++ +++ ++
C28 +++ ++ ++ + -H-
+/- occasional 
OC some +
C35 ++ occasional 
OC
++ ++ +/- ++ -H-+
Tabl£JY,2t MQnpglQnal amitxxiy reactivities directed against osteoclasts of the developing osteophyte, 
The differential staining of some of the antibodies is illustrated in this table. Some Mabs stain only 
occasional osteoclasts in the sections (e.g. C3, C20, C26). However, in other osteophyte sections they 
stain all the osteoclasts present to the same degree (e.g. C3, C35). Some Mabs appear to stain all the 
osteoclasts within the sections to the same degree (C4, C13, C22, C27). N.D. = not done, OC = 
osteoclasts, +/- = weak staining, +++ = strong staining.
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mononuclear inflammatory cells (Fig IV. 8), C22 appeared to stain all giant cells with a 
predominantly membrane pattern (Fig IV.9) and C35 stained only very occasional giant 
cells (Fig IV. 10. The negative control is shown in fig IV. 11). The staining of the 
osteoclasts associated with the spicules of bone within this inflammatory tissue was 
similar to that seen in the bone sections described earlier.
IV.4(iii) Characterization on tissues and blood cell substrates
The anti-osteoclast selectivity of the Mabs was checked by screening them on a variety 
of tissues (Table IV. 1), blood cells (Table IV.3) and cultured cells (Table IV.4).
A number of staining profiles were detected. This ranged from broad reactivity of C4 
and C13 to a more selective C35 which, apart from its osteoclast reactivity, only reacted 
with a cytoplasmic constituent of hepatocytes. Other interesting reactivities included C8 
which reacted with human leukocytes and a number of tissue substrates including nerve 
bundles present in the muscle tissue. C27 reacted strongly and selectively with tissue 
macrophages in liver (Fig IV. 12), tonsil (Fig IV. 13) and spleen (Fig IV. 14) and also 
with blood monocytes.
The reactivity detected on the cultured peripheral blood mononuclear cells (Table IV.4) 
was similar to that seen on the fresh cells. However, there did appear to be a decrease 
in the reactivity of C l3 over the culture period. C22 detected only platelets present in 
the cultures and C27 stained only large mononuclear cells and the occasional 
contaminating neutrophil. None of the Mabs reacted against the ROS 17/2.8 rat 
osteosarcoma cell line and only C4 reacted against the human K562 line. This Mab also 
demonstrated reactivity with the HEp2 cells as did C8 (weak reactivity) and C27 
(polarised reactivity in some cells).
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Reactivities of Mabs C27. C22 and C35 against giant cells in human 
lQng-Isrm-marrQw cultures,
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Fig IV.5. C27 demonstrated strong reactivity with all the giant cells (G) in these 
cultures and also the majority of mononuclear cells (M). APAAP x200.
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Fig IV.6. In contrast with the above staining, C22 reacted with only a minor population 
of giant cells (G) in these cultures and the pattern of reactivity was an uncharacteristic 
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Fig IV.7. C35, although very selective for osteoclasts in bone, showed no reactivity 
against the giant cells (G) or mononuclear cells (M) in these human long-term marrow 
cultures. APAAP / haematoxylin counterstain x200.
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Reactivities of Mabs C27. C22 and C35 against giant cells in human 
inflammatory osteoarthritic svnovium / granulation tissue.
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Fig IV.8. This study was carried out on serial sections of the inflammatory tissue so 
that each figure shown should represent the same area of tissue on consecutive slides. 
This shows the strong reactivity of C27 against giant cells (G) and a population of 
mononuclear cells (M) present in this substrate. APAAP x200.
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Fig IV.9. C22 demonstrates strong membrane staining with a large number of giant 
cells (G) and a population of mononuclear cells (M). APAAP x200.
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Fig IV. 10. C35 reacted with only a very small number of giant cells (G) in this tissue, 
often weakly. Some positively stained mononuclear cells (M) were also seen. This type 
of selective staining has also been demonstrated in the rheumatoid pannus tissue 
(unpublished observation). APAAP x200.
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. Mab RBCs Platelets MONOS PMNS Western Blotting 
( K d )
C3 - - - - NOT
DETECTED
C4 - - + + NOT
DETECTED
C8 - - + + NOT
DETECTED
C13 - - + + NOT
DETECTED
C20 - - - - 87
C21 - - - - ND
C22 - ++ - +/- NOT
DETECTED







C28 - - - - 77
C35 - - - - NOT
DETECTED
Table IV ,3 , The characterization Qf the Mab§ by indirect immunofluorescence on fixed  h u m an  
peripheral blood c e lls  and bv W estern b lotting.
R B C s=  red b lo o d  c e lls , M on os= m on on u clear  c e lls , P M N s =  p o lym orp h on u clear  neutroph ils, K d =  
k ilo d a lto n s. T h e d egree  o f  p ositiv ity  w as graded as d escrib ed  for table 1.
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Tissue reactivities o f C27
C27 demonstrated reactivity against blood-bome monocytes and against tissue 
macrophages in many of the tissue substrates screened. This is an interesting 
observation with regard to the theory that these cell types are believed, by some, to be 
derived from the same ontogenic pathways. The following figures show the reactivity 
of this Mab against three of the tissue substrates by indirect immunofluorescence.
Fig IV.12. The reactivity of Mab C27 is demonstrated against kuppfer cells in the liver 
(K). The hepatocytes show a degree of autofluorescence which appears as a non­
specific yellow colouration. FITC x400.
1 3 2
Fig IV.13. This section of tonsil shows reactivity of C27 against a resident macrophage 
(M). FITC x400.
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C20 - - - - - -
C21 - - - - - -
C22
(++ platelets) (++ platelets) (++ platelets)
- - -
C26 - - - - - -
C27 ++ PMNs and 
large monos






C28 - - - - - -
C35 - - - - - -
T ab le IV .4 . C haracterization  o f  M abs on cultured P B M s and c e ll lin es
O ccasion a l co n tam in atin g  neutrophils (P M N s) w ere d e tec ted  in  the P B M  cu ltures and w ere  sta ined  
strongly  w ith  M ab C 2 7 . P B M s=peripheral b lood  m on on u clear  c e lls . + +  p la te le ts  in d ica tes  the 
strength o f  sta in in g  o f  con tam inating  p latelets present in the cu ltures. T h e  d eg ree  o f  p o s itiv ity  w as  
graded as d escr ib ed  for tab le  IV . 1.
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IV.4(iv) Reactivities against rat, rabbit and marmoset bone
The majority of the Mabs demonstrated no reactivity against any of these substrates 
(C l3, C20, C22 and C27). However, C21 showed strong and selective staining 
against osteoclasts in all of the tissues. OB/I reacted strongly with osteoclasts in fabbit 
bone but very non-selectively against many of the cell and bone elements in the rat and 
marmoset sections (see chapter V, section V.4(ii) for the characterization of OB/I). 
Although C35 did not react with rat and rabbit osteoclasts there was some weak 
reactivity seen in some marmoset osteoclasts (Table IV.5).
IV.4(v) Effect of fixation on the reactivity of the Mabs
This study demonstrated that the reactivity of all but one of the Mabs was completely 
ablated by fixation in methanol and was drastically reduced in the remaining one (C27). 
A similar removal of activity was produced by fixation of the tissue in formaldehyde 
and gluteraldehyde based fixatives. However, reactivity was maintained when the 
sections were fixed in parafomaldehyde, but some non-specific background staining 
was apparent in the majority of these preparations (Table IV.6). The time course 
experiment, in which sections of osteoclastoma were fixed for varying lengths of time 
in methanol, revealed that the reactivity of the antigen recognised by C35 was almost 
completely destroyed after 10 seconds fixation (Figs IV. 15-16).
IV.4(vi) Western Blotting
Two of the Mabs, C20 and C28 demonstrated reactivity by this technique against 87 
and 77 Kd protein bands respectively (Table IV.2). All the other Mabs failed to 
recognise the denatured proteins. To check if the lack of reactivity was due to the 
antigen source this procedure was repeated using antigen preparations derived from 
different osteoclastomas. For C l3, C27 and C35, preparations of U937 cells have been 
used (see chapter VI, section VI.3 (ii-iv)). Different methods for preparing the antigens 
were tried, including boiling them directly in SDS sample buffer to preparing detergent 
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staining
Table IV.5 Characterization of the Mabs against rat, rabbit and marmoset bone. 
* Demonstrated by indirect IF. The remainder were tested by APAAP.
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Table IV.6. Effect of various fixatives on the reactivity of the Mabs, Cryostat sections of osteoclastoma were air dried and fixed in the above 
fixatives for 10 minutes at room temperature. They were then overlayed with the appropriate Mab and the binding visualised using the 
APAAP technique. CD 13 - reacts with granulocytes, monocytes/macrophages and osteoclasts. CD68 - Pan-mononuclear phagocyte system 




Effect o f methanol fixation on the reactivity of the antigen recognised by
Mab C35
Fig IV. 15. Fixation for just 10 seconds in methanol almost completely ablates the 
reactivity of the antigen recognised by C35, as shown by this section of osteoclastoma 
tissue. One very weakly stained osteoclast (OC) can be seen but the rest of the tissue is 
completely negative. APAAP x200.
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Fig IV. 16. In contrast to the above section, the strong reactivity of C35 against 
osteoclasts (OC) can be seen in this section after 10 minutes fixation in acetone. A 
similar degree of reactivity was observed at each time point and was comparable to that 
of unfixed sections of osteoclastoma that were stained in parallel. APAAP x200.
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All methods gave negative results. In light of the finding that the antigens with which 
the Mabs reacted were destroyed by methanol fixation, the transfer of the proteins to the 
nitrocellulose was performed using methanol-free buffers. This did not restore 
reactivity.. To check if the problem was one of sensitivity, first an 125I-labelled second 
antibody was used, and then a biotinylated C35 antibody in conjunction with an avidin / 
alkaline phosphatase second label were used. Again these were unsuccessful. Dot blots 
were performed using osteoclastoma-derived, and U937-derived proteins. These were 
prepared by either sonication or detergent lysis (0.2% Triton in PBS) in the presence of 
a cocktail of protease inhibitors. A chequerboard titration was performed in which the 
proteins were dispensed onto nitrocellulose in a range of concentrations (0 - 30 pg / dot 
blot well) and were probed with different dilutions of the Mabs (0 - 1:200). The only 
positive reactivity consistently detected was with the immune serum derived from the 
mice used for the anti-osteoclast fusion program.
IV.4(vii) Enzyme dot blots
In agreement with the results obtained for the majority of Mabs in the Western blotting 
and osteoclastoma protein dot blots, all 11 Mabs were negative against each of the 
enzymes used in this assay.
IV.4(viii) Dynabead separation of osteoclasts
C22-coated Dynabeads were used to isolate osteoclasts from collagenase treated 
osteoclastoma cell suspensions (Fig IV. 17). Enriched osteoclasts (Fig IV. 18) were 
shown to be viable by their ability to adhere to plastic petri dishes and their expression 
of TRAP activity (Fig IV. 19) after 24 hours in culture. In addition, it was possible to 
enrich the number of osteoclasts obtained from the cryopreserved cell suspensions and 
settle them onto dentine slices. After 24 hours in culture the osteoclasts had adhered to 
this substrate and resorbed pits as demonstrated by toluidine blue staining (Fig IV.20)
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C22-coated magnetic beads for the separation of osteoclasts from
CQlla&enase treated u stm lastQ m a tissue
Fig IV. 17. This demonstrates the appearance of the osteclastoma-derived cell 
suspension prior to the isolation of the osteoclasts coated with the Mab coated magnetic 
beads. Giemsa xlOO
Fig IV. 18. The appearance of an osteoclast, coated with beads is shown after 
separation from the total cell suspension. Giemsa x900 (water immersion).
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Fig IV. 19. The viability of the osteoclasts (OC) was demonstrated by overnight culture 
in Petri dishes. The adherent cells were fixed and stained for TRAP activity as shown 
above. TRAP x200.
4 *
Fig IV. 20. The presence of beads on the surface of the osteoclasts did not prevent the 
adhesion of the osteoclasts to the whale dentine or inhibit their resorptive function, as 
demonstrated above. RP = resorption pits. Toluidine blue xlOO.
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IV.5 Discussion
In this panel of Mabs 9 of the 11 antibodies described were reactive with cytoplasmic 
antigens. This may be due to the use, in our immunization protocol, of cell suspensions 
stored in liquid nitrogen. The thawing process may have caused disruption of the cells 
with the resultant release of cytoplasmic constituents. In contrast, Horton et al (1985) 
produced six antibodies reactive with plasma membrane antigens. This increased the 
frequency of membrane reactive antibodies may have been due to the use, at least in 
part, of fresh tumour preparations as immunogen. Nelson et al, (1991) used 
cryopreserved osteoclastoma in their immunization protocol and produced two 
osteoclast membrane reactive antibodies from 111 screened hybridomas.
The selectivity of the Mabs to the osteoclast lineage was checked by screening them on 
a number of human tissue and blood cell substrates. Some of the Mabs, such as C4 and 
C l3, showed broad reactivity against the substrates used. Conversely C35, was very 
osteoclast selective. With respect to the notion that osteoclasts share their origin with 
monocytes, the staining properties of C27 are of interest. This Mab selectively stained 
differentiated macrophages in liver, tonsil and spleen sections and also selectively 
stained blood-borne monocytes in mononuclear leukocyte preparations. This 
observation differs from that reported by Horton et al (1984, 1985) who concluded 
that the osteoclast was not derived from the macrophage / monocyte lineage because of 
the lack of staining obtained when osteoclasts from rodent and human sources were 
reacted with a battery of monocyte reactive Mabs. It does, however, coincide with the 
observations of Nijweide et al (1985) who raised quail osteoclast-reactive Mabs with 
similar staining on tissue-derived macrophages as C27.
C22, one of only two membrane reactive Mabs in our panel, also showed an interesting 
pattern of reactivity on the substrates used. There was strong staining in the red pulp of
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the spleen and weak staining of the renal tubules, but more striking was the strong 
reaction against platelets. The pattern of reactivity on these substrates, coupled with the 
lack of reactivity seen on avian (Dr M Horton, personal communication) and rodent 
osteoclasts, is highly suggestive of reactivity to the vitronectin receptor and more 
precisely its p3 subunit. This required clarification, and characterization of its reactivity 
is described in chapter V (section V.4(i)a-(i)c).
We have successfully used the plasma membrane reactive Mab C22 to coat magnetic 
Dynabeads and to isolate osteoclasts from osteoclastoma-derived cell suspensions. In 
addition to mature osteoclasts, a population of mononuclear cells also selectively bound 
to the beads. However these cells were difficult to characterize because they bound too 
many beads for us to define their morphology, TRAP activity, and their ability to react 
with other Mabs from our panel. This system is being optimized for mononuclear cells 
so that a predefined number of beads per cell can be used, thus allowing further 
characterization of this putative precursor population. Interestingly it was possible to 
isolate the osteoclasts with the coated beads and seed them onto dentine, into which 
they subsequently resorbed pits. This indicates that the binding of the beads did not 
inhibit the ability of the osteoclasts to bind to the substrate and suggests that this may be 
an ideal way of isolating homogeneous populations of these cells. Isolated osteoclasts 
could then be used in resorption assays or as a substrate for testing factors with putative 
effects on their function In a recent paper by Collin-Osdoby et al (1991), they describe 
the use of magnetic beads coated with osteoclast-selective antibody for the purification 
of chick osteoclasts from mixed cell populations. In agreement with the observations 
above they found that the binding of these beads did not impair their ability to bind to 
plastic, or to resorb pits in cortical bone slices. Similar to my observations, they 
concluded that magnetic beads provided a gentle method for the isolation of viable 
osteoclasts from heterogeneous cell populations.
143
Ch IV
Only two of the Mabs showed any reactivity against protein bands by the Western 
blotting technique. This is not an unexpected result since Mabs by definition are highly 
specific for a single epitope on an antigen. It is likely, therefore, that this site is totally 
denatured during preparation of the antigen, thus making it unrecognisable by the 
antibody (Goding, 1986). A recent publication by Nelson et al, (1991) in which they 
describe the production of two osteoclast-reactive Mabs, also indicates a lack of 
reactivity of both antibodies by Western blot analysis. They suggest that the target 
epitopes were conformational as an explanation for their lack of reactivity. In addition, 
they also make the point that their antibodies do not react with formalin-fixed paraffin- 
embedded sections of osteoclastoma. They therefore suggested that the epitopes were 
denatured by the fixation process. This is a similar finding to that observed with a 
selection of our antibodies (Dr Starkie, personal communication) and suggests that 
acetone-fixed tissue expresses antigens that are destroyed by harsher techniques. Also, 
it was demonstrated that the reactivity of Mabs such as C35 were very sensitive to 
methanol fixation; short exposures of 10 seconds in this solvent completely ablated any 
reactivity of C35. Since many transfer buffers used in Western blotting techniques 
contain methanol, it was suggested that this may have an adverse effect on the success 
of this technique using antibodies such as C35. However the removal of methanol from 
the transfer buffer did not affect the reactivity, indicating that this was possibly only 
part of the problem regarding the lack of reactivity in this technique.
The selectivity of these Mabs for osteoclasts was demonstrated by IF and by APAAP 
on sections of undecalcified adult human bone. This tissue expressed large numbers of 
osteoclasts in various states of activation and proved to be an ideal substrate for 
screening our antibodies. To find out how selective the antibodies were for human 
osteoclasts some of the antibodies were tested on bone derived from rat, rabbit and 
marmoset long-bones. Some antibodies (Cl3, C20, C22 and C27) demonstrated no 
reactivity on these substrates, C35 demonstrated only weak reactivity with osteoclasts 
in marmoset bone, but C21 reacted selectively with osteoclasts in them all. This latter
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antibody has been used in experiments to localize its reactivity in rat osteoclasts by 
electron microscopy (Lynn Neff, personal communication). These studies indicate that 
the reactivity is localized to cytoplasmic vesicles often associated with the ruffled 
border. This work is being pursued using human osteoclastoma-derived tissue to 
localize the reactivity of this and other antibodies in the panel. This may help localize 
their reactivity to certain organelles and assist in identifying the reactive antigens, since 
the organelles could be isolated by differential centrifugation on sucrose gradients and 
studied in isolation.
Another interesting finding was that some of the Mabs (C20, C21,C26, C35) showed 
differential staining of the osteoclasts in the osteophyte substrate, while others stained 
all the osteoclasts present (C22, C27, C28). Similarly, differential staining was also 
observed on sections of inflammatory synovium from the osteoarthritic femoral head 
and on cells derived from long term cultures of human bone marrow. On the sections, 
C27 and C22 appeared to stain all the giant cells present. In addition, while C27 also 
stained the majority of mononuclear cells, C22 only stained a small population of these 
cells. Conversely C35, the most selective Mab, only reacted with very occasional giant 
cells. Also of interest was the staining patterns observed on the bone marrow cultures. 
It has been suggested that the cells in these cultures fulfil a number of histological, 
structural and functional criteria of osteoclasts (MacDonald etal, 1987). However, C35 
did not react with any of the giant cells, C27 stained all the giant cells and the majority 
of mononuclear cells present and C22 appeared to stain only occasional giant cells with 
an uncharacteristic granular cytoplasmic pattern. In a similar way Athanasou et al 
(1988) also detected differential staining of osteoclasts in foetal bone imprints using 
Mabs reactive with the CD 15 group of antigens. They noted that certain cells in these 
preparations did not express these antigens on their surface. The reasons for the 
differential reactivity may be three-fold. First, it may indicate that the Mabs are 
detecting osteoclasts at different stages of activation, although we were unable to 
correlate the staining to resorption since some cells away from the bone surface also
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stained. Second, the population of cells termed osteoclasts may encompass a 









The previous chapters describe the production and initial characterization of a panel of 
osteoclast-reactive monoclonal antibodies. This chapter describes the further 
characterization of Mab C22 and introduces another osteoclast-selective Mab, derived 
from an osteoblast immunization schedule, designated OB/I.
C22, has now been shown to be reactive against the p3 chain of the vitronectin 
receptor. Apart from anti-osteoclast reactivity, C22 also reacted against normal human 
platelets. In contrast, platelets derived from patients suffering from Glanzmann's 
thrombasthenia, which are deficient in glycoprotein Ilb/IIIa (Ilia is the p3 moiety), 
showed no reactivity. Immunoprecipitation analysis of C22 against a melanoma cell line 
rich in the vitronectin receptor showed reactivity with a 160/85 Kd heterodimer 
characteristic of this integrin.
The reactivity of OB/I is also of great interest, not least because it was produced using 
1,25D3 treated human trabecular bone cells as the immunogen (Walsh et al, 1991). In 
addition to raising eleven osteoblast reactive antibodies from this immunization 
schedule, three others demonstrated strong reactivity against human osteoclasts, OB/I 
being the most selective. It showed strong reactivity against osteoclasts and a select 
population of mononuclear cells in osteoclastoma tissue and significandy with 
osteoclasts in adult bone sections. Surprisingly, no reactivity was demonstrated against 
osteoblast-like cells that had been cultured in the presence or absence of 1,25D3 (normal 
human osteoblasts, osteosarcoma and MG63 cells and rat ROS 17/2.8 cells), or 
osteoblasts in sections of bone. The staining pattern of OB/I ranged from diffuse 
cytoplasmic to a localised reactivity on the cytoplasmic side of the plasma membrane. In 
addition to its anti-osteoclastic reactivity OB/I also demonstrated reactivity against a 
number of human substrates by indirect immunofluorescence. This included reactivity 
against cultured cell lines such as Chang liver cells and the myelomonocytic leukaemia
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cell line U937. Strong staining was also detected in select clusters of spleen cells and 
against renal tubules and erythrocytes. In some cadaver skin specimens reactivity of 
OB/I was observed in a linear pattern along the basement membrane and on select cells 
in the epidermis and upper dermis. In a similar fashion to the osteoclast-reactive 
antibodies OB/I was sensitive to some fixatives which completely abolished its 
reactivity. Preliminary dot blot analysis suggests that OB/I may be reacting with 




One of the membrane reactive Mabs, designated C22, demonstrated a pattern of 
reactivity on a number of tissue substrates which indicated that it may be reacting 
against the p3 chain of the vitronectin receptor. To summarize its reactivities, strong 
staining was observed by immunocytochemistry against osteoclasts, platelets and a 
population of cells in the red pulp of the spleen, but no reactivity was demonstrated in 
rat or avian osteoclasts (Dr M Horton personal communication).
The vitronectin receptor is a heterodimeric glycoprotein consisting of a 135-160 KD a 
chain and a smaller 85-100 KD p chain. It shows homology with a number of other 
receptors which are collectively called integrins (Hynes, 1987). These molecules are a 
widely distributed supergene family of heterodimeric membrane proteins that are 
involved in cell adhesion (Du et al, 1991). They recognize their ligands, at least in part, 
via the Arg-Gly-Asp (RGD) tripeptide (Pierschbacher and Ruoslahti, 1984). Horton et 
al (1985) have raised two Mabs that demonstrate reactivity against different epitopes on 
the a  chain of the VNR and have recently described the production of two Mabs 
reactive against the p3 chain of the vitronectin receptor on rat osteoclasts (Helfreich et 
alt 1992).
Glanzmann's thrombasthenia is a congenital platelet disorder with an autosomal 
recessive pattern of inheritance and is characterized by a normal platelet count, 
prolonged bleeding time, abnormal clot retraction and absent platelet aggregation in 
response to a number of factors such as ADP and thrombin. A number of groups have 
shown that these platelets are deficient in two membrane glycoproteins designated nb 
(otllb) and Ilia (p3) and that these are required for normal platelet function (Nurden and 
Caen, 1974; Phillips and Poh Agin, 1977).
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Part of this chapter describes the characterization of Mab C22, demonstrating its 
reactivity with the p3 chain of the vitronectin receptor on human osteoclasts. This was 
achieved by indirect immunofluorescence on fixed normal platelets and FACs analysis 
of viable platelets derived from normal and thrombasthenic individuals. In addition, 
immunoprecipitation was carried out using human DX3 melanoma cells which are rich 
in the vitronectin receptor.
The distribution of reactivity in various tissue and blood cell substrates, and preliminary 
dot blot analysis suggests that Mab OB/I may be reacting with the carbonic anhydrase II 
isoenzyme. During osteoclastic resorption of bone the acidification of the resorption 
compartment is maintained by the secretion of protons across the ruffled border. These 
protons are supplied by the carbonic anhydrase II isoenzyme which is found in 
abundance in the cytoplasm of these cells. It achieves this by catalyzing the reversible 
hydration of CO2 to produce bicarbonate ions, whose accumulation is dealt with by the 
chloride exchanger, and protons. The presence of CAII has been demonstrated in 
osteoclasts by histochemistry, in which its reactivity could be inhibited in the presence 
of the specific inhibitor acetazolamide (Marie and Hott, 1987), and 
immunocytochemistry (Gay et al, 1983) techniques. Sly et al (1983) have described a 
condition caused by a deficiency of this enzyme in which osteopetrosis is found in 
association with renal acidosis and cerebral calcification.
The antigens with which these two antibodies react may play an important role in the 
control of osteoclast function and may provide good phenotypic markers for the 




V.3(T) Characterization of C22
V.3(i)a Indirect immunofluorescence of normal human platelets
All steps were carried out at room temperature. Normal donor platelets were separated 
according to the method described by Haeney (1981). 20 ml of venous blood was 
placed into 5 ml of acid citrate dextrose (ACD). Following centrifugation at 400 g for 
10 mins the platelet-rich plasma was removed, washed x3 in fresh ACD and the density 
adjusted to 2xl06/ml in phosphate buffered saline (PBS). 50 pi of this suspension was 
deposited onto individual wells of poly-l-lysine coated 10-well multispot slides and 
incubated for 30 mins. Excess buffer was removed, the preparations fixed for 10 mins 
in acetone and wrapped in foil and stored at -70°C until required. A standard method 
for indirect immunofluorescence was carried out using PBS, supplemented with 2% 
foetal calf serum as the wash buffer and an FITC-labelled goat anti-mouse 
immunoglobulin as the second antibody. The preparations were mounted using 90% 
glycerol in PBS (v/v) and examined microscopically.
V.3(i)b FACS analysis
The staining protocol used for labelling human platelets from both thrombasthenic and 
normal individuals was that of Tschope et al (1990). 9 ml of venous blood was added 
to 1ml of anticoagulant (130mM sodium citrate, 55 pM acetyl-salicylic acid, 30 pm 
prostaglandin E in PBS) and platelet-rich plasma obtained by centrifugation for 10 mins 
at 200g. The platelets were sedimented by further centrifugation at 700g for 5 mins, the 
supernatant was removed and the pellet was resuspended in 1.8 ml of a dilution 
medium (3.8% sodium citrate in PBS). The platelets were preincubated with 200 pi of 
rabbit serum and their count adjusted to 5xlOVml. 50 pi of primary antibody was 
overlayed onto 200 pi of platelet suspension and incubated for 60 mins. Following 
washing, the platelets were incubated for a further 30 mins with 100 pi of optimally
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diluted sheep anti-mouse F(ab)2-HTC secondary antibody. The platelets were finally 
washed and diluted to 2.5 ml and analysed by flow cytometry (488nm excitation 
wavelength).
V.3(i)c Immunoprecipitation
The (33 chain of the vitronectin receptor was immunoprecipitated from the DX3 human 
melanoma cell line. Starved cells were metabolically labelled with 35S-methionine for 2 
hours at 37°C, re-fed overnight and then lysed on ice in RIPA lysis buffer (150 mM 
NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% sodium dodecylsulphate, 50 mM TRIS, 
pH 7.5) for 30 mins. The lysate was centrifuged and the supernatant precleared with 
Sepharose-protein A. 200 pi volumes of C22 and control tissue culture supernatants 
(13C2,23C6) were incubated with rabbit anti-mouse coated Sepharose-protein A 
beads for 1 hour in a total volume of 500 pi TRIS buffer. Following extensive washing 
the antibody coated beads were incubated with the cell lysate overnight at 4°C. The 
beads were washed as before, boiled in SDS sample buffer and the proteins resolved 
by electrophoresis in a 7.5% polyacrylamide gel. The gel was dried and exposed for 24 
hours on X-ray film.
V.3(iD Immunocvtochemical characterization of OB/I
OB/I was initially screened as part of the osteoblast panel of monoclonal antibodies, but 
its reactivity on osteoclastoma and bone tissue demonstrated its strong reactivity against 
osteoclasts and its lack of reactivity against osteoblasts. Following its initial screening 
on the osteoclastoma and osteophyte substrates it was extensively screened on many 
human tissue and blood cell substrates, cultured cell lines and tissue derived from rat 
rabbit and marmoset long-bones. This was carried out according to the method 




V.4(i)a C22 reactivity on fixed normal platelets
The reactivity of Mab C22 against osteoclasts in osteoclastoma tissue and bone is- 
demonstrated by immunocytochemistry in Figs 131.4 and IV. 1 respectively. In addition 
. the distribution of its reactivity against other human tissue and blood cell substrates is 
listed in tables IV. 1-3. C22 demonstrated strong reactivity against the platelet 
preparations (Fig V.l) using indirect immunofluorescence on the fixed preparation of 
normal human platelets. In contrast the av chain reactive antibodies, 23C6 and 13C2 
demonstrated no reactivity using this technique. Since the platelets are devoid of nuclear 
material it was not possible to counterstain the preparations with ethidium bromide for 
their demonstration by indirect immunofluorescence. Therefore these negative data are 
not shown.
V.4(i)b FACS analysis of C22 against normal and thrombasthenic 
platelets
No reactivity was detected with the C22 antibody when reacted against two siblings 
homozygous for Glanzmann's syndrome (Fig V.2a). Consistent with the literature 
(Philips and Poh-Agin, 1977) platelets derived from their parents, who are 
heterozygous for this condition, did react with the antibody but this positivity was less 
than that seen with the normal donor platelets (Fig V.2b).
These results suggested that C22 was reacting with either the whole Ilb/IIIa (allb/p3) 
complex or its individual components.The idea that C22 was reacting with the p3 chain 
was derived by a process of elimination. It was shown to react strongly with 
osteoclasts that express the av/p3 integrin and also with normal platelets which express 
cdlb/p3. However, since it does not react with the thrombasthenic platelets which are 
lacking the allb/p3 chain it is most likely that C22 reacts with the p3 chain. It should be 
noted, however that the vitronectin receptor has been isolated from platelets (Lam et al,
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1989) but it is present in small amounts. FACS analysis at the 4th Leukocyte 
Workshop (Knapp et al, 1989) demonstrated that the level of reactivity of anti-av 
antibodies (13C2, 23C6) against platelets was very low in comparison to that of anti-p3 
reactive antibodies. This was confirmed in our laboratory since no reactivity was- 
demonstrable against normal, fixed platelets by indirect immunofluorescence using 
. 23C6 antibody. In order to verify the reactivity of C22, immunoprecipitation was 
carried out using a cell line rich in the p3-containing vitronectin receptor.
V.4(i)c Immunoprecipitation of the vitronectin receptor
The autoradiograph (Fig V.3) demonstrates that Mab C22 immunoprecipitates an av/p3 
heterodimer, identical in molecular weight to the positive controls 23C6 and 13C2. 
These latter Mabs have been shown to be reactive with different epitopes on the av 
chain of the vitronectin receptor.
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Reactivity o f C22 with normal human platelets
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Fig V .l. Very strong reactivity of this antibody was demonstrated against the platelet 
preparations. This was in stark contrast to the lack of reactivity demonstrated by the av- 
reactive Mabs 23C6 and 13C2 which did not react with these preparations using this 
technique (data not shown). FITC x400.
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V.4(ii) Immunocytochemical characterization of OB/I
The reactivities of OB/I against an extensive range of tissue and blood cell substrates 
was demonstrated using indirect immunofluorescence (Tables V.l-3). OB/I, like the 
majority of Mabs from the osteoblast-immunization schedule was of the IgM isotype 
(Table V.l), and because of the limitations of the APAAP technique used in this study 
- it was not possible to use it for screening these antibodies. OB/I demonstrated strong 
reactivity against osteoclasts in both osteoclastoma tissue (Fig V.4) and bone (Fig V.5). 
The pattern of reactivity varied from a diffuse pattern throughout the cytoplasm in 
some osteoclasts to a more localized pattern, where the reactivity was associated with 
the plasma membrane. This latter pattern was the most often seen in osteoclasts in 
osteoclastoma tissue. Although quite variable in number there were often numerous 
positive mononuclear cells present in the osteoclastoma and bone tissues. In human 
spleen, the reactivity was very localised to small clusters of cells throughout the tissue 
section (Fig V.6) and in kidney tissue the positivity was detected in tubules (Fig V.7). 
The only other reactivity noted in the substrates screened was against cadaver skin (Fig
V.8). The appearance of this reactivity was intermittent and positivity was demonstrated
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Fig V.3. When reacted with 35S labelled DX3 melanoma cells, Mab C22 
immunoprecipitated a dimer of 160 and 85 Kd, characteristic of the vitronectin receptor. 
The reactivity was identical to that of other vitronectin receptor reactive Mabs such as 
23C6 and 13C2. The negative control, consisting of an irrelevant antibody, did not 
react in this system. 1 = Negative controls, 2 = ocv/(53 reactive antibodies, 3 = C22.
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Table V.l. Characterization of OB/I on human tissue substrates bv indirect immunofluorescence. *OB/I reacted with the basement membrane and some mononuclear cells 
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Table V. 2. Characterization of OBfl on cultured cell lines.
Ch 
V








Speckled Negative Negative Negative Negative NOT
DETECTED
Table Y.3. The characterization of OB/I by IF on cvtospin preparations of peripheral blood cells and bv Western blotting, RBCs= red blood 
cells, Monos=mononuclear cells, PMNs = polymorphonuclear neutrophils, Kd = kilodaltons. *Denotes cells also analysed by FACS (same 
results obtained).
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on two occasions but was negative one other occasion. With regard to the cultured cell 
lines OB/I demonstrated reactivity against Chang liver cells and weakly against HEp2 
cells derived from a human laryngeal carcinoma. Strong staining of U937 
myelomonocytic cells was demonstrated (Fig V.9), but no reactivity could be detected 
in the HL-60 leukaemic cell line. No staining was demonstrated in the rat osteosarcoma 
. cell line ROS 17/2.8, either in the presence or absence of 1,25D3. Similarly, the SV-40 
transformed human osteoblast-like cell line, BOP 31 were unreactive, as were the 
human umbilical vein endothelial cells (Table V.2). Cytospin preparations of human 
blood cells and bone marrow showed that the only population demonstrating reactivity 
were the erythrocytes (Fig V.10), which showed a strong speckled pattern of 
fluorescence. Western blot analysis using boiled osteoclastoma tissue and collagenase- 
derived osteoclastoma cell suspensions were negative.
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Immunocvtochcmical characterization of OB/I
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Fig V.4. Staining of osteoclasts (OC) and a population of mononuclear cells (M) is 
demonstrated in this section of osteoclastoma. The pattern of reactivity shows strong 
reactivity around the inner area of the plasma membrane. This was the most common 
pattern, but a general diffuse speckling throughout the cytoplasm was sometimes 
observed. FITC x400
Fig V.5. Numerous osteoclasts (OC) can be seen in this section of osteophytic tissue. 
The localised plasma membrane-associated distribution of staining was characteristic of 
this Mab. FITC x400
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Fig V.6. Very discrete packets of cells were stained in the spleen (S) as shown in this 
high magnification photograph. The small clusters can be observed demonstrating weak 
reactivity. FITC x900 (water immersion).
Fig V.7. Renal tubules (R) are observed demonstrating strong and selective brush 
border staining. FITC x400.
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Fig V.8. Very localized staining along the basement membrane (B) in a section of 
cadaver skin is shown. A small population of mononuclear cells (M) in the upper 
dermis also show reactivity. FITC x900 (water immersion).
Fig V.9. Wild-type U937 cells demonstrated strong cytoplasmic reactivity. FITC x400
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F ig  V . 10 . A  s p e c k le d  p a ttern  o f  s ta in in g  w a s  o b s e r v e d  in  n o r m a l h u m a n  e r y th r o c y te s .  
T h is  w a s  th e  o n ly  p o p u la t io n  o f  h u m a n  b lo o d  c e l l s  that d e m o n s tr a te d  r e a c t iv ity .  B o n e  




Part of this chapter reports on the characterization of C22, a Mab reactive against the (33 
chain of the vitronectin receptor.This is the first time that a (33-reactive antibody has 
been produced using human osteoclastoma derived giant cells as the immunogen. Apart 
from megakaryocytes, the osteoclast and its mononuclear precursor are the only 
haemopoietic elements that express high levels of the vitronectin receptor (Horton, 
1990). This may make it an excellent marker for the identification of osteoclasts in 
sections of bone. This is especially so since tartrate resistant acid phosphatase activity, 
the classic osteoclast marker, is also demonstrable in some macrophages (Efstratiadis 
and Moss, 1985).
The ligand for the vitronectin receptor is unknown, but it is likely to be a matrix protein 
containing the Arg-Gly-Asp sequence, such as osteopontin, thrombospondin or bone 
sialoprotein. Possible roles for the vitronectin receptor in osteoclast function have been 
suggested from a number of observations. Chambers et al (1986) demonstrated that 
bone resorption could be inhibited by the addition of antibodies to the vitronectin 
receptor. Also it has been recently demonstrated that the (33 subunit of the vitronectin 
receptor is concentrated in osteoclast podosomes (Zambonin-Zallone et al, 1989).
These are believed to be responsible for the formation of sealing zones juxtaposed to 
the bone surface and for the maintenance of the acidic microenvironment important for 
the process of bone resorption. Horton (1990) suggests that if this receptor was solely 
involved in adhesion then it would be polarized to the membrane apposed to the bone 
surface. However, since immunocytochemical techniques show it to be evenly 
distributed over the osteoclast membrane, he proposes that the receptor may also act by 
transmitting regulatory signals to the osteoclast.
It has been demonstrated that antibodies to the vitronectin receptor have potential uses 
both as laboratory and therapeutic tools. We have successfully used C22 to coat
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magnetic beads for the isolation of osteoclasts from osteoclastoma tissue. It is 
anticipated that this approach can be used to isolate the elusive osteoclast precursor in 
order to study the steps in its differentiation to the mature multinucleated cell. 
Antibodies to p3 containing integrins have been successfully used to block the in-vivo 
growth of human melanomas (Boukerche etal, 1989).
The production of osteoclast-reactive Mabs from an immunization schedule using 
primary cultures of human osteoblasts as the immunogen (Walsh et al, 1991) is 
intriguing and raises questions regarding their origin. The cells in these primary 
cultures are notoriously slow growers and would have been in culture for at least a 
month before being used. Since osteoclasts rarely last long in culture this would have 
been more than enough time for any osteoclasts to die. Ones first impression is that 
perhaps the monophyletic theory of bone cell origin is not such an anachronism and that 
the osteoclast and osteoblast do originate from a common precursor and share 
phenotypic markers. However on closer inspection it is apparent that the osteoblasts do 
not express the OB/I antigen. Reactivity could not be demonstrated by indirect 
immunofluorescence against either normal osteoblasts in bone sections or cultured 
osteoblast-like cells.
If, as the preliminary characterization program suggests, OB/I is reacting against CAII 
it would be interesting to compare the distribution of its reactivity with the known 
distribution of the enzyme. In a study by Marie and Hott (1987) on the histochemical 
localization of carbonic anhydrase in foetal rat bone, they demonstrated its presence in 
both osteoclasts and chondroclasts. They also observed weak reactivity in osteoblasts 
and bone marrow cells in undecalcified sections, but this was removable by 
decalcification in double distilled water and was not inhibited by acetazolamide, a 
specific inhibitor. This suggested that it may have been non-specific reactivity.
However it has been demonstrated that CAII is widely distributed; for example in brain, 
kidney, erythrocytes, cartilage lung and gastric mucosa (Tashian et al, 1983) and that
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the other carbonic anhydrase have a more limited tissue distribution. It may be 
conceivable that within the heterogeneous population of cells used for the 
immunizations there may have been a minor population that contained this isoenzyme. 
The reactivity of OB/I against a number of substrates strongly suggests that it is 
reacting with CAD. Apart from the strong reactivity in osteoclasts, staining was also 
observed in human erythrocytes and kidney tubules, both important CAII-containing 
substrates (Whyte, 1988). Unfortunately, while strong reactivity of OB/I could be 
demonstrated in U937 leukaemic cells, no reactivity was seen in HL-60 cells (see 
chapter VI). These latter cells have been shown to express CAII and have been used in 
studies where they have been induced to differentiate into cells with an osteoclastic 
phenotype (Yoneda et al, 1991). To test whether the cells used in the study were not 
expressing this enzyme, or that OB/I was not reacting with CAII the HL-60s will be 
tested using the specific sheep anti-human CAII antibody.
The reactivity against discrete foci of cells in human spleen may not be a particularly 
exciting observation, in light of the fact that CAII is a fairly ubiquitous isoenzyme. 
However in the mouse system this tissue has been used as a source of blast cells with 
the capacity to form multinucleated osteoclast-like cells under the appropriate 
conditions. Perhaps a population of human spleen cells has the same capacity and these 
may represent an osteoclast precursor population. The demonstration of intermittent 
binding of OB/I to the basement membrane of skin is an interesting observation made 
independently by three people. Although the reasons for these differences are not 
known, the delay in obtaining the tissue may have a bearing, since autolysis of the 
tissue may ablate reactivity. Skin from different sites or different donors may also react 
differently. To redress these problems it would be logical to test the reactivity on fresh 
skin biopsy material. When it was realised that the reactivity of OB/I may be against 
CAII a polyvalent sheep anti-human CAII antibody was obtained. Unfortunately, since 
obtaining this antibody no reactivity against skin has been demonstrated with it, or 
OB/I. A similar lack of reactivity was apparent in cadaver brain tissue, but this may
1 70
Ch V
have been due to many of the reasons suggested for the spurious reactivity given by the 
skin, such as autolysis of the cadaver tissue. Alternatively the antigen may not be 
universally distributed throughout the brain and the tissue that was used could have 
been devoid of it.
Preliminary dot blot analysis using CAII as the antigen also suggested that OB/I may be 
reacting with this enzyme. Strong reactivity was obtained with this and the polyvalent 
sheep anti-human CAII antibody, but some reactivity was also seen with the negative 
controls. These consisted of mouse IgM myeloma protein and an IgM osteoblast- 
reactive Mab. Although the reactivity of these controls was not as high as that seen with 
OB/I, this non-specific binding needs to be eradicated before the reactivity of OB/I can 
be properly defined. Western blotting with the protein will be tried but since it has been 
extremely difficult to get any blotting data from any of the Mabs, the chances of getting 
a positive result are not good. Another approach will be to coat magnetic beads with 
OB/I and incubate these with the native enzyme. Protein in the beads could removed by 
boiling in SDS sample buffer and resolved by gel-electrophoresis. Beads labelled with 
irrelevant antibody could be used as a control.
It is apparent from these characterization experiments that Mabs such as C22 and OB/I 
may provide excellent tools not only for the study of osteoclast ontogeny but also in the 










Potential sources of osteoclast-like cells for in vitro studies were investigated. These 
included the HL-60, U937 and FLG 29.1 cell lines derived from human myeloicf/ 
monoblastic leukaemias at various stages of differentiation, and on human long-term 
bone marrow cultures. The reactivity of the cells with the osteoclast-reactive Mabs was 
investigated over time in culture and under various culture conditions. U937 and HL-60 
cells demonstrated constitutive reactivity with a selection of the Mabs including C35. 
FLG 29.1 cells did not react with this Mab either in their undifferentiated or 
differentiated forms. C35 reactivity was lost in U937 cells after culture in phorbol ester, 
but weak reactivity remained in the HL-60 cells. In contrast, a mix of IL-lp, IL-3, IL-6 
and GM-CSF, and retinoic acid alone ablated the reactivity of C35 in HL-60 cells but 
not in U937s. The human marrow cultures demonstrated reactivity with C22 and C27 
over the time course but C35 only reacted with cells in one out of three experiments. 
Co-culture systems were analysed using osteoclastoma-derived stroma, or MG-63 
osteoblast-like cells in conjunction with bone marrow-derived haemopoietic cells. The 
method for detecting differentiation in these cultures was the demonstration of TRAP 
activity. Preliminary results suggest that osteoclastoma stroma is capable of inducing 
differentiation in the absence of 1,25D3 and dexamethasone while these factors are an 
absolute requirement for differentiation induced by MG-63 cells. The non-adherent 
population of cells derived from osteoclastoma tissue by collagenase digestion 
demonstrated reactivity with a number of the Mabs. The most striking reactivities were 
with OB/I and C22 which stained approximately 40% and 30% of the mononuclear 
cells in these preparations respectively. The plasma membrane reactive Mab, C22 may 




One of the greatest problems facing researchers of human osteoclast biology is the lack 
of an homogeneous population of these cells for in vitro studies. Cell lines of this 
phenotype would allow us to study the origins of the elusive mononuclear precursor, 
and also allow the identification of factors that affect osteoclastic function either by 
blocking their differentiation or inhibiting their activity. These could, of course have 
important implications in drug therapies in diseases where profound osteoclastic 
dysfunction may be a problem, such as in post-menopausal osteoporosis.
Unfortunately the best human models available, such as the traditional long-term 
mairow culture system, consists of heterogeneous populations of cells which may 
complicate biochemical studies. However, a number of potential sources of osteoclastic 
cells are being studied and include cell lines derived from human myelomonocytic 
leukaemias. The promyelocytic cell line HL-60 (Yoneda et al, 1991) and the 
monoblastic leukemia-derived cell line FLG 29.1 (Gattei, 1992) are two examples of 
leukaemia-derived cell lines that the authors suggest have the potential to differentiate 
into osteoclast-like cells. They have been induced to differentiate, using various factors, 
to produce osteoclast-like cells in the absence of a co-culture partner such as 
osteoblastic cells. There is controversy over this latter point since some researchers 
believe that co-culture with a stromal cell population is an absolute requirement for the 
formation of osteoclasts in in vitro culture (Burger et a/,1982, 1984; Kurihara et al, 
1989). Another potential source of osteoclasts comes from a refinement in the human 
long-term marrow culture system (Kurihara, 1990). GM-CFUs from semi-solid 
medium are cultured with osteotropic factors such as 1,25D3 and PTH to form "mature 
osteoclasts", again in the absence of a co-culture partner.
In an attempt to find a potential source of osteoclast precursors for our own in vitro 
studies a number of systems have been examined in conjunction with the anti-osteoclast
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reactive Mabs. These have included the leukaemic cell lines HL-60s and U937s which 
may have the potential, under the appropriate conditions, to be induced to form 
osteoclasts. The reasoning behind choosing these cell lines is that they are derived from 
human myelomonocytic leukaemias and consequently are arrested at an early stage of 
differentiation. If the theory that osteoclasts are derived from cells of the monocytic 
lineage is correct, it is not inconceivable that these immature cells may have the potential 
to differentiate towards the osteoclast phenotype. This theory is strengthened by the 
observation that both cell populations constitutively express a number of antigens with 
which the osteoclast Mabs react. In addition, the FLG 29.1 cells, which are derived 
from the monocytic lineage, can be induced using phorbol ester to form cells that 
express a number of osteoclastic features, such as multinuclearity, TRAP activity and 
the expression of calcitonin receptors (Gattei, 1992).
Although little success was achieved with regard to the demonstration of Mab reactivity 
against giant cells formed in human long-term marrow cultures, this system was re­
examined as a potential source of osteoclasts. In these time-course experiments the 
differentiation of the cells was monitored over the 21 day culture period to see if antigen 
expression was induced earlier in the culture period and then subsequently lost
In addition, the potential to form osteoclasts or their precursors has been studied in co- 
culture systems, using various osteotropic factors in an effort to induce osteoclastic 
differentiation. Although the mechanisms by which osteoblastic stromal cells support 
osteoclast differentiation are not known, it would appear that direct cell to cell contact is 
essential. Consequently MG-63 cells, a human osteoblast-like cell line, and 
osteoclastoma-derived stromal cells have been co-cultured with bone-marrow derived 
haemopoietic cells, and their potential to induce formation of osteoclast-like cells was 
observed by the demonstration of TRAP positive cells in the cultures. The potential for 
osteoclastoma stroma to support the differentiation of progenitors into osteoclasts was 
examined using both whole stroma, and a cloned cell line derived from this stroma by
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flow cytometry. Osteoclastoma-derived stroma was chosen as a co-culture partner in 
these experiments because it appears to be these cells that support the differentiation of 
the osteoclasts in the tumour. This statement is based on the fact that the osteoclasts are 
present in normal bone in small numbers, so it suggests that the innumerable "  
osteoclasts present in these neoplasms were not attracted to the tissue by chemotaxis. It 
seems reasonable to assume that the precursors pass through the highly vascularized 
tumour and are induced to differentiate in-situ by as yet unidentified factors. Equally, if 
the osteoclast precursor is of haemopoietic origin the use of bone marrow haemopoietic 
cells as the co-culture partner should give rise to osteoclasts. These co-cultures were 
directly compared with another set of experiments in which the osteoclastoma stroma 
was substituted with MG-63 cells (Franceschi et al, 1985). These cells were originally 
derived from a human osteosarcoma and demonstrate a number of osteoblastic 
characteristics, such as alkaline phosphatase, osteocalcin and type I collagen synthesis. 
Osteoblast-like cell lines have been used previously in co-culture to produce osteoclast­
like cells in mouse systems (Udagawa et al, 1989; Yamashita et al, 1990) so their 
efficacy in this system was tested using human cells.
Finally, not only was the osteoclastoma tissue tested for its capacity to induce 
differentiation in haemopoietic cells, but fresh collagenase digested samples were also 
probed with the Mabs for the presence of a potential in vivo precursor population. The 
reasoning behind this approach has already been outlined above, and the results suggest 
that there may be a population of cells in the non-adherent fraction that react particularly 




VI.3(i) Immunocytochemical analysis of FLG 29.1 cells.
The FLG 29.1 cell line was produced from an M5 monoblastic leukaemia (Gattei-er al, 
1992). The cells were prepared for immunocytochemical study according to the 
methods previously described i.e. cells were immobilised onto glass slides, air dried 
and fixed in acetone for 10 minutes. They were transported to our laboratory on dry ice 
and on arrival stored at -70°C until required for use. Within a week they were probed 
with the osteoclast-reactive antibodies and visualized using either APAAP or IF 
depending on the isotype of the antibody, as previously described (chapter n, sections 
H.l(v) and Il.l(iv) respectively).
VI.3(ii) U937 and HL-60 cells in culture with 1,25D3 and retinoic acid
Previous work by Bhalla et al (1989) demonstrated that 1,25E>3 induces the 
differentiation of U937 cells into a more mature monocytic cell, as demonstrated by the 
induced expression of the CD 14 antigen. They suggested that the addition of 1,25D3 
inhibited the proliferation of these cells but induced their differentiation along the 
monocytic pathway, so that after 72 hours they expressed a more mature phenotype. 
Retinoic acid, however, did not induce CD 14 expression but did, in their hands, inhibit 
cell proliferation. This retinoid has been previously shown, however, to induce the 
differentiation of HL-60s into more mature granulocyte-like cells (Breitman et al,
1980). Since both these cell types constitutively express some of the antigens 
recognised by the osteoclast-reactive Mabs, it was decided as a starting point to see if 
these induced changes in phenotype would be matched by a similar gain or loss in the 
expression of antigens recognized by the osteoclast-reactive Mabs.
U937 and HL-60 cells were maintained in culture in RPMI-1640 supplemented with 
10% FCS as described in chapter II (section II.4(i)). Cytospin preparations of the 
untreated cells were made according to the protocol in chapter II (section Il.l(iii)).
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These were fixed in acetone for 10 minutes and stored at -20°C wrapped in foil until the 
rest of the experiment was completed. These preparations corresponded to time point 0. 
Cells in log-phase were cultured in 25 cm2 culture flasks at a density of 2xl05 cells / ml 
in either 1,25D3 (10-8 M), retinoic acid (10 7 M) or the corresponding volume of~ 
ethanol as a control. Aliquots of cells were removed at 72 hours and were prepared for 
immunocytochemistry as described above. APAAP was performed for the IgG, and IF 
for the IgM Mabs according to the methods outlined in chapter II (sections n. l(v) and 
n.l(iv) respectively). An optimally diluted CD 14 Mab (UCHM1, neat for IF and 1:5 
for APAAP) was also used to detect the differentiation of the U937 cells.
VI.3(iii) U937 and HL-60 cells cultured with a mix of IL-lp, IL-3, IL-6 
and GM-CSF
A further study was devised in which a number of factors with putative actions on bone 
cells were cultured with each of the cell lines, to see if further differentiation towards an 
osteoclast phenotype could be induced.
The cells were again cultured in a 25 cm2 tissue culture flask in the presence of a mix of 
recombinant human preparations of IL-lp (10 U/ml), IL-3 (10 U/ml), IL-6 (100 U/ml) 
and GM-CSF (100 pg/ml). A flask of cells with no treatments were used as a control. 
After 72 hours they were prepared for immunocytochemical analysis as described 
above.
VI.3(iv) TPA treatment of U937 and HL-60 cells
Previous studies have demonstrated that U937 and HL-60 leukaemic cell lines can be 
induced to differentiate towards the monocytic / macrophage phenotype in the presence 
of TPA and 1,25D3 (Rovera et al, 1979; Bar-Shavit et al, 1983; Hewison et al, 1989) 
while Gattei et al (1992) have demonstrated that the FLG 20.1 cells were induced to 
form cells with a number of characteristic features and phenotype of osteoclasts. This 
experiment was performed to observe the differences in phenotype between the
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undifferentiated and differentiated cells using the osteoclast-reactive Mabs. In addition 
these could be directly compared with the results from the from the 1,25D3 and retinoic 
acid experiments, since both should induce a similar monocytic phenotype in the U937 
cells.
The cells were cultured for 72 hours at 37°C in 25cm2 culture flasks in the presence of 
0.1 pM TPA or an equivalent volume of DMSO as a control. The cells were removed 
from culture and Cytospin preparations produced as described in chapter II. The cells 
were probed with the Mabs using the appropriate immunocytochemical method and 
CD 14 was again used as a control to monitor differentiation.
VI.3(v) Human long-term marrow cultures
Human long-term bone marrow cultures have been used as a model for osteoclast 
formation in vitro (MacDonald et al, 1987). Although no reactivity was detected with 
the most selective Mab, C35, in the earlier studies it was decided to pursue this 
approach further. Two major questions needed to be answered. Firstly , during 
differentiation were antigens, recognised by Mabs such as C35, expressed earlier in the 
culture period and then lost? Secondly, was there a population of non-adherent cells 
within the cultures that expressed some of the osteoclastic antigens? To answer these 
questions, slide cultures were performed in which 4-well multispot slides were 
overlayed with bone marrow cells. At predefined time points slides were removed from 
culture, the medium was removed from the wells and Cytospin preparations were made 
from the non-adherent cells present. The 4-well slides represented the adherent 
populations. At the end of the culture period both populations, from each time point 
were probed with Mabs C21, C22, C27, C35 and OB/I.
Bone marrow from rib samples, derived from lung resection operations was prepared 
for culture and dispensed onto individual wells of 4-well multispot slides, as described 
in chapter II (section Il.l(viii)). Eight Cytospin preparations were made from whole
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bone marrow and stored until the experiment was completed. These slides represented 
the first time point. The remainder of the cells were cultured for the first 7 days in 
medium supplemented with 100 pg / ml of GM-CSF and for the last 14 days in medium 
supplemented with 108 M 1,25D3. Throughout the experiment, two slides were — 
removed from culture on each of six predefined time points (2,4,6,11,16,and 21 days). 
The medium was removed from each of the eight wells by aspiration into individual 1.8 
ml cryotubes. The cells were pelleted by centrifugation, resuspended in 250 pi of PBS, 
and a Cytospin preparation made for each (chapter n, section Il.l(ix)). The 4-well 
slides were washed in warm PBS and fixed in acetone for 10 minutes along with the 
Cytospins. These were air dried and stored at -20°C until the experiment was 
completed. The reactivity of the Mabs was detected by either APAAP (C22, C27, and 
C35) or IF (C21, OB/I). Negative controls were set up in parallel, and the reactivity of 
the Mabs was verified on sections of osteoclastoma as described previously.
VI.3(vi) Co-culture experiments
These experiments were performed with either MG-63 cells or osteoclastoma-derived 
stromal cells, co-cultured with bone marrow cells, either in the presence or absence of 
1,25D3 and dexamethasone. This, as with the other experiments in this section, was 
performed to determine whether an osteoclastic population of cells could be induced 
under these conditions, and this was observed by the demonstration of TRAP activity. 
The osteoclastoma stroma consisted of two types, one represented the whole stromal 
population and the other was derived from single cell cloning of the same population of 
cells on a FACS.
Preparation of adherent cell populations
The osteoclastoma stromal cells were prepared from collagenase digests. An aliquot of 
the isolated cells was plated out into a 10 cm Petri-dish and cultured for four passages 
before being used in this experiment. The adherent cells were released from the plastic 
using trypsin /EDTA and were washed in fresh medium / 15% DHS by centrifugation
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at 400 g for 5 minutes. The cells were added in sextuplicate to wells of two 24-well 
tissue culture plates at 5x103 cells / well. The first three wells were cultured with 
haemopoietic cells and the remaining three, representing the control, without the 
haemopoietic cells. Two plates were used so that one could be cultured with, ancTthe 
other without, 1,25D3 and dexamethasone. The cells were cultured overnight to allow 
the cells to adhere before adding the haemopoietic cells.
The cloned osteoclastoma-derived stroma was prepared from cells of the above culture. 
This was achieved using the automatic cell distribution unit on the FACS. The cells 
were sorted to one cell /  well in 84 wells of a 96-well tissue culture plate. The plate 
contained 100 pi / well of RPMI-1640 supplemented with 20% FCS. The remaining 12 
wells received 50 cells / well as a back-up in case the other cells did not grow. Cloned 
cells were grown up to confluency and prepared for this experiment as described 
above.
The adherent MG-63 cells cells were released from the plastic culture flask, washed and 
their density was adjusted according to the method described for the osteoclastoma 
cells. They were also aliquoted in the same numbers as above, and were cultured 
overnight to allow them to adhere before adding the haemopoietic cells.
Preparation of bone marrow
Bone marrow cells were derived from rib samples and were prepared as in chapter II 
(section Il.l(viii)). The isolated mononuclear cells were placed in a 10 cm Petri-dish 
overnight at 37°C to remove the adherent population. The non-adherent cells were 
removed from the plates and pelleted by centrifugation at 400 g for 5 minutes. The 
density was adjusted to lxlO5 / ml and 500 pi was added to each of the relevant wells 
of the above 24-well plates. Half the cells required were prepared in medium / DHS 
only, and the other half with medium supplemented with 1,25D3 (10 8 M) and 
dexamethasone (lO 7 M).
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When the co-cultures had reached confluency after 12 days of culture the medium was 
removed and the cells fixed and prepared for TRAP staining as described in chapter n  
(section Il.l(ii)). —
VI.3(vii) Immunocytochemical analysis of osteoclastoma-derived cell 
populations
Fresh tumour was collagenase digested to isolate the cell populations as described in 
chapter El (section EI.3(ii)b). The single cell suspension was washed by centrifugation 
and the density finally adjusted to 2x10s/  ml in medium / 10% FCS. 10 ml of this was 
dispensed into each of five 10 cm Petri dishes and these were cultured overnight at 
37°C. The medium containing the non- adherent cells was removed from the plates into 
a sterile 50 ml centrifuge tube. These were pelleted by centrifugation at 400 g for 5 
minutes and washed once in fresh medium. Cytospin preparations were then made and 
fixed according to the protocol in chapter n  (section II.l(iii)). The whole-cell 
preparations were made by dispensing 150 pi of medium / 10% FCS onto each well of 
sterile poly-l-lysine coated 4-well multispot slides (104 cells /  well). The slides were 
placed at 37°C overnight in a sterile plastic dish. The excess buffer was removed and 
the cells washed in warm PBS to remove any serum. The slides were then fixed and 




VI.4(i) FLG 29.1 cells.
The reactivities of the Mabs are summarised in table VI.I. C27 showed reactivity*" 
against the undifferentiated cells as very discrete cytoplasmic dots (Fig VI.I). In the 
differentiated cells, however, this reactivity became more diffuse, although cytoplasmic 
dots were also present (Fig VI.2). Mabs C l3 and C22 (Fig VI.3) demonstrated no 
reactivity in the undifferentiated cells. The post-differentiation population showed 
reactivity in a very small minority of cells with C l3 (< 1%), but C22 was positive in up 
to 70% of the cells (Fig VI.4). The reactivity with this latter antibody was variable; 
some cells showed strong reactivity and some relatively weak reactivity. C20, C35 (by 
APAAP), C21 and OB/I (by IF) demonstrated no reactivity with either population of 
cells.
VI.4(ii) U937 and HL-60 cultures
The results of the experiments culturing these cells with 1,25D3, retinoic acid, and the 
mix of factors are shown in table VI.2a and 2b. U937s constitutively expressed a 
number of antigens with which the Mab panel react. These included Cl 3, C27, OB/I 
(see chapter V, section V.4(ii)) and C35 (Fig VI.5). A negative control is also shown 
as a comparison (Fig VI.6). The differentiation towards the monocytic phenotype was 
demonstrated by the induction of the antigen recognized by Mab CD 14. This 
expression was weak with both 1,25D3 and mix cells, but was not detected in the wild- 
type cells. It would appear that the mix of factors used also induces differentiation 
along the monocyte lineage. There was no induction of expression of any antigens 
recognized by the Mab panel that were not already present in the wild-type cells. 
Although only a subjective observation, it appeared that there was an increase in 
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Table VI.I Reactivity of the osteoclast-reactive Mabs with FLG 29.1 
monoblastic leukaemia-derived cell line. The cells were tested in their 
undifferentiated form and also in their post-TPA differentiated form. APAAP - 




R e a c t i v i t y  o f  C27 a n d  C22 w i t h  u n d i f f e r e n t i a t e d  a n d  d i f f e r e n t i a t e d  
populations of FIG  2?, I cells
Fig VI.I. C27 demonstrates a very localised, punctate pattern of staining in these 
undifferentiated cells. The preparation is uncounterstained because the positivity was 
often masked using stains such as haematoxylin. APAAP x400.
Fig VI.2. In these differentiated preparations C27 staining was observed as a more 




Fig VI.3. In the undifferentiated population of cells no reactivity could be detected with 
Mab C22. APAAP x400.
Fig VI.4. In contrast to the above preparation, upto 70% of the differentiated cells 
demonstrated reactivity with the C22 Mab. The degree of staining was variable with 
some cells demonstrating very strong reactivity, while others were only weakly positive 
APAAP x400.
1 8 6
U937 NEG C13 C20 C22 C27 C35 CD14
0 HRS - + - - + + -
72 HRS 
CONTROL
- + - - + + -
MIX (72 HRS) - + - - + + +/-
1,25D3 (72 HRS) - + - - + + +/-
RETINOIC ACID 
(72 HRS)
- + - - + + -
Table VI.2a. Reactivity of the Mabs against wild-tvpe U937 cells and cells treated with 1.25-dihvdroxwitamin Dt (T.25EK. IQ'8 M) retinoic 
acid (10-7 M) and the mix of factors. This table summarizes the results obtained from culturing various factors with U937 cells. The only 
change in expression was observed with the CD 14 Mab after the cells had been cultured with the mix and 1,25D3. This Mab reacts with an 
antigen on mature cells of the monocyte lineage. Mix = IL-ip (10 U/ml), IL-3 (10 U/ml), IL-6 (100 U/ml) and GM-CSF (100 pg/ml). +/- = 
weak reactivity, + = strong reactivity
HL-60 NEG C13 C20 C22 C27 C35 CD14
0HRS - + - - + +/- -
72 HRS 
CONTROL
- + - - + +/- -
MIX (72 HRS) - + - - + - +/-
1,25D3 (72 HRS) - + - - + +/- +
RETINOIC ACID 
(72 HRS)
- + - - + - -
Table VI.2b. Reactivity of the Mabs against wild-type HL60 cells and cells treated with 1.25-dihvdroxvvitamin Dt (1.250^ IQ-8 MI retinoic 
acid and the mix of factors. This table also summarizes the results observed for various factors cultured with HL-60 cells. The only change in 
antigen expression was observed with Mab C35 which disappeared after 72 hours of culture with the mixture of factors. Mix = IL-lp (10 
U/ml), IL-3 (10 U/ml), EL-6 (100 U/ml) and GM-CSF (100 pg/ml). +/- = weak reactivity, + = strong reactivity.
Ch VI





♦ V ? ’
.  V  * * :
" *  ICj ,# JP
*>
Fig VI.5. U937 cells constitutively expressed the antigen recognized by Mab C35. 
APAAP x400.
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Fig VI.6. No reactivity against the U937 cells was demonstrated with the negative 










Fig VI.7. The U937 cells are shown after 72 hours culture in l,25D3.The staining often 
looked more intense than with the wild-type cells, although this has not yet been fully 




Fig VI.8. This demonstrates the reactivity of Mab C35 against wild-type HL-60 cells. 
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Fig VI.9. CD 14 Mab was used to monitor the differentiation of the cells towards a 
monocytic phenotype. Although not many cells were positive this was the level of 
positivity consistently seen after 72 hours in culture with 1,25D3. APAAP x400




The HL-60 cells constitutively expressed antigens recognized by C13, C27 and C35. 
Unlike U937 cells there was no expression of OB/I. In addition, the expression of C35 
was weaker than that seen in the U937 cells (Fig VI.8). After 72 hours culture with the 
mix of factors the reactivity of C35 appears to be completely ablated, while the 1,25D3 
does not have this effect. In addition, there was no reactivity of C35 with these cells 
after culture in retinoic acid. This factor has been shown to induce differentiation of 
these cells along the myeloid lineage towards a granulocytic phenotype. C35 does not 
recognize this cell type in blood preparations. The monocytic phenotype of the cells 
was demonstrated by the presence of CD 14 reactivity (Fig VI.9. The negative control is 
shown in Fig VI. 10)
VI.4(iii) U937 and HL-60 cells cultured with TPA
The results of this experiment are shown in table VI.3. The interesting observations 
from this experiment, with regard to the U937 cells, are the disappearance of reactivity 
with C35 and an induction of expression of the antigen recognised by Mab C20. The 
reactivity demonstrated on the HL-60 cells was similar to that seen on the cells cultured 
with the other factors described above. Many of the cells demonstrated a monocytic 
phenotype as shown by the reactivity of CD 14 Mab.
VI.4(iv) Human long-term marrow culture time course
Adherent population of cells
The results of this time course are summarized in table VI.4. After day 11 C22 began to 
stain cells positive in clumps of cells (Fig VI. 11). This level of staining had increased 
by day 21. The staining was restricted to non-fibroblastic cells within clumps and in 
isolation. C27 demonstrated positivity in the majority of cells (Fig VI. 12). There was 
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NEGATIVE NEGATIVE Occasional 
positive cells in 
clumps
Positive cells in 
clumps
Positive cells in 
clumps and in 
isolation
C27 Approx 50% of 
cells positive
> 90% of cells 
positive
> 95% of cells 
positive
> 95% of cells 
positive





All cells appear 
positive
All cells appear 
positive








OB/I* NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
C21* NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
Table VI.4. Immunocvtochemical characterization of human long-term marrow culture cells (time coursel. * analysed by indirect 
immunofluorescence.* *These are the results for one experiment, two subsequent experiments were negative throughout the time course.
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Reactivity of Mabs £22 , £2and C35 on the human long-term marrow 
culture time course .Experiments.
Fig VI.I 1. Mab C22 demonstrated reactivity against occasional cells at day 11 as 
shown here. This reactivity was characterized by a cytoplasmic pattern of staining, 
which was in keeping with the earlier experiments and contrasts the membrane staining 
observed in bone and osteoclastoma tissues (see chapter IV). APAAP x200.
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Fig VI. 13. In one experiment C35 demonstrated rather weak reactivity against 
numerous cells in the cultures. This had been evident at days 4 and 6 (day 6 shown) but 
staining had disappeared by day 16. However in two subsequent experiments no 
staining was evident at any of the time points. APAAP x200.
Fig VI. 14. This figure shows the lack of reactivity demonstrated by Mab C35 at day 16 
of the above experiment. All the cell populations are negative. APAAP x200.
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The staining demonstrated with Mab C35 was of special interest because of its apparent 
selectivity for osteoclastic cells in bone. In one experiment all the cells were negative 
from days 0 to 4, but on days 6 and 11 weak staining was demonstrated in somerells 
(Fig VL13), which subsequently disappeared by day 16 after culture in the 1,25D3 (Fig
VI. 14). However in the following two experiments this result could not be repeated. 
OB/I and C21 demonstrated no reactivity with these cultures at any time point.
Non-adherent population
Mab C22 was mostly negative throughout the time-course except on day 4 when two to 
four positively stained multinucleated cells were seen, demonstrating cytoplasmic 
staining. Between days 0 and 11 C27 showed reactivity with the majority of cells in 
these preparations. On days 16 and 21 the cells were very weakly stained. No staining 
was observed with C35 throughout the time-course on these populations of cells. 
Similar to the results obtained with the adherent population of cells, no staining was 
observed with OB/I or C21.
VI.4(v) Co-culture experiments
The results for these preliminary studies are shown in table VI.5. MG-63 cells did not 
constitutively express TRAP activity in the control wells. In addition, the co-cultures of 
these MG-63s with haemopoietic in the absence of 1,25D3 and dexamethasone did not 
produce TRAP positive cells. However, in the presence of these factors there were 
TRAP positive cells present in the cultures. In contrast with these data it was observed 
that both the whole osteoclastoma stroma and the cloned cells were capable of 
supporting the formation of TRAP positive mononuclear cells.
197
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VI.4(vi) Immunocytochemical analysis of osteoclastoma-derived cell 
populations
Within the whole cell populations most Mabs demonstrated a degree of reactivity with 
some cells after overnight culture. The exceptions to this were C35 and OB/I which 
showed no reactivity at all against these populations (Table VI.6). Fig VI. 15 shows the 
-reactivity of C22 with the osteoclasts in the whole cell preparation but seemingly only a 
small population of mononuclear cells. In contrast C27 demonstrates strong reactivity 
with the majority of cells in this preparation, both mono- and multinucleated (Fig
VI. 17). Within the non-adherent populations of cells there was some reactivity with all 
the Mabs tested. Most notably, with regard to the isolation of potential osteoclast 





+ 1 ,2 5  D 3  and  
d e x a m e th a s o n e  
TRAP POSmVE 
MONONUCLEAR CELLS
- 1 ,2 5  D 3  a n d  
d e x a m e th a s o n e  
TRAP POSITIVE 
MONONUCLEAR CELLS
MG-63 /  B o n e  m a r r o w  
h a e m o p o ie t ic  c e l l s
POSITIVE NEGATIVE
MG-63 a lo n e NEGATIVE NEGATIVE
O s te o c la s to m a  s tr o m a  /  
B o n e  m a r r o w  
h a e m o p o ie t ic  c e l l s
POSITIVE POSITIVE
O s te o c la s to m a  stro m a  
a lo n e
NEGATIVE NEGATIVE
T a b le  V I .5 . T h e  c o -c u ltu r e  s y s t e m s  r e v e a le d  that M G - 6 3  c e l l s  w e r e  a b le  to  in d u c e  
th e  d if fe r e n t ia t io n  o f  a  p o p u la t io n  o f  h a e m o p o ie t ic  c e l l s  in to  T R A P  p o s i t iv e  c e l l s  in  
th e  p r e s e n c e  o f  1 ,25Di a n d  d e x a m e t h a s o n e ,  w h ile  o s t e o c la s t o m a  s tr o m a l c e l l s  w e r e  
c a p a b le  o f  th is  p r o c e s s  b o th  in  th e  p r e s e n c e  and  a b s e n c e  o f  th e s e  fa c to r s . T h e  
o s t e o c la s t o m a  r e su lts  are  p r e se n te d  a s  o n e  re su lt  s in c e  b o th  th e  w h o le  c e l l  an d  








Approx 5% of cells strong 
+ve
Cyto staining of giant cells, 
fibroblast-like & monos
C20 Approx 2-5% of cells +ve Occassional +ve cell
C22
Approximately 30% of 
mononuclear cells +ve. 
Many weaker staining cells
Similar to C13
C27
Majority of cells very 
strongly +ve
Occasional weakly stained 
cell
C35
Occasional strongly stained 







C21 Very occasional +ve cell V. occasional +ve cell seen






Table VI.6. Reactivity of the Mabs against non-adherent and adherent populations 
of cells derived from collagenase treated osteoclastoma tissue. Both non-adherent 
and a whole cell preparation, derived from fresh collagenase isolated osteoclastoma 
cells, were probed with the Mabs. +ve = positive.
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Fig VI. 15. The reactivity of Mab C22 on the whole cell preparation is primarily against 
multinucleated osteoclasts, although some reactivity against mononuclear cells was 
evident. The positive mononuclear cells comprised 8% of the total number of 
mononuclear cells present. APAAP x200.
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Fig VI. 16. In contrast with the above staining, the cells expressing the majority of 
reactivity with C22 in the non-adherent populations are mononuclear. The positive 
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Fie VI. 17. The staining observed with Mab C27 was directed against both the 





From these preliminary studies a number of interesting observations have been made 
regarding potential sources of osteoclast-like cells for in vitro studies. The phorbol 
ester-induced osteoclast-like cell line, FLG 29.1 has been shown to express a number 
of osteoclastic characteristics including multinucleation, TRAP activity and the presence 
of calcitonin receptors. However, they do not express a ruffled border and 
consequently do not possess the ability to resorb pits in dentine slices. In addition, in 
our hands, they did not show C35 reactivity. This Mab appears to be a very selective 
marker for osteoclasts, although differential staining of these cells has been 
demonstrated in bone (see Chapter IV, section IV.4(i)). The only Mab to react with the 
undifferentiated cells was C27, whose pattern of reactivity changed in the differentiated 
cells. The only marked induction of antigen expression, as recognised by the 
osteoclast-reactive Mabs, was with C22. This Mab appears to react with the p3 chain of 
the vitronectin receptor (see chapter V, sections V.4(i)a-(i)c) and its reactivity with 
these cells corresponds to the observations of Gattei et al, (1992) who demonstrated an 
induction of the av chain of the vitronectin receptor using the Mabs 23C6 and 13C2.
In contrast to the above cell line it was demonstrated that both HL-60 and U937 cells do 
constitutively express the C35 antigen. Since this antigen is not expressed in blood- 
borne monocytes or tissue macrophages it may suggest that these cells are sufficiently 
immature to be induced to differentiate into osteoclast-like cells. Another interesting 
observation was the loss of C35 reactivity in U937 cells after culture with phorbol 
ester. There are two potential explanations for this phenomenon. The first, and most 
likely explanation, is that the phorbol ester treatment of these cells has induced a mature 
macrophage phenotype (Rovera et al, 1979) which C35 does not recognize. Secondly, 
since Su et al (1990) recently demonstrated that the activation of protein kinase C 
inhibits bone resorption in rat osteoclasts, it is tempting to suggest that C35 may
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recognize an antigen involved in resorption and that its expression is switched off by 
this agent.
It has been demonstrated that HL-60 cells can be induced to form osteoclast-likexells 
under the appropriate conditions (Yoneda et al, 1991). This process requires the 
- formation of colonies in methylcellulose, followed by sequential culture in 1,25D3 
supplemented medium and then tumour-conditioned medium derived from a squamous 
cell carcinoma cell line. These complicated manipulations are compounded by the fact 
that the end result is a population of cells that express a number of osteoclastic 
characteristics, but only very few resorption pits are formed per cell on whale dentine 
slices (10 pits /  105 cells). Since this latter function is the hallmark of bona fide 
osteoclasts, the true relationship of these cells to osteoclasts has to be questioned. In 
defence of this approach, it should be noted that HL-60s have been shown to be 
capable of differentiation into four cell types; granulocytes, monocytes, macrophages 
and eosinophils. However, these differentiated cells usually lack one or more 
characteristic of their normal counterparts, thus suggesting that these transformed cells 
are unable to differentiate into fully mature cells. The models of osteoclast formation 
described by Gattei and Yoneda may therefore be the closest it is possible to get to an 
osteoclast cell line using transformed leukaemia cell lines.
In mouse marrow culture experiments there is evidence to suggest that the presence of 
GM-CSF may reduce the appearance of osteoclasts in a dose dependent manner by 
inhibiting the effects of M-CSF (reviewed by Horowitz and Jilka, 1992). If this is also 
the case with human cultures, then this may explain the lack of reactivity of the most 
osteoclast-selective Mab in the panel, C35. If GM-CSF is suppressing the activity of 
M-CSF and diverting the progenitors along the monocyte lineage then the likelihood is 
that the predominant population of mature cells will be of that phenotype. This seems to 
be supported by the fact that there was very strong reactivity of the vast majority of the 
cells in the cultures, both mono- and multinucleated, with Mab C27. The
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characterization of this antibody showed that it reacted with blood-borne monocytes and 
macrophages, as well as osteoclasts in bone (see chapter IV, tables IV. 1-4). C35, on 
the other hand, demonstrated no reactivity with either of the monocyte /  macrophage 
cell populations. This suggests that either the multinucleated cells in the cultures are not 
sufficiently mature osteoclasts to express the C35 antigen, or that the multinucleated 
xells in the cultures were macrophage polykaryons. Since U937 and HL-60 cells are 
believed to be arrested at an early point along the monocyte / myeloid lineage, and both 
constitutively express C35 antigen, this seems to support the latter argument.
The co-culture experiments yielded some interesting points. It would appear that the 
osteoclastoma-derived stroma, whether whole or cloned, is capable of inducing the 
formation of TRAP positive mononuclear cells in the presence or absence of 1,25D3 
and dexamethasone. If TRAP activity can be used as a marker for osteoclast formation, 
these results seem to support the idea that these cells contribute to the differentiation of 
precursors into osteoclasts in vivo . In contrast, it was observed that the MG-63 cells 
could only support the differentiation of these cells in the presence of 1,25D3 and 
dexamethasone. Interestingly, it has been suggested that the MG-63 cells demonstrate 
some osteoclastic features, such as TRAP positivity (Myers et al, 1991), but this was 
not corroborated in this study. Although very preliminary, the results with the 
osteoclastoma stroma are very encouraging because they suggest that differentiation of 
normal cells can be induced, which is the situation in situ where the neoplastic stroma 
support the formation of normal osteoclasts. The next step is to immunolocalize any 
reactivity in both the adherent and non-adherent populations and to see if these 
mononuclear cells can be induced further to differentiate into multinucleated osteoclasts.
The observation that OB/I and particularly C22 reacted with a population of cells in the 
non-adherent fraction within osteoclastoma tissue is of interest. In studies by Kurihara 
et al (1990) they produced osteoclast-like cells from human long-term marrow cultures. 
They noted that the polygonal mononuclear precursors of these cells reacted very
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strongly with Mab 23C6, which recognizes the av chain of the vitronectin receptor. 
Approximately 30% of the mononuclear cells in the non-adherent population of 
osteoclastoma tissue reacted with C22. This Mab reacts with the p3 chain of the 
vitronectin receptor (see chapter V) and may be recognizing a similar population-of cells 
to that of Kurihara and his colleagues. In previous studies, using magnetic beads coated 
.with C22 to isolate osteoclasts from whole-tumour digests, it was noted that a number 
of mononuclear cells also selectively bound to the beads (see chapter IV). Knowing that 
the number of positive mononuclear cells can be increased approximately 4-fold by the 
removal of the adherent population of cells, it should be easy to adjust the magnetic 
bead/  cell ratio to obtain populations of cells for further study. Although these numbers 
may vary from tumour to tumour it should be possible to work out the number of 
positive cells within the non-adherent population before the isolation step is performed, 







The Mabs described in this thesis have provided valuable reagents for the 
immunocytochemical identification of human osteoclasts. It has been demonstrated in 
the study that they can be used to screen potential osteoclast progenitors for their 
expression of osteoclast-selective antigens, and can be used as a powerful tool for the 
isolation of these cells from heterogeneous populations of cells (vide infra). Mature 
osteoclasts have also been isolated in this way, and it has been observed that their 
functional capacity to resorb bone was not impaired. The Mabs have also been used to 
study the osteophyte model of human bone formation and remodelling (Dodds et al, 
submitted) in which the antigenic heterogeneity of the osteoclasts was observed with 
regard to their reactivity with the Mabs (vide infra). Despite their obvious uses in the 
systems described, this approach to the identification of osteoclasts and their putative 
precursors does have its drawbacks, which are mainly related to the monoclonality of 
the antibodies. Some of these potential problems are discussed below with reference to 
those encountered with the biochemical identification of the osteoclast-reactive Mabs.
VII.I Problems associated with Mab technology
The specificity of conventional polyclonal antisera is dependent upon the combined 
reactivity of innumerable clonal products. These bind to epitopes all over the antigen 
(Benjamin et al, 1984) so that any small change in the antigenic structure induced by 
denaturation may have very little effect on the binding of these antisera. Monoclonal 
antibodies in contrast are very specific. This means they only recognize a single epitope 
on the antigen molecule and if the conformation of this epitope should change the 
antibody may not bind. The characterization of the osteoclast-reactive Mabs has brought 
this problem to light and has drawn attention to the potential technical drawbacks that 
may have arisen as a result of the protocol used to screen the original hybridoma 
supernatants. The major difficulty encountered revolved around the apparent inability of 
the Mabs to recognize denatured antigens. This ultimately meant that they could not be 
used in techniques such as Western blotting, which would have given valuable 
information regarding their molecular weights. Although it is accepted that many
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monoclonal antibodies do not work in this denaturing system (Goding, 1986) there are 
ways of increasing the chances of selecting Mabs that do. For example, instead of 
screening on acetone fixed tissue it may have been more salient, if the facilities had 
been available, to screen on formalin fixed, paraffin embedded tissue. In this way only 
antibodies recognizing denatured proteins would be selected. The alternative to this 
would be to use formalin fixed cell suspensions for the immunizing step so that the 
original antibody response is to denatured antigens. In a similar way it would be 
possible to design the screening protocol so that only short incubation periods were 
used for the supernatants, thus only high affinity antibodies would be selected. A recent 
problem that arose regarding the reactivity of Mab C35 was its failure to bind to antigen 
when incubated in the cold. It has been previously demonstrated that certain Mabs will 
precipitate in the cold and then redissolve when warmed. An antibody demonstrating 
this property is termed a cryoglobulin (Grey and Kohler, 1973) and such a property 
will diminish or completely ablate its reactivity at low temperatures.
Another problem that may have arisen from the immunizing protocol, and which has 
been discussed in chapter IV (section IV.5), is the preponderance of cytoplasmic 
reactive Mabs in the panel. These antibodies are technically more difficult to work with 
than plasma- membrane reactive antibodies, especially if the antigens need to be 
identified. One approach to the identification of antigens involves screening for their 
expression on cells that have been transfected with the relevant gene. The expression of 
a particular gene can be detected by antibodies against its product. With repeated 
transfection cycles, it is possible to eventually isolate the gene. With surface antigens 
there are few problems in doing this, but cytoplasmic antigens require the cells to be 
permeabilized or lysed to identify positivity. In an effort to overcome these problems 
preliminary studies utilising saponin permeabilization of membranes (Sander et al,
1991) have been tried with a selection of Mabs reactive with U937 cells. Although 
reactivity could be detected with C27, as measured by flow cytometry (data not shown) 
no reactivity has thus far been achieved with the very osteoclast-selective Mab, C35.
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This antibody has been of particular interest because of its selective reactivity, 
suggesting that the antigen with which it reacts might be important in osteoclastic 
function. However, despite concerted efforts to try to biochemically characterize the 
antigen none of the techniques so far have been forthcoming. This particular antibody 
demonstrates many of the physico-chemical idiosyncrasies that are characteristic of 
many Mabs, and these may explain its lack of reactivity in the biochemical assays used 
so far.
VII.2 Osteoclast precursors for in vitro studies
The ultimate aim of this project is the identification and isolation of an osteoclast 
precursor population for in vitro studies. A population of cells such as this would allow 
the characterization of the effects of agents known to activate resorption. It would be 
possible to see if they have direct effects on these cells or if they are mediated via other 
cell populations. Important information regarding the maturation of these cells into 
mature multinucleated osteoclasts would also be gained. It would answer the question 
of whether direct cell to cell contact with osteoblasts or marrow stroma is required for 
this process, or whether it is mediated by secreted factors. An osteoclast-precursor 
population may provide important insights into the role of these cells in metabolic bone 
disease processes such as osteoporosis. This may provide information regarding drug 
targeting to arrest the disease process. This approach may give rise to much more 
selective drugs that could target the osteoclast lineage per se without affecting cells of 
other lineages. Take for example M-CSF. This colony stimulating factor has been 
shown to be important in the differentiation of murine osteoclasts (Felix et al, 1990). If 
the same is true for human osteoclasts then this factor would appear to be a good target 
for drug therapy in diseases such as osteoporosis. However, this factor is also 
important in the maturation of monocytes and macrophages (Kodama et al, 1991), so 
these drugs would also retard the differentiation of these cells. This effect may have far 
reaching implications regarding the normal functioning of the immune system, since 
these cells are central to processing and presentation of antigen to other cells within the
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immune system. If however a precursor population was available, it may be possible to 
target factors that may affect the differentiation of osteoclasts further down the 
ontogenic pathway, thus sparing other functionally important cell populations. On the 
differentiation pathway, outlined in table VII. 1, this is represented by the late pre- 
osteoclasts which represents a putative differentiation stage at which the mononuclear 
cells are committed to the osteoclast lineage. The osteoclast-reactive Mabs may also 
provide valuable information regarding targets for drug therapies. The characterization 
of the antibodies may reveal that some of them are reacting with antigens that are 
important to the resorptive process of osteoclasts. It should be possible to design drugs 
that target and block these functions.
The mononuclear cells detected in the collagenase digested osteoclastoma tissue with 
Mab C22 may provide us with a precursor population that is phenotypically similar to 
the one described by Kurihara et al, (1990). This group have described a human long­
term marrow culture system in which they identified putative osteoclast precursors 
using the monoclonal antibody 23C6. This Mab, which is selective for osteoclasts in 
bone (Horton et al, 1985), has been shown to be reactive with the av chain of the 
vitronectin receptor. In this thesis the characterization of a Mab, designated C22, is 
described and demonstrated to be reactive with the p3 chain of the same receptor. 
Although this Mab, in our hands, does not react with the giant cells formed in the 
human long-term marrow cultures to any great degree it has been demonstrated that it 
does react with a fairly minor population of mononuclear cells in collagenase digested 
osteoclastoma tissue (see chapter VI, section VI.4(vi)). Significantly, this Mab does not 
react with blood-borne mononuclear cells, and like the 23C6 Mab it is very selective for 
osteoclasts in bone. It may be that this population is similar in phenotype to those 
described by Kurihara and his colleagues, and may represent a bona-fide osteoclast 
precursor population. Although other Mabs in the panel demonstrated reactivity with 
the cells in these preparations, particularly OB/I, the vast majority were reactive with 
cytoplasmic antigens and therefore unsuitable for isolation techniques. However, using
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C22 coated magnetic beads may permit the isolation of these cells in the same way that 
the mature osteoclasts were purified. All the system requires is that the adherent cells 
are removed by overnight culture on plastic dishes. The number of C22 reactive 
mononuclear cells in the non-adherent population can be quickly assessed by IF and the 
number of beads required to isolate them adjusted accordingly. In previous attempts to 
isolate osteoclasts for resorption studies it was noted that labelled mononuclear cells 
were also present, but were often overloaded with the beads. This meant that the cells 
were effectively masked and could not be characterized further. However, the improved 
methodology means that this should not be a problem in the future. The purification of 
these cells means that they can be characterized biochemically and phenotypically using 
the antibodies available. In addition, the isolated cells could be used to immunize mice 
to generate Mabs that actually recognize a selection of markers on the precursor 
population. This could be developed further by also immunizing with cells that were at 
various stages of differentiation towards maturity. With the antibodies already raised 
against mature osteoclasts it would be possible to phenotypically map their 
differentiation pathway. In this way it would be possible to detect the loss of antigens 
associated with the immature precursors and detect the induction of antigens associated 
with the mature phenotype using the panels of antibodies.
VII.3 Establishment of osteoclast precursor cell lines
As a result of work in this laboratory (Williams et a/,1990) and in others (Keeting et al,
1992) human osteoblast-like cell lines have successfully been produced by transfecting 
primary bone cell cultures with SV40 DNA. It was hoped that osteoclast precursor cell 
lines could be established in the same way. However, there has been no success to date 
using fairly heterogeneous populations of osteoclastoma-derived cells. This may be due 
to the methodology, since in a heterogeneous population such as this, it is impossible to 
optimize the transfection conditions for all the cell populations present. For example the 
glycerol shock step in the calcium phosphate precipitation technique is critical to the 
success of the procedure. If the incubation time is too short, the DNA will not enter the
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cells, and if it is too long the cells will die. Similarly, the same rules apply for the 
electroporation technique; not enough current and the DNA does not enter the cell, too 
much and the cells die. The success of these techniques may be increased using 
homogeneous populations derived from the immunomagnetic beads experiments. This 
will enable the conditions to be optimized for a single cell population.
VII.4 Osteoclast ontogeny
It is now accepted that osteoclasts are derived from haemopoietic cells (Roodman et al, 
1985) but the lineage of its precursors is still debated. There is accumulating evidence 
to suggest that a pluripotential stem cell, under the appropriate stimulation can 
differentiate into either a granulocyte, a monocyte, or an osteoclast. Therefore the most 
likely stem cell is the CFU-GM. If shared reactivity can be used as an indication of 
shared ancestry then the characterization of the panel of Mabs described in this thesis 
against human blood cell populations would appear to support this theory. Mab C35 
appeared very selective for osteoclasts and demonstrated no reactivity against blood or 
marrow-bome cells. Similarly, C22 was very selective for osteoclasts in the bone 
environment, but strong reactivity was also seen against platelets. A potentially 
important point in terms of differentiation is that this Mab, together with OB/I also 
reacted against a putative precursor population in osteoclastoma tissue. The Mabs that 
supported the link with the monocyte / myeloid lineages were C13 and C27. The latter 
antibody demonstrated strong reactivity against osteoclasts, and in addition 
macrophages and granulocytes. C l3 reacted in a similar way with reactivity against 
osteoclasts, monocytes and granulocytes, although no reactivity was demonstrated 
against macrophages in the tissue substrates tested. The theoretical ontogenic pathway 
for the osteoclast from its precursor to the mature multinucleated cell is given in Fig 
VH.l. This is superimposed with the stages at which some of the Mabs are likely to 
react, although this is probably a gross over-simplification of the real events involved in 
the ontogeny of these cells. For example, it does not fully take into account the
2 1 3
□ □








m L I ' 1
Immature
osteoclast
Fig VII. 1. This diagram presents a model for osteoclast ontogeny and suggests where some of the Mabs from the panel might fit into 
the scheme. The early cells in the lineage from the CFU-GM to the bi-potential precursors have the potential to differentiate along the 
osteoclast or myeloid / monocytic lineage. Once up to the late pre-osteoclast stage the cells are committed to the osteoclast lineage. The 





differential staining of the osteoclasts and giant cells that was demonstrated in the 
osteophyte tissue, inflammatory synovium and long term marrow cultures. At this point 
in time it is not known if this staining was due to the fact that the antibodies were 
recognising differentiation antigens, and that some of the cells were not sufficiently 
mature to express the antigens. Or it may be just as likely that they were activation 
antigens and differential staining was a reflection of the function of the cells. Finally, it 
may be that the cells represent heterogeneous populations of polykaryons, both 
osteoclast and macrophage and that the reactivity of the Mabs reflected their reactivity 
against the blood and tissue substrates. The concept of antigen expression or loss with 
regard to the state of activation of the osteoclasts is in keeping with the work in our 
laboratory of Dodds et <2/(1991). They demonstrated histochemically that the 
expression of TRAP activity in osteoclasts and giant cells was linked to their function 
and environment. Similarly, they later demonstrated that osteoclasts actively resorbing 
bone did not express the enzymes associated with glycolysis, but those cells not 
actively resorbing did express them (Dodds et al, 1992).
It is clear that one way forward in the study of osteoclast biology, and ultimately the 
understanding of the malfunctions that occur in these cells in certain metabolic bone 
diseases, is dependent on the production of a stable, homogeneous precursor cell line. 
Most of the models described in the literature so far are lacking on two counts. The 
human long-term marrow culture system consists of heterogeneous populations of 
cells, and cell lines derived from leukaemic populations often give rise to mature cells 
that lack one or more of the functional characteristics of mature osteoclasts. It remains 
to be seen whether Mab technology can be used to isolate an homogeneous precursor 
population that can be induced to differentiate into mature osteoclasts that possess all 
the functional characteristics of these cells. The advantages of an isolation technique 
from osteoclastoma are that the precursors would be normal and from the preliminary 
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